Identification and characterization of protein kinase CK2 as a novel interacting protein of neuronal CDK5 kinase and its functional role in microtubule dynamics by LIM CHEE BENG
 
IDENTIFICATION AND CHARACTERIZATION 
OF PROTEIN KINASE CK2 AS A NOVEL 
INTERACTING PROTEIN OF NEURONAL CDK5 







LIM CHEE BENG 






A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
 
INSTITUTE OF MOLECULAR AND CELL BIOLOGY 




Robert Qi, my supervisor, for guidance, constant support and encouragement, his 
critical reading of all my manuscripts. Also for his constant inspiration throughout all 
the years. 
 
Walter Hunziker, my co-superviser, for his support, guidance, encouragement and 
critical reading of all my manuscripts. 
 
Edward Manser and Cao Xinmin, my supervisory committee members, for useful 
advices and critical comments on my work. 
 
Alice Tay for her administrative support, Tang Bor Luen for sharing his materials and 
helpful discussions and Wong Boon Seng for helpful advices and critical comments of 
my manuscript. All the past and present members of IMCB and our laboratory for 
making it a great place to work in, as well as for all the help, advices and scientific 
discussions 
 
My parents and siblings for their constant moral support. 
 
Finally, the biggest Thank-you to my wife Liting, for her love, encouragement and 
support throughout all the years. 
 II
Table of Contents 
 
Title page         I 
Acknowledgements       II 
Table of Contents        III 
Abbreviations        VII 
Abstract         XI 
 
 
1 Introduction       1 
 
 
1.1 Protein Kinase CK2:Composition and Structure   3 
1.1.1 Tissue-specific distribution and subcellular localization  7 
1.1.2 Regulation of CK2       9 
1.1.3 Biological effects of CK2      13 
1.1.3.1 Regulation of adhesive proteins     13 
1.1.3.2 Regulation of cytoskeletal elements     14 
1.1.3.3 Regulation of substrates involved in signal transduction  15 
1.1.3.4 Regulation of proteins associated with synaptic vesicle recycling 16 
1.1.3.5 Regulation of transcription factors     17 
1.2 Cyclin-Dependent Protein Kinase Family    19 
1.3 Neuronal Cdk5 kinase      23 
1.3.1 Regulation of Cdk5       27 
1.3.2 Physiological roles of Cdk5 and its mediated functions  30 
1.3.2.1 Cdk5 in cytoskeletal dynamics and microtubule-based transport 30 
1.3.2.2 Cdk5 in synapses and focal adhesion sites    31 
1.3.2.3 Cdk5 in neurosignaling      33 
 III
1.3.2.4 Cdk5 in transcriptional machineries     34 
1.3.3 Molecular organization of Cdk5 complexes    36 
1.3.3.1 Methods used in isolating protein-interacting partners  38 
1.4 Microtubule Dynamics      40 
 
 
2 Materials and Methods      46  
 
2.1 Materials        47 
2.1.1 Chemicals and reagents      47  
2.1.2 Cell lines        48  
2.1.3 Antibodies        48 
2.2 Experimental Procedures      50 
2.2.1 Plasmid constructions       50 
2.2.2 Recombinant protein preparation     50 
2.2.3 Isolation of p35-binding proteins     52 
2.2.4 Mass spectrometry       53 
2.2.5 Biochemical binding assays      53 
2.2.6 Protein size exclusion chromatography    54 
2.2.7 Cdk5 In vitro kinase assay      55  
2.2.8 Transient transfections      55 
2.2.9 Immunoprecipitation       55 
2.2.10 Microtubule assembly       56 
2.2.11 Differential tubulin extraction from intact cells   56 
2.2.12 RNAi         57 
2.2.13 Immunofluorescence microscopy     57 
2.2.14 Miscellaneous techniques       58 
 IV
2.2.15 Statistical analysis and presentation of data    58 
 
 
3 Results and Discussion      60  
 
3.1 Isolation of p35-associated proteins and identification of  
protein kinase CK2 as an inhibitor of neuronal Cdk5 kinase 61 
3.1.1 Introduction        62 
3.1.2 Results        64 
3.1.2.1 Isolation of p35-binding proteins by affinity purification and co-
immunoprecipitation        64 
3.1.2.2 Identification of CK2α as a p35-binding protein   67 
3.1.2.3 CK2α associates with p35 and Cdk5 in vivo    69 
3.1.2.4 Direct association of CK2 with p35 and Cdk5   71 
3.1.2.5 CK2 inhibits Cdk5 activation      74 
3.1.2.6 CK2 inhibits Cdk5 in a phosphorylation-independent manner 78 
3.1.2.7 CK2 blocks complex formation between Cdk5 and p35  80 
3.1.3 Discussion        83 
3.2 Direct regulation of Microtubule Dynamics by Protein  
Kinase CK2        87 
3.2.1 Introduction        88 
3.2.2 Results        90 
3.2.2.1 CK2 forms a direct complex with microtubules   90 
3.2.2.2 CK2 induces microtubule polymerization    94 
3.2.2.3 CK2 stabilizes microtubule in vivo     101 
3.2.3 Discussion        105 
   
 V
 
4 Summary and Perspectives     108  
 
 
5 References        116 
 
 
6 Appendix        139 
 
6.1 Tables         140 




a.a.   amino acid 
AD   Alzheimer’s disease 
APP   amyloid precursor protein 
ATP   adenosine triphosphate 
c-abl   c-Abelson 
CAK   Cdk activating kinase 
CaMKII  Ca2+/calmodulin-dependent protein kinase II 
cAMP   cyclic adenosine monophosphate 
Cdk   cyclin-dependent kinase 
Cdk5   cyclin-dependent kinase 5 
cDNA   complementary deoxyribonucleic acid 
CK1   casein kinase 1 
CK2   casein kinase 2 
CKI   Cdk inhibitor 
CNS   central nervous system 
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DARPP-32  dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa 
dATP   deoxy-adenosine triphosphate 
dbpA   DNA-binding protein A 
DEAE   diethylamino-ethylcellulose 
DMEM  Dulbecco’s modified Eagle’s medium 
DNA   deoxyribonucleic acid 
DTT   1,4-dithiothreitol 
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ECL   enhanced chemiluminescence 
EDTA   ethylenediaminetetra acetic acid 
EGTA   ethyleneglycoltetra acetic acid 
ER   endoplasmic reticulum 
FAK   focal adhesion kinase 
FCS   fetal calf serum 
FPLC   fast protein liquid chromatography 
GSH   glutathione 
GSK-3  glycogen synthase kinase-3 
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GTP   guanosine 5’-triphosphate 
HA   hemagglutinin 
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JNK   c-Jun N-terminal kinase 
kDa   kilo Dalton 
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LB   Luria-Bertani medium 
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MAPK  mitogen-activated protein kinase 
MEF2   myocyte enhancer factor 2 
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nickel-NTA  nickel nitrilotriacetic acid 
NLS   nuclear localization signal 
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PAK   p21-activated protein kinase 
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PKA   cAMP-dependent protein kinase 
PKC   protein kinase C 
PMSF   phenylmethylsulphonyl fluoride 
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PP2A   protein phosphatase 2A 
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PVDF   polyvinylidene difluoride 
 IX
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RT   reverse transcription 
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sec   second 
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Neuronal cyclin-dependent kinase 5 (Cdk5) has been shown to play an 
important role in a variety of cellular processes, including neuronal cell 
differentiation, apoptosis, neuron migration and synaptic plasticity (Dhavan and Tsai, 
2001; Lim et al., 2003). The active kinase consists of a catalytic subunit, Cdk5, and a 
regulatory subunit, p35 or p25, which are expressed primarily in neurons. Little is 
known about the regulation of Cdk5/p35 kinase turnover/activity, apart from the fact 
that it is degraded through the ubiquitin proteosome pathway (Patrick et al., 1998). 
We were interested to explore the regulation of neuronal Cdk5 activity. To achieve 
this, p35 and its fragments were made as GST-tagged fusion proteins and utilized in 
biochemical affinity purification attempts to isolate novel p35-binding proteins. We 
have also employed a co-immunoprecipitation approach in our search for novel 
interacting proteins. Using the former approach, the catalytic α subunit of protein 
kinase CK2 (formerly known as casein kinase 2) was isolated from rat brain extracts. 
The direct associations of CK2 with p35, as well as with Cdk5, were demonstrated 
and the CK2-binding sites of p35 were delineated. We showed that CK2 exhibited a 
strong inhibition on Cdk5 activation by p35 in vitro and in vivo. Cdk5 inhibition 
however is not associated with CK2 kinase function, since a kinase-dead CK2 mutant 
displayed a similar level of Cdk5 inhibitory activity as the wild-type protein. 
Interestingly, further analysis revealed that CK2 acts by blocking the formation of a 
complex between Cdk5 and p35. Hence, CK2 exerts a direct negative effect on Cdk5 
activation by p35 through its physical interaction with p35. 
Regulation of microtubule dynamics is essential for many vital cellular 
processes such as morphogenesis and motility and Cdk5-p35 complex co-exists with 
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microtubules in the brain (Sobue et al., 2000; Paudel et al., 1993). Since we have 
identified CK2 as a p35-interacting protein and previous studies have implied that 
CK2, a ubiquitously expressed protein kinase involved in diverse cellular functions 
(Litchfield, 2003; Meggio and Pinna, 2003), may be involved in regulating 
cytoskeleton reorganization (Serrano et al., 1987; Diaz-Nido et al., 1988; Serrano et 
al., 1989), we therefore investigated if CK2 is also involved in mediating microtubule 
dynamics. The CK2 holoenzyme is composed of two catalytic α or α’ subunits and 
two regulatory β subunits. We showed that the α subunit of CK2 binds directly to 
both microtubules and tubulin heterodimers. The CK2 holoenzyme (but not its 
individual subunits) exhibited a potent effect in inducing microtubule assembly and 
bundling. Moreover, polymerized microtubules were strongly stabilized by CK2 
against cold-induced depolymerization. In addition, the kinase activity of CK2 is not 
required for its microtubule-assembly and stabilizing function since a kinase-inactive 
mutant of CK2 displayed similar microtubule-assembly activity as the wild-type. 
Knockdown of CK2α/α' in cultured cells by RNA interference dramatically 
destabilized their microtubule networks. The destabilized microtubules were thus 
readily disrupted by colchicine at a very low concentration. Further, over-expression 
of chicken CK2α or its kinase-inactive mutant in CK2α/α'-depleted cells fully 
restored microtubule resistance to low doses of colchicine. To our knowledge, these 
findings demonstrate for the first time that CK2 is a microtubule-associated protein 















The ability of cells to function and proliferate depends largely on their 
response to the immediate intracellular environments as well as the external stimuli. 
These cellular signals trigger a specific set of mechanisms within the cells to bring 
about a change in cell function. These mechanisms are highly regulated to control 
cellular functions, commonly by means of changes in protein conformation. A process 
of signal transduction conveys the external message to the internal cellular organelles. 
 
Protein phosphorylation is one such mechanism, and is catalyzed by enzymes 
known as protein kinases, while protein phosphatases catalyze the reverse process, 
dephosphorylation (Cohen, 2002; Hunter, 2000). Protein kinases are classified into 
the serine/threonine-specific, tyrosine-specific, histidine-specific or the dual 
specificity (Ser/Thr and Tyr) class of kinases, depending on the residue being targeted 
for phosphorylation. All known protein kinases of this class share a related catalytic 
domain and are distinguished by their unique regulatory domains. 
 
Mammalian brains are highly compartmentalized into groups of functionally 
specialized neurons. Cell migration and neurite outgrowth must be tightly 
orchestrated to achieve this level of organization. Likewise, cellular processes such as 
DNA replication and cell division must also be tightly regulated during 
embryogenesis to produce a viable organism. Many protein kinases have emerged to 
be important regulators of these processes. Together, they play distinct roles in 
coordinating the transition of different cellular functions. 
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1.1  Protein Kinase CK2: Composition and Structure  
 
Casein kinases are multifunctional, highly conserved, serine/threonine protein 
phosphotransferase that are ubiquitous in yeast and higher eukaryotes (Pinna, 1990). 
They are cyclic-nucleotide-independent protein kinases that preferentially 
phosphorylate acidic proteins (Hathaway and Traugh, 1982). Two distinct casein 
kinases have been found in many different cell types. They have been designated 
casein kinase 1 (CK1) and casein kinase 2 (CK2) according to the elution profile 
obtained by diethylamino-ethylcellulose (DEAE-cellulose) chromatography 
(Hathaway and Traugh, 1979). 
 
Protein kinase CK2 is an oligomeric enzyme with molecular mass (Mr) of 130-
150 kDa, as determined by sedimentation velocity and equilibrium analysis 
(Hathaway and Traugh, 1979; Pinna, 1990), with the exception of a porcine liver CK2 
of 210 kDa (Baydoun et al., 1986) and a monomeric human spleen CK2 of 43 kDa 
(Gounaris et al., 1987). The holoenzyme of CK2 consists of subunits α, α’ and β 
which associate to form several distinct heterotetramers, namely α2β2, α’2β2 and 
αα’β2. A number of studies have reported that these subunits may also exist 
individually in the cells which are devoid of their counterparts (Stigare et al., 1993; 
Heriche et al., 1997; Kusk et al., 1999). The reported Mr for the β subunit, as 
determined by gel electrophoresis in sodium dodecyl sulfate (SDS), is usually 24-26 
kDa, while the values for the α and α’ subunits ranges from 35 to 44 kDa (Hathaway 
and Traugh, 1982; Litchfield et al., 1990). 
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The α, α’ and β subunits are the products of three distinct genes (Allende and 
Allende, 1995). All subunits have an extraordinarily high degree of evolutionary 
conservation. Firstly, the sequence of the α subunit is largely conserved across 
mammalians and other species (Drosophila, chicken, mouse, rat, pig, bovine, human) 
where sequence identity ranges from 67 to 90%. Secondly, the α and α’ subunits are 
structurally very homologous, despite the differences in their C-terminal regions 
(Lozeman et al., 1990). Thirdly, the cDNA sequences of the β subunit of Drosophila, 
mouse, rat, pig, bovine and human are also highly homologous (Pinna, 1990). 
 
The α and α’ subunits are catalytically active, whereas the β subunit is 
inactive. Identification of catalytic subunits CK2α and CK2α’ was based on their 
enzymatic activity in the absence of the β subunit. The functions of the β subunit are 
to confer stability, regulate the enzymatic activity of the holoenzyme and the 
specificity of the catalytic subunit (Faust and Montenarh, 2000). The catalytic domain 
of the α subunit is homologous to the catalytic domains of other protein kinases. 
There is a short N-terminal segment, termed “glycine-loop on phosphate anchor”, 
which makes contact with the β-phosphate of the bound ATP and is involved in the 
recognition of peptide substrates (Fig. 1). A stretch of basic residues, which is 
probably the most striking hallmark of CK2, is located just downstream from the 
invariant lysine (Lys-68) and is recognized as an essential residue involved in ATP 
binding in all protein residues. This high concentration of adjacent basic residues is 
unique among protein kinases in this region. This is the region which interacts with 
the β subunit and is involved in the down-regulation by the β subunit towards some 
substrates (Marin et al., 1997; Sarno et al., 1998). In addition, it is also implicated in 
the inhibition of CK2 by heparin (Vaglio et al., 1996). Another intriguing function for 
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this basic sequence is based on the fact that it falls into the description of a nuclear 
localization signal (NLS) that are known to mediate the attachment of molecules to 
transporter proteins for their regulated nuclear import (Boulikas, 1996). It is 
interesting to note that none of the other protein kinases possess a NLS motif with 
more than three basic residues. Although it cannot be fully excluded that the NLS 
sequences of α and α’ subunits have little to do with nuclear transport since these 
subunits lack an acidic stretch close to the NLS which enhances binding with 
transporter proteins (Boulikas, 1996), it is nevertheless possible that these strong 
NLS-like motifs allow targeting of the kinase to the nucleus ascribed to this kinase 
(Rihs et al., 1991). The next segment contains the functional elements termed the 
‘activation loop’, followed by a C-terminal tail that has been shown to be 
phosphorylated by the protein kinase p34cdc2 (Litchfield et al., 1992). 
 
Within the N-terminal of the β subunit of CK2 lies an autophosphorylation 
site, which has been shown to be phosphorylated readily in vitro (Meggio et al., 
1989). A cyclin-like ‘destruction box’ also lies within this region of the protein, which 
is followed by an acidic region known to be responsible for the intrinsic down-
regulation of CK2 (Meggio et al., 1994). The C-terminal segment is responsible for β-
β dimerization, association with the α subunit, protection against denaturation and 
proteolysis, and up-regulation of activity (Boldyreff et al., 1993; Boldyreff et al., 
1996; Marin et al., 1997; Krehan et al., 1996). In addition, this region possess a 
phosphorylatable Ser209 which has been shown to be phosphorylated by p34cdc2, 




FIG. 1. Schematic diagram depicting various motifs of the CK2 proteins. Within the α subunit of 
human CK2, the domain in grey includes the invariant Lys-68 which is involved in ATP binding, 
followed by a cluster of basic residues which associates with the β subunit, and a strong karyophilic 
putative NLS signal. The domain in pink comprises a series of six basic residues regularly spaced, 
which appear to be involved in the recognition of peptide substrates, and the catalytic loop. The domain 
in blue contains the functional elements termed ‘activation loop’. There are four phosphorylatable 
residues (Thr-344, Thr-360, Ser-362 and Ser-370) which are identified as potential targets for Cdc2 
(Litchfield et al., 1992). Within the β subunit of human CK2, the domain in yellow is highly conserved 
between organism, and it includes seven acidic residues and is responsible for negative regulation of 
CK2 and its association with plasma membrane. The domain in purple is mainly responsible for β-β 
dimerization and α-β structural interaction. There is a phosphorylatable serine residue (Ser-209) at the 
C-terminal end (Litchfield et al., 1992). 
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1.1.1 Tissue-specific distribution and subcellular localization 
 
CK2 is expressed by various species at different stages of development. In 
fact, almost all tissues of all higher organisms express CK2. By in situ hybridization 
and CK2 transcripts, Mestres and co-workers showed that both CK2 protein subunits 
were detected in nearly all organs of the mouse embryo, suggesting a general role 
during embryonic development (Mestres et al., 1994). In general, the level of CK2 
transcripts correlates with protein expression. A survey was also made of the activity 
of CK2 in extracts made from various tissues of adult rat. The highest activity was 
found in brain, testis and liver, whereas CK2 activity in kidney and spleen is low 
(Singh and Huang, 1985; Nakajo et al., 1986; Guerra et al., 1999). CK2 activity, as 
well as its immunoreactivity, were also present in all brain regions studied (Girault et 
al., 1990). CK2 activity was also studied in mouse cortex and caudate-putamen during 
development (De Camilli and Greengard, 1986). Its levels was found to be high at 
embryonic day 16 and during the early post-natal period, and appeared to decrease 
slightly in the adult. 
 
Numerous workers have investigated the subcellular localization of CK2 
though many of the initial results were somewhat confusing. However, it turned out 
that CK2 was present not only in the nucleus and the cytoplasm (as reported initially) 
but nearly everywhere in the cell. Oligomeric forms of CK2 were observed to be 
closely associated with the plasma membranes prepared from A431 cells and from 
SF9 insect cells expressing the catalytic and regulatory subunits of CK2 (Sarrouilhe et 
al., 1998). The holoenzyme seems to be targeted to the plasma membrane by the β-
subunit of CK2. On the other hand, others have reported that CK2 activity and its 
immunoreactivity as predominantly cytoplasmic (Singh and Huang, 1985; Girault et 
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al., 1990). Using immunofluorescence and immunoelectron microscopy, Yu and 
coworkers showed that CK2α and CK2β are localized to the cytoplasm during 
interphase and are distributed throughout the cell during mitosis (Yu et al., 1991). In 
contrast, CK2α’ is localized in the nucleus during G1 phase and in the cytoplasm 
during the S phase (Yu et al., 1991). Likewise, CK2 immunoreactivity had been 
reported to be either associated with the nucleus or distributed between the nucleus 
and cytoplasm (Schneider and Issinger, 1989). It is apparent that the variety of nuclear 
substrates found for CK2 makes a nuclear/nucleolar function for this protein kinase 
likely (Meggio and Pinna, 2003). 
 
A closer look at the subcytosolic localization of CK2 reveals that this enzyme 
is also associated with cytosolic organelles. CK2 has been purified from bovine 
kidney mitochondria (Damuni and Reed, 1988). An in vivo localization of CK2 at the 
membrane of the mitochondria seems to be reasonable since some potential substrates 
of CK2 are localized in the matrix of mitochondria (Meggio and Pinna, 2003). CK2 
has been identified as an endoplasmic reticulum (ER)-associated kinase responsible 
for the in vitro phosphorylation of calnexin and signal sequence receptor-α (Ou et al., 
1992). These proteins are implicated to function as chaperones in the ER. Moreover, 
the cytosolic domain of calnexin was found to be phosphorylated in vivo at CK2 sites 
Ser534 and Ser 544 and these modifications play a role in targeting calnexin to the 
ribosomes (Chevet et al., 1999). 
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1.1.2 Regulation of CK2 
 
CK2 was initially isolated as a cyclic nucleotide-independent protein kinase 
that preferentially phosphorylates acidic proteins (Hathaway and Traugh, 1982), 
which led to much debate and controversy over its regulation in cells (Litchfield et al., 
1994). The fact that CK2 activity is generally detected in cell or tissue extract even in 
the absence of any stimulation or addition of cofactors, or when it is expressed in 
bacteria, lends itself to the conclusion that CK2 is constitutively active or unregulated. 
Till now, studies reporting on the activation of CK2 in response to a diverse array of 
stimuli have not yielded any consistent insights into the mechanisms responsible for 
CK2 regulation in cells. Some of the mechanisms that contribute to the regulation of 
CK2 in cells include regulated expression and assembly, modulation by covalent 
modification and regulatory interactions with protein and/or non-protein molecules. 
 
In the case of the Cdks, it is evident that their kinase activity is absolutely 
dependent on the presence of regulatory cyclin subunit (Pines, 1995). In this respect, 
CK2β is analogous to the cyclins that it modulates the catalytic activity and substrate 
specificity of CK2 as well as the assembly of CK2 complexes. The existence of a 
putative destruction box within the sequence of CK2β and the demonstration that 
CK2β is ubiquitinated and degraded through a proteasomal pathway further 
emphasizes its potential similarities with the cyclins (Zhang et al., 2002a). 
Furthermore, it has been reported that CK2 activity oscillates during the cell cycle, 
analogous to the Cdks (Carroll and Marshak, 1989; Bosc et al., 1999). Generally, it 
appears that CK2 levels correlate to proliferation rate, as cells with higher 
proliferation rates generally exhibit higher levels of CK2 (Munstermann et al., 1990). 
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As noted above, CK2 has traditionally been considered a tetrameric enzyme, 
with CK2β exerting control over the catalytic activity of CK2 at a number of possible 
levels. However, there is mounting evidence to suggest that the catalytic subunits of 
CK2 exist outside the tetrameric CK2 holoenzyme. It is intriguing that there are 
substrates which can be phosphorylated by CK2α or by CK2α’ but not the tetrameric 
CK2 (Marin et al., 1999; Litchfield, 2003). There is a possibility that tetrameric CK2 
complexes undergo regulated disassembly in cells. This is supported by recent studies 
on the dynamic localization of individual CK2 subunits showing independent 
movements of CK2α and CK2β within cells (Martel et al., 2001; Filhol et al., 2003). 
Furthermore, recent crystal structure of tetrameric CK2 revealed that the surface 
contact between the catalytic and regulatory subunits were considerably fewer than 
those typically observed in stable protein complexes (Niefind et al., 2001). In this 
respect, CK2 may indeed undergo regulated disassembly and reassembly in cells 
(Allende and Allende, 1998). 
 
For many protein kinases, it is apparent that stimulus-dependent 
phosphorylation of sites within an activation loop is required for their activation. By 
comparison, the catalytic subunit of CK2 exhibit robust activity when expressed in 
bacteria in either presence or absence of CK2β (Grankowski et al., 1991; Hinrichs et 
al., 1993). Similarly, there has been limited support for the suggestion that 
phosphorylation regulates the activity of CK2 in response to cellular stimulation 
(Agostinis et al., 1987; Ackerman et al., 1990; Mulner-Lorillon et al., 1990; Palen 
and Traugh, 1991; Litchfield et al., 1991). Taken together, these data indicate that 
phosphorylation is not absolutely required to activate CK2. On the other hand, both 
CK2α and CK2β are phosphorylated in a cell cycle-dependent manner (Litchfield et 
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al., 1992; Litchfield et al., 1991). Though these sites do not appear to directly effect a 
dramatic change in the catalytic activity of CK2, they may, by controlling the stability 
of CK2β autophosphorylation, indirectly regulate cellular CK2 activity (Zhang et al., 
2002a). The C-terminal phosphorylation of CK2α may also regulate CK2 indirectly 
through interaction of phosphorylated CK2α with the peptidyl-prolyl isomerase Pin1 
(Messenger et al., 2002). Interactions between Pin1 and CK2 do not appear generally 
to influence CK2 activity, but do inhibit the CK2-catalyzed phosphorylation of 
topoisomerase IIα in vitro. 
 
CK2 is typically known to be independent of those small molecules that are 
involved in the activation of second messenger-dependent kinases. However, it has 
been established that CK2 is inhibited by negatively-charged compounds such as 
heparin and activated by positively-charged compounds such as polyamines (Tuazon 
and Traugh, 1991). Further finding that CK2 level and activity were elevated in mice 
with enhanced polyamine levels, resulting from forced overexpression of ornithine 
decarboxylase, supports the possibility that CK2 levels can indeed be modulated by 
polyamines in vivo (Leroy et al., 1997). 
 
A large body of evidence indicates that protein-protein interactions represent a 
major mechanism for the regulation of specific protein kinases (Pawson and Nash, 
2000). The identification of several proteins that interact with CK2 is consistent with 
this conjecture that CK2 may be directly, or indirectly, regulated by interacting 
proteins. CK2 interacts with proteins such as fibroblast growth factor 1 and HSP-90 
that may directly alter or stabilize its catalytic activity (Skjerpen et al., 2002; Miyata 
and Yahara, 1995). Studies have demonstrated that CK2 also interacts with other 
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proteins, such as tubulin and FAS-associated factor 1, that may be involved in the 
targeting of CK2 to specific sites or structures within the cells (Faust et al., 1999; 
Jensen et al., 2001). Overall, it is evident that many distinct mechanisms may 
contribute to the regulation of CK2 in the cells. In this respect, it is conceivable that 
many distinct, independently regulated subpopulation of CK2 exist in cells in order to 
carry out its myriad of cellular functions. 
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1.1.3 Biological effects of CK2 
 
In the last few decades, a great deal of research has been devoted in the study 
of CK2 and its cellular implications (Litchfield, 2003; Meggio and Pinna, 2003). By 
its interaction with more than 300 binding partners and substrates, CK2 modulates the 
action of proteins that are involved in cell signaling and adhesion, cytoskeletal 
structure, synaptic-vesicle recycling, as well as transcriptional machineries. Moreover, 
CK2 is instrumental and necessary for promoting cell survival (Litchfield, 2003; 
Ahmed et al., 2002), which further substantiates the mandatory roles of CK2 in the 
cells. 
 
1.1.3.1 Regulation of adhesive proteins 
Studies have shown that phosphorylation might function as a regulatory 
mechanism for adhesive components of the cell (Stepanova et al., 2002; Serres et al., 
2000; Seger et al., 1998). Till now, the phosphorylation by CK2 has been linked to 
the functions of several cell adhesion molecules, including vitronectin and E-cadherin. 
 
Vitronectin, a secretory product of the astrocytes, is known to be an important 
adhesive glycoprotein. It participates in the regulation of the complement function and 
promotes cell attachment spreading and migration through an Arg-Gly-Asp (RGD) 
sequence that is known to be recognized by integrins, one type of the adhesive 
transmembrane receptors present in focal adhesions (Hynes, 2002). Interestingly, 
vitronectin was unearthed to be a substrate of CK2. The phosphorylation by CK2 on 
vitronectin is selectively targeted to two threonine residues that are vicinal to the 
RGD sequence, resulting in a significant modulation of cell adhesion (Seger et al., 
1998). Hence, CK2 phosphorylation converts vitronectin from cellular ‘glue’ to a 
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cellular ‘super glue’. More recently, it was discovered that this phosphorylation 
increases cell adhesion via the αvβ3 integrin and this event is phosphatidylinositol 3-
kinase-dependent (Seger et al., 2001). 
 
Among the many types of cell-cell adhesion molecules, cadherins play a 
critical role in establishing adherens-type junctions by mediating Ca2+-dependent cell-
cell adhesion (Takeichi, 1995; Huber et al., 1996; Yagi and Takeichi, 2000). 
Cadherin-based cell-cell adhesion is critically involved in early embryonic 
morphogenesis, as exemplified by the early embryonic lethality of mice lacking E-
cadherin, a prototype classical cadherin (Riethmacher et al., 1995; Larue et al., 1994). 
β-catenin, a member of the Armadillo repeat protein family, binds directly to the 
cytoplasmic domain of E-cadherin, linking it via α-catenin to the actin cytoskeleton. 
E-cadherin has been shown to be a substrate of CK2 and phosphorylation of the E-
cadherin cytoplasmic domain by CK2 appears to modulate the affinity between β-
catenin and E-cadherin, ultimately modifying the strength of cell-cell adhesion (Serres 
et al., 2000; Lickert et al., 2000). 
 
1.1.3.2 Regulation of cytoskeletal elements 
CK2 can phosphorylate a variety of cytoskeletal proteins, including β tubulin, 
myosin heavy chain, spectrin, tau, MAP-1A and MAP-1B (Meggio and Pinna, 2003), 
but the role of these post-translational changes is still not well understood. In neuronal 
cells, one of the proposed roles for these changes has been the promotion of 
neuritogenesis, which involves elongation and maturation of both axonal and dendrite 
arbors. Depletion of CK2 with anti-sense oligonucleotide causes a site-specific 
dephosphorylation of MAP-1B and blocks neuritogenesis in neuroblastoma cells 
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(Ulloa et al., 1993). In line with these findings, a CK2-related activity was also found 
to phosphorylate brain MAP-1B in vitro. More importantly, brain MAP-1B 
phosphorylated in vitro by CK2 was shown to coassemble efficiently with 
microtubule proteins in the same way as in vivo phosphorylated MAP-1B from 
neuroblastoma cells (Diaz-Nido et al., 1988). These results led to the proposal that 
MAP-1B phosphorylation by CK2 may favor microtubule nucleation and stabilization 
during neurite outgrowth. In addition, CK2 phosphorylates a neural-specific isoform 
of tubulin, preferentially in the polymerized form (Serrano et al., 1987; Diaz-Nido et 
al., 1990), though no physiological relevance has been shown so far. However, it has 
been suggested that CK2-induced MAP-1B phosphorylation is a prior step to CK2-
induced tubulin phosphorylation. 
 
1.1.3.3 Regulation of substrates involved in signal transduction 
Many substrates of CK2 are involved in signal transduction pathways (Meggio 
and Pinna, 2003). p34cdc2 is phosphorylated by CK2 during G1 phase of the 
mammalian cell cycle (Russo et al., 1992). In addition, the α and β subunits of 
mammalian CK2 are phosphorylated in vitro by p34cdc2 and their phosphorylation 
increases dramatically in cells arrested at mitosis (Litchfield et al., 1992; Litchfield et 
al., 1991). Unfortunately, nothing has been reported about the effect of these 
modifications. p53 is one of the most powerful negative regulators of growth. CK2 
phosphorylates murin p53 at Ser386, which has been shown to control several 
independent functions of p53 including site-specific DNA binding, strand 
renaturation, transcription repression and anti-proliferative effect (Agarwal et al., 
1998). Recently, studies have reported that Ser386 is highly resistant to 
dephosphorylation, suggesting that, once phosphorylated at this CK2 site, p53 
remains in an activated form throughout its lifespan (McKendrick et al., 1999). 
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 Synergistic phosphorylation by glycogen synthase kinase-3 (GSK-3) and CK2 
has been demonstrated in glycogen synthase, regulatory subunit (R2) of PKA and the 
inhibitor-2 of PP1 (DePaoli-Roach et al., 1981; DePaoli-Roach, 1984; Meggio et al., 
1981; Carmichael et al., 1982; Hemmings et al., 1982; Edelman et al., 1987). 
Evidence is that prior serine/threonine phosphorylation of glycogen synthase, 
inhibitor-2 and R2 by CK2 makes these proteins better substrates for GSK-3. It 
appears that free CK2α, by phosphorylating protein phosphatase 2A (PP2A) and 
thence by stimulating its activity, could indirectly cause down-regulation of the PP2A 
substrate MEK and thus block the activation of the Raf-MEK-MAPK kinase cascade 
(Heriche et al., 1997). Raf activation-dependent disruption of the CK2α-PP2A 
complex might be indeed a necessary step for maximal activation of the MAP kinase 
pathway (Lebrin et al., 1999). Likewise, CK2 phosphorylation of stathmin, a 
microtubule depolymerizing factor, remains unclear functionally. Recent work has 
shown that the microtubule depolymerization activity of unphosphorylated stathmin is 
slightly enhanced if the protein is phosphorylated by CK2 prior to depolymerization 
assays in vitro (Moreno and Avila, 1998). However, no apparent in vivo CK2 
phosphorylation of stathmin has been detected. 
 
1.1.3.4 Regulation of proteins associated with synaptic vesicle recycling 
A number of phosphoproteins are associated with synaptic vesicles and appear 
to be involved in neurotransmitter release (Sudhof, 1995). Among these components, 
synaptotagmin, syntaxin and dynamin I can be phosphorylated by CK2 (Bennett et 
al., 1993; Robinson et al., 1994). Synaptotagmin is a single transmembrane protein 
that contains a cytoplasmic phospholipid-binding region. This region is involved in 
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mediating the interaction of synaptic vesicles with the presynaptic plasma membrane. 
Syntaxin, as a neuronal protein at the synaptic sites, appears to mediate the interaction 
of synaptotagmin with the N-type calcium channel, possibly providing a mechanism 
for docking synaptic vesicles at the presynaptic membrane (Littleton and Bellen, 
1995). Dynamin I has received prominent attention as a result of its protein kinase C 
(PKC) phosphorylation on repolarization-induced calcium removal and its 
dephosphorylation on depolarization-induced calcium influx accompanying synaptic 
vesicle recycling. Interestingly, CK2 phosphorylates the phospholipid-recognizing 
site of synaptotagmin. Furthermore, CK2 phosphorylation of dynamin I prevents 
phosphorylation by PKC, providing a model for potential interaction between distinct 
signaling pathways in the presynaptic regulation of endocytosis and exocytosis of 
synaptic vesicles (Robinson et al., 1994). It is therefore conceivable that CK2 
phosphorylation of synaptotagmin, syntaxin and dynamin I may represent one 
mechanistic basis of increasing presynaptic efficacy through the regulation of the 
synaptic vesicle-membrane trafficking. 
 
1.1.3.5 Regulation of transcription factors 
A cursory examination of CK2 substrates (Meggio and Pinna, 2003) reveals 
that a number of them are involved in regulation of genes, including c-Jun, c-Fos, c-
Myc, Max, Sp1 and p53. Phosphorylation by CK2 has been found to affect either 
positively or negatively binding of these sequence-specific transcription factors. The 
early signal transducer c-Jun is a major component of the inducible complex AP1 that 
binds to tumor-promoting agent response element either as a homodimer or as a 
heterodimer with other Jun or Fos proteins (Hunter and Karin, 1992). c-Jun is 
phosphorylated on six major sites (Hunter and Karin, 1992; Lin et al., 1992), and so 
far, only phosphorylation by CK2 and GSK-3 has been shown to inhibit c-Jun-DNA 
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binding. In vitro, CK2 phosphorylates Thr231 and Ser249, which are the negative 
regulatory C-terminal sites located immediately to the N-terminal side of its DNA-
binding domain (Hunter and Karin, 1992; Lin et al., 1992). 
 
Max is a DNA-binding protein that can form homodimer and heterodimer with 
members of the Myc proto-oncogene family. The DNA-binding capability of 
Max/Myc heterodimer binding is unaffected (Berberich and Cole, 1992). It is 
therefore possible that CK2 phosphorylation of Max may have an important role in 
modulating or eliminating any potential competition for Max/Myc target genes by the 
Max homodimers. 
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1.2  Cyclin-Dependent Protein Kinase Family  
 
The regulation of cell cycle progression is a tightly controlled process. The 
timing through the various phases of G1/S/G2 and M is mediated through an ordered 
progression of Cdk activation (Morgan, 1997; Pines, 1999). Cyclin-dependent kinases 
(Cdks) are the cell cycle-associated protein kinases that regulate proliferation, 
differentiation, senescence and apoptosis (Li and Blow, 2001). Members of the Cdk 
family are proline-directed serine/threonine kinases (30-35 kDa) whose activities are 
controlled through a complex series of regulatory mechanisms, including binding to 
their appropriate cyclin partners, activating and inactivating phosphorylation 
modifications, and endogenous inhibitors of the Cdk activity (Morgan, 1997; Tannoch 
et al., 2000). In general, each Cdk periodically interacts with a specific subset of 
cyclins to regulate the Cdk activity. There are at least nine different Cdks (Cdk1-
Cdk9) and many more cyclins (cyclin A through T). Cyclin/Cdk complexes are in turn 
regulated in defined stoichiometric combinations with specific small inhibitory 
proteins, the Cdk inhibitors (CKIs). There are two families of CKIs: the INK4 
(inhibitor of Cdk4) family members, p16ink4a, p15ink4b, p18ink4c and p19ink4d, 
specifically inhibit cyclin D-associated kinases, and the KIP (kinase inhibitor protein) 
family members, p21cip1/waf1, p27kip1 and p57kip2, bind and inhibit the activity of cyclin 
E/Cdk2, cyclin A/Cdk2 and cyclin B/Cdk1 complexes (Sherr and Roberts, 1999; 
Pines, 1995). 
 
Generally, members of Cdk family share greater than 40% sequence identity 
and have a cyclin-binding and -activating domain (Morgan, 1995). The typical Cdk 
subunit contains a 300 amino acid catalytic core that is completely inactive when 
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monomeric and unphosphorylated. Cellular Cdks levels tend to remain in constant 
excess throughout the normal cell cycle, and regulation of catalytic activity is 
primarily post-translational. 
 
Kinase activity of all Cdks requires the binding of a positive regulatory cyclin 
subunit. Homology among cyclins is often limited to a region of about 100 amino 
acids, which adopts a conserved structural domain called the cyclin-box fold, and this 
region is required for Cdk binding and activation. Each phase of the cell cycle is 
characterized by the expression of distinct type of cyclins, and fluctuations in cyclin 
levels represent the primary mechanism by which Cdk activity is regulated. Cyclins 
are thought to contain regions that target the Cdk to specific substrates or subcellular 
localizations. In addition to simply activating the associated Cdk, they can thus 
promote activity towards specific substrates (Hoffmann et al., 1993; Peeper et al., 
1993; Dynlacht et al., 1994). The enhanced activity of certain complexes is probably 
due to positive interactions between the cyclin and the substrate. 
 
The assembly of a Cdk with its corresponding cyclin yields only a partially 
active complex, full activity being achieved only after phosphorylation of the Cdk on 
a conserved threonine residue proximal to the ATP-binding cleft (Kaldis, 1999). 
Cyclin-Cdk binding precedes the activating phosphorylation on the threonine residue 
located at the T-loop, a region of amino-acids that blocks access of ATP to the 
catalytic domain. The crystal structure of the human Cdk2 apoenzyme shows that it is 
held in an inactive state by at least two major structural restraints (De Bondt et al., 
1993; Morgan and De Bondt, 1994). Firstly, the substrate binding site is blocked by 
an extended loop termed the T loop. Secondly, side chains in the ATP-binding site are 
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oriented so that the ATP phosphates are poorly positioned for efficient phosphate 
group transfer. Analysis of the crystal structure of cyclin A/Cdk2 complexes indicates 
the cyclin/Cdk interaction causes a conformational change in the Cdk, making the T-
loop more accessible for the activation phosphorylation (Russo et al., 1996; Jeffrey et 
al., 1995). The phosphorylation causes a further conformational change in the T-loop, 
making the catalytic cleft fully accessible to ATP. In addition to stimulating kinase 
activity, the activating threonine phosphorylation has also been suggested to enhance 
the stability of some cyclin/Cdk complexes (Ducommun et al., 1991; Desai et al., 
1995). 
 
In mammals, Cdk-cyclin complexes can be inhibited by phosphorylation at 
two sites near the amino terminus. Phosphorylation of Cdk1 (Cdc2) and Cdk2 at 
Thr14 and Tyr15 by the dual-specificity kinases Wee1, Myt1 and Mik1 inhibits their 
activities (Mueller et al., 1995b; Mueller et al., 1995a; Watanabe et al., 1995), and 
this is particularly important in the control of Cdc2 activation during mitosis. Thr14 
and Tyr15 are both dephosphorylated by a dual-specificity phosphatase termed Cdc25 
whose activity is enhanced during mitosis. Another mechanism for Cdk regulation 
involves a diverse family of proteins termed the CKIs. Most CKIs bind tightly to 
Thr160/161-phosphorylated Cdk-cyclin complexes (Thr160 of Cdk2 and Thr161 of 
Cdk1) and directly inhibit kinase activity. 
 
 Though most known Cdks are involved in cell cycle control, this definition of 
Cdks does not limit their biological function (Morgan, 1995). The classical Cdks are 
also involved in regulating numerous neuronal processes such as differentiation, 
senescence, and apoptosis through modification of gene transcription (Tannoch et al., 
 21
2000). In proliferating cells, aberrations in the regulation of Cdks is associated with 
tumor formation, whereas their disappearance/inhibition in precursor of neuronal cells 
coincides with terminal differentiation (Okano et al., 1993). 
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1.3  Neuronal Cdk5 kinase  
 
Since its discovery in the early 1990s, Cdk5 has emerged to be an important 
regulator of neuronal migration in the developing central nervous system (CNS) 
(Dhavan and Tsai, 2001). Cdk5 was initially identified independently by virtue of its 
close sequence homology to human Cdk1, by biochemical purification from bovine 
brain based on its proline-directed Ser/Thr kinase activity and by affinity isolation as 
a cyclin D1-associated protein in fibroblasts (Meyerson et al., 1992; Lew et al., 
1992a; Xiong et al., 1992). Cdk5 is an atypical member of the Cdk family. Despite its 
close sequence homology with Cdk1, it is not activated by any known cyclins, 
although it can bind cyclin D1 and cyclin E (Xiong et al., 1992; Miyajima et al., 
1995) . The first known activators of Cdk5 are p35 (Fig. 2) and its proteolytic product 
p25, which were isolated as a binding partner of Cdk5 in the brain extract (Lew et al., 
1994). p25 is a 208 residues peptide derived from carboxyl terminal of p35 and it 
retains the Cdk5-binding and activating domain of p35 (Zheng et al., 1998; Qi et al., 
1995). Another activator of Cdk5, p39, was identified by its sequence homology to 
p35, with which it shares 57% amino acid identity (Tang et al., 1995; Humbert et al., 
2000a). Monomeric Cdk5 does not display any enzymatic activity. The binding to 
p35, p25 or p39 activates its kinase activity in the absence of any Cdk5 modification 
and association of any other protein factors (Lew et al., 1994; Tsai et al., 1994; 
Ishiguro et al., 1994). Though Cdk5 is a ubiquitously expressed protein, its kinase 
activity is restricted to the nervous system by the neuron-specific expression of its 
activators p35 and p39 (Ko et al., 2001). Interestingly, several groups have since 
demonstrated the presence of active Cdk5 in many non-neuronal tissues (Dhavan and 
Tsai, 2001). 
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 FIG. 2. Schematic diagram depicting motifs of p35. Within the human p35 sequence, there is an N-
terminal myristoylation site (Gly-2). This is followed by a calpain cleavage site, which cleaves p35 into 
p25 as well as an N-terminus polypeptide (p10). A short proline-rich sequence, with no reported 
function, follows the calpain cleavage site. The C-terminus of p35 constitutes the Cdk5-binding and 
activation domain, which is present in both p35 and p25. 
 
Although Cdk5 is a member of the Cdk family, it is not involved in cell cycle 
regulation. Since its discovery more than a decade ago, Cdk5 has been shown to play 
an important role in many cellular processes occurring within neurons in the CNS 
(Homayouni and Curran, 2000). For example, Cdk5 is known to participate in the 
regulation of cytoskeleton organization, axon guidance, membrane transport, synaptic 
function, dopamine signaling and drug addiction (Dhavan and Tsai, 2001). Gene 
targeting experiments have demonstrated an essential role for Cdk5 in the cellular 
organization of the CNS. Mice that are deficient of Cdk5 die just before or after birth, 
and show widespread disruptions in the neuronal layering of many brain structures 
(Ohshima et al., 1996; Gilmore et al., 1998; Ohshima et al., 1999). The lethality of 
the Cdk5-deficient mice is likely to be a result of defects in the nervous system, since 
it can be completely rescued by expressing the Cdk5 transgene under the p35 
promoter (Tanaka et al., 2001). Contrary to Cdk5-deficient mice, p35-/- mice are 
viable and fertile, though they have increased susceptibility to seizures (Chae et al., 
1997; Kwon and Tsai, 1998). p35-deficient mice show an inverted layering of cortical 
neurons comparable to that observed in the Cdk5-/- mice, but have only mild 
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disruptions in the hippocampus and have a fairly normal cerebellum. p39/p35 double 
knockout display the same phenotype as Cdk5-/- mice, further establishing these 
proteins as the primary activators of Cdk5 (Ko et al., 2001). The viability of the 
p35/p39-/- mice may dictate that p35/p39 may perform other cellular functions that are 
independent of its activation of Cdk5. 
 
Cdk5, p35 and p39 are abundantly expressed in adult brains and high levels of 
Cdk5 kinase activity are detected in post-mitotic neurons of the nervous system in 
accordance with the expression pattern of p35 and p39. As early as E10, a restricted 
expression of p35 in developing CNS of mouse embryos had been observed by in-situ 
hybridization. Expression studies of E12 and E15 mouse brains revealed that there is 
no p35 in proliferating neuronal precursors but that it is expressed in post-mitotic 
neurons of the developing cortex (Delalle et al., 1997; Ino et al., 1994; Tsai et al., 
1993). As neurons differentiate, cell cycle Cdks are down-regulated while the Cdk5 
activity is increased (Zheng et al., 1998). p35 is highly expressed in the post-mitotic 
neurons of developing cortex but is not found in proliferating neuronal precursors. On 
the other hand, the highest level of p39 expression in the CNS occurs postnatally. 
Apparently, p35 and p39 display an overlapping, but distinct temporal and spatial 
pattern of their expression in the brain (Delalle et al., 1997). Thus, Cdk5-p39 may 
arbitrate functions distinct from those involving Cdk5-p35 during neurodevelopment. 
 
Cdk5 plays an indispensable role in the central nervous system. Recently, the 
crystal structure of Cdk5-p25 has been reported (Tarricone et al., 2001). p25 binds 
Cdk5 in the region of the PSSALRE helix in the kinase small lobe and there are also 
extensive contacts between p25 and the activation loop (T-loop) of the kinase. Despite 
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its partial structural similarity with the cyclins, p25 displays an unprecedented 
mechanism for the regulation of a cyclin-dependent kinase. p25 tethers the 
unphosphorylated T-loop of Cdk5 in the active conformation. Biochemical data 
showed that Ile 153 and Ser 159 (equivalent to Thr 160 in Cdk2) in the T-loop of 
Cdk5 are critical for p35 interaction. Substitution of Ser159 to a threonine residue 
prevents p35 binding, while a substitution to an alanine residue affects neither binding 
nor kinase activity. Cdk5 is a proline-directed kinase where it has a strong preference 
for positively charged residues in the +3 position. For Cdk2-cyclin A, the 
phosphorylation of Thr160 is essential to encode this specificity. Biochemical and 
structural studies showed that Glu240 in p35 plays an inevitable role in the 
recognition of the basic residue in the +3 position, indicating that p35 directly 
participates in substrate recognition (Tarricone et al., 2001). 
 
It has been shown that cellular Cdk5 exists in three forms: free monomeric 
Cdk5, a heterodimeric complex of Cdk5-p25, and multi-protein complexes of Cdk5-
p35 (Lee et al., 1996a; Rosales et al., 2000). As revealed by protein fractionation, 
Cdk5-p35 exists as large molecular complexes of more than 670 kDa in brain extracts. 
Accumulating evidence implies that Cdk5-p35 is a multifunctional enzyme that exists 
in many cellular protein complexes. Consistently, an increasing number of proteins 
have been reported to associate with Cdk5-p35, providing important clues on the 
physiological function of Cdk5 as discussed below. 
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1.3.1 Regulation of Cdk5 
 
The association with a cyclin is essential in activating Cdks. However, Cdk5 
activity has not been found to associate with any cyclin. Instead, p35 and p39 were 
found to be the two specific activators of Cdk5. Although p35 and p39 have little 
sequence similarity to any cyclin, studies by computer modeling and mutagenesis 
suggested that p35 might adopt a cyclin-like tertiary structure (Tang et al., 1997; 
Chou et al., 1999; Lim et al., 2001). Recently, these predictions were further 
established by the crystallization of a Cdk5-p25 complex (Tarricone et al., 2001). 
 
Members of the Cdk family are also regulated by at least three distinct 
phosphorylation/dephosphorylation events (Fig. 3). Phosphorylation of Cdk1 and 
Cdk2 at Thr14 and Tyr15 by the dual-specificity kinases Wee1, Myt1 and Mik1 
inhibits their activities (Mueller et al., 1995b; Mueller et al., 1995a; Watanabe et al., 
1995). In contrast, phosphorylation of Thr160 in the T-loop of Cdk2 (or Thr161 of 
Cdk1) by the Cdk-activating kinase (CAK) is necessary for its maximal activation 
(Gu et al., 1992). Although Thr14 and Tyr15 are conserved and Thr160 in Cdk2 is 
conservatively substituted with Ser159 in Cdk5 and their surrounding sequences are 
highly homologous to those of the authentic Cdks, Cdk5 appears to adopt regulatory 
mechanisms distinct from those of the classical Cdks at these three phosphorylation 
sites. The Thr14 and Tyr15 sites in Cdk5 are not phosphorylated by Wee1 in vitro 
(Poon et al., 1997). Moreover, Tyr15 of Cdk5 can be phosphorylated by a cytosolic 
tyrosine kinase c-Abl, and such phosphorylation is facilitated by the association of 
Cdk5 with Cables, an Abl-binding protein. Surprisingly, the phosphorylation of Cdk5 
at Tyr15 is stimulatory and enhances Cdk5 kinase activity (Zukerberg et al., 2000). In 
addition to c-Abl, Fyn, which is a member of the Src family of tyrosine kinases, is the 
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other enzyme observed to catalyze the stimulatory Tyr15-phosphorylation of Cdk5 
(Sasaki et al., 2002). Cdk5 phosphorylation by Fyn is necessary for semaphorin-3A-
induced neuronal growth cone collapse (Sasaki et al., 2002). Lastly, the 
phosphorylation of Cdk5 at Ser159, which occupies a position equivalent to the 
Thr160 site in the conserved T-loop of Cdk2 (Thr161 of Cdk1), not only is 
dispensable for but also dampens the activation of Cdk5 (Tarricone et al., 2001). The 
crystal structure of Cdk5-p25 revealed that the interaction between the regulatory 
subunit alone is sufficient to stretch the activation loop of unphosphorylated Cdk5 
into a fully extended active conformation, analogous with the phosphorylated Cdk2-
cyclin A complex (Tarricone et al., 2001). 
 
Another mode of Cdk regulation involves a diverse family of inhibitory 
proteins (CKIs) that bind Cdks or Cdk-cyclin complexes to inhibit the Cdk activity 
(Li and Blow, 2001). The initial evidence of the existence of Cdk5 inhibitors comes 
from the biochemical separation of Cdk5 complexes in brain extracts. The Cdk5-p35 
macromolecular complexes are neither enzymatically active nor activable by the 
addition of a truncated form of p35 (Lee et al., 1996a). Furthermore, the kinase 
activity was recovered when the Cdk5-p35 complexes was further fractionated by 
size-exclusion chromatography in the presence of 10% ethylene glycol, suggesting 
that an inhibitor(s) could be dissociated from the complexes under this stringent 
condition. Interestingly, Cdk5 is not regulated by any of the known CKIs, such as 
members of the INK and CIP/KIP families of inhibitors (Lee et al., 1996b), 
confirming the distinct structural and regulatory properties of Cdk5-p35 in the 
macromolecular complexes. A few protein candidates have been reported to be 
endogenous inhibitors of Cdk5. C42, which is a p35-binding protein, has been shown 
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to specifically inhibit the activation of Cdk5 by p35 (Ching et al., 2002). The 
inhibitory domain of C42 was mapped to a region of 135 amino acids, which is 
conserved in Pho81, a yeast protein that inhibits the yeast cyclin-dependent protein 
kinase Pho85 (yeast functional homologue of mammalian Cdk5) (Huang et al., 2001). 
DNA binding protein dbpA and ribosomal protein L34 are two other reported 
inhibitors of Cdk5 (Moorthamer et al., 1999; Moorthamer and Chaudhuri, 1999). 
They were identified in a yeast two-hybrid screen as Cdk5-binding proteins. In 
addition to the inhibitors, the nuclear protein SET was found to enhance Cdk5 activity 
upon its physical association with Cdk5-p35. The SET protein binds p35 in its N-
terminal region, which is lacking in p25, and therefore does not affect the activity of 
Cdk5-p25, suggesting specific modulation of the Cdk5-p35 activity in nucleus (Qu et 
al., 2002). 
 
FIG. 3. Regulation of Cdk5 and Cdk2 by phosphorylation. Phosphorylation of Thr160 on Cdk2 by 
Cdk-activating kinase (CAK) results in a 200-fold activation of the kinase. CAK does not 
phosphorylate Cdk5 on the equivalent Ser159. Structural analysis of the p25–Cdk5 complex indicates 
that phosphorylation on Ser159 would be inhibitory. The dual-specificity kinases Wee1 and Myt1 
phosphorylate Cdk2 on Thr14 and Tyr15, resulting in an inhibition of kinase activity. Neither of these 
kinases phosphorylates Cdk5. However, Tyr15 of Cdk5 is phosphorylated by c-Abl and Fyn, which 
stimulate its kinase activity. A kinase activity purified from bovine thymus can phosphorylate Thr14 on 
both Cdk5 and Cdk2, resulting in inhibition of activity. Green and red arrows represent stimulatory and 
inhibitory phosphorylation events, respectively.  
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1.3.2 Physiological roles of Cdk5 and its mediated functions 
 
Over the last decade, a number of proteins have been identified to act as direct 
substrates of Cdk5 (Table B), providing a good deal of knowledge on the biological 
roles of Cdk5 in brain. It appears that Cdk5 acts prominently in many essential 
cellular processes, including cytoskeletal dynamics, cell adhesion, axonal guidance, 
dopaminergic signaling and synaptic membrane functions. 
 
1.3.2.1 Cdk5 in cytoskeletal dynamics and microtubule-based transport 
A body of evidence has implicated an indispensable role of the Cdk5-p35 
kinase in axonal guidance, cell motility and neurite outgrowth. Overexpression of p35 
in cultured neurons induces the formation of longer neurites whereas inhibition of the 
Cdk5 activity or expression of a dominant negative form of the kinase prevents 
neurite outgrowth (Nikolic et al., 1996). Cdk5-p35 colocalizes with F-actin, Rac and 
p21-activated kinase (PAK1) in the periphery of growth cones. Since Cdk5-p35 
down-regulates PAK1 kinase activity by phosphorylating it at Thr212, it has therefore 
been proposed to have a role in regulating actin repolymerization and therefore 
growth cone dynamics (Rashid et al., 2001). 
 
Another group of Cdk5 substrates are the intermediate and heavy chains of 
neurofilament proteins (NFM and NFH, respectively). NFM and NFH contain many 
KSP (Lys-Ser-Pro) repeats in their long carboxyl terminal tails. Phosphorylation at the 
KSP sites occurs during the axonal transport of the neurofilaments and the 
phosphorylation is required in maintaining axonal morphology. Cdk5 was originally 
isolated from the brain as a neurofilament kinase to catalyze the KSP phosphorylation 
at the tail region of NFM and NFH (Lew et al., 1992b). Phosphorylation of these 
 30
domains by Cdk5 reduces its association with microtubules, as well as retarding the 
axonal transport of these proteins (Wada et al., 1998). In vitro, NFH phosphorylated 
by Cdk5 displayed the same electrophoretic motility shift as that of natively 
phosphorylated NFH (Grant et al., 2001). Moreover, p35 associates with NFM and 
NFH in a region adjacent to the KSP-rich domains, suggesting a role of p35 in 
docking Cdk5 to the substrates (Qi et al., 1998). 
 
It has been found that Cdk5 associates with microtubules and can be co-
purified with microtubules from bovine brain (Ishiguro et al., 1992; Sobue et al., 
2000). Several microtubule-associated proteins (MAPs), such as tau and MAP1B, are 
substrates of Cdk5. Phosphorylation of tau by Cdk5 abolishes the ability of tau to bind 
microtubules and therefore its ability to promote microtubule assembly (Wada et al., 
1998). In addition to the phosphorylation of the MAPs to mediate microtubule 
stability, Cdk5 has been implicated to play a role in regulating dynein-mediated 
axonal transport. Nudel is a cytoplasmic dynein-associated protein that is highly 
expressed in the brain. Cdk5 can phosphorylate Nudel in vitro and in vivo, and this is 
of importance since the introduction of a non-phosphorylatable mutant of Nudel into 
the cultured neurons led to axonal swelling, analogous to the disruption of dynein 
function in Drosophila neurons (Liu et al., 2000). 
 
1.3.2.2 Cdk5 in synapses and focal adhesion sites 
Cdk5, p35 and p39 are present in the subcellular fractions enriched for 
synaptic membrane and they are localized to the pre- and post-synaptic compartments 
(Humbert et al., 2000b; Niethammer et al., 2000), indicating that they may be 
involved in synaptic functions. Indeed, several synaptic proteins have been identified 
as Cdk5 substrates, including Munc 18, synapsin I and amphiphysin, which are 
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proteins implicated in synaptic vesicle exocytosis (Fig. 4) (Fletcher et al., 1999; 
Matsubara et al., 1996; Floyd et al., 2001). Phosphorylation of Munc 18 by Cdk5 
results in disassembly of the Munc 18-syntaxin I complex, implying a role for Cdk5 
in modulating neurosecretion (Shuang et al., 1998). Most recently, interesting 
findings by Tan and co-workers have established that Cdk5 has a role in synaptic 
vesicle endocytosis (Tan et al., 2003). Cdk5 phosphorylates dynamin I in vitro as well 
as in vivo at the nerve terminals of neuronal cells to facilitate synaptic endocytosis. 
Roscovitine, an antagonist of Cdk5 activity, blocks the rephosphorylation of dynamin 
I after repolarization of the synaptosomes. Furthermore, phosphorylation by Cdk5 
also increases the GTPase activity of dynamin I (Tan et al., 2003). Hence, Cdk5 may 
play a major role at synapses since multiple Cdk5 substrates are involved in the 
synaptic vesicle recycling. In a yeast two-hybrid screen, α-actinin 1 and the α-subunit 
of Ca2+/calmodulin-dependent protein kinase II (CaMKIIα) were identified as p35- 
and p39-interacting proteins (Dhavan et al., 2002). Either of these two proteins forms 
a complex with Cdk5 through the interaction with p35 or p39 and these interactions 
potentially localize Cdk5 to the post-synaptic density where it may play a role 
contributing to synaptic plasticity, memory and learning. 
 
N-cadherin is a member of the transmembrane molecules that promote cell 
adhesion by their calcium-dependent homophilic interactions. The cytoplasmic tail of 
cadherins interacts with α- and β-catenin to anchor the cadherins to the actin 
cytoskeleton. Cdk5-p35 is associated with β-catenin and controls the N-cadherin/β-
catenin-mediated cell adhesion through the phosphorylation of β-catenin (Kwon et al., 
2000; Kesavapany et al., 2001). Additionally, phosphorylation of β-catenin by Cdk5 
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has also been shown to affect its binding to presenilin, which is a pathological 
molecule of the Alzheimer’s disease (AD) (Kesavapany et al., 2001). 
 
FIG. 4. Cdk5 in neurotransmitter release and endocytosis at the presynaptic terminals. In the 
absence of Cdk5, Munc-18 binds syntaxin 1A, interfering the interaction between syntaxin 1A and v-
SNAREs, which is required for synaptic vesicle to gain competency for membrane fusion. Upon 
phosphorylation by Cdk5, Munc-18 is dissociated from syntaxin, allowing the syntaxin 1A/v-SNAREs 
interaction and leading to enhanced neurotransmitter release. In contrast, Cdk5 inhibits 
neurotransmitter release through phosphorylation of P/Q type voltage-dependent calcium channel 
(VDCC), resulting in the dissociation of VDCC from SNAREs, which attenuates the efficiency of 
neurotransmission. Cdk5 also phosphorylates synapsin I and amphiphysin1/dynamin1, which are 
potentially involved in neurotransmitter release and endocytosis, respectively, although the 
physiological significance remains to be determined. 
 
1.3.2.3 Cdk5 in neurosignaling 
Accumulating evidence suggests that Cdk5 is involved in many of the 
neuronal signal transduction pathways. DARPP-32 (dopamine- and cAMP-regulated 
phosphoprotein, Mr of 32 kDa) is a Cdk5 substrate that plays a key role in dopamine 
signaling occurring in the dopaminoceptive neurons. When DARPP-32 is 
phosphorylated by the cAMP-dependent protein kinase (PKA), it becomes a potent 
inhibitor of protein phosphatase 1 (PP1). It appears that the Cdk5 phosphorylation of 
DARPP-32 transforms it into an inhibitor of PKA, exerting an opposing effect on 
dopamine signaling (Bibb et al., 1999; Greengard et al., 1999). In the MAPK 
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(mitogen-activated protein kinase) and JNK (c-Jun N-terminal kinase) pathways, 
Cdk5 is associated with JNK-3 where it inhibits the JNK-3 activity by 
phosphorylating JNK-3 at Thr131 to mediate neuronal apoptosis (Li et al., 2002). 
Meanwhile, Cdk5 down-regulates the MAPK signaling by phosphorylating MEK1 
(MAPK kinase 1) at Thr286 and thereby inhibiting its activity (Sharma et al., 2002). 
In addition, Cdk5 has been shown to mediate the activities of the P/Q-type voltage-
dependent calcium channel and the N-methyl-D-aspartate (NMDA) class of glutamate 
receptors through a direct phosphorylation modification (Tomizawa et al., 2002; Li et 
al., 2001). 
 
1.3.2.4 Cdk5 in transcriptional machineries 
Recent studies have pointed to the localization of Cdk5-p35 in the nucleus 
where it may play a role in transcriptional regulation. In an early report, Cdk5 was 
found to bind and phosphorylate the retinoblastoma susceptibility gene product  (pRb) 
(Lee et al., 1997). p53 is a phosphorylation-regulated transcription factor that plays a 
pivotal role in cell cycle progression and cell death. Cdk5 is able to modulate the p53 
transcriptional activity through the direct phosphorylation of p53 as well as the 
elevation of p53 expression in the cells (Zhang et al., 2002b). More recently, myocyte 
enhancer factor 2 (MEF2) was identified as a Cdk5 substrate (Gong et al., 2003). 
Members of the MEF2 family are transcription factors that play critical roles in 
diverse cellular processes including neuronal survival. Phosphorylation of MEF2 by 
Cdk5 results in the inhibition of the MEF2 transactivation activity, while MEF2 
mutants that are resistant to the Cdk5 phosphorylation rescue neurons from 
neurotoxin/Cdk5-induced apoptosis, suggesting MEF2 phosphorylation by Cdk5 as a 
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part of the molecular mechanism by which neurotoxin/Cdk5 mediates apoptosis 
(Gong et al., 2003). 
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1.3.3 Molecular organization of Cdk5 complexes 
 
A body of evidence has suggested that Cdk5-p35 kinase shows high affinity 
binding to specific cellular proteins. To date, there are about 30 or more proteins with 
diverse functions that have been identified to associate with Cdk5-p35 or Cdk5-p39 
(Table A). Cdk5 itself appears to bind directly with a smaller subset of these proteins, 
which include Cables, tau, PP1, dbpA and ribosomal protein L34. Many of the other 
proteins interact with Cdk5 via p35 or p39, suggesting that p35 and p39 are not only 
acting as the activators of Cdk5 but are also important mediators of the Cdk5 
function. In addition, a number of proteins have been established to be substrates of 
Cdk5 (Table B). Identification of these substrates, as well as the Cdk5/p35- and 
Cdk5/p39-associated proteins, has revealed numerous important functional and 
regulatory properties of Cdk5. 
 
By immunocytochemistry and cellular fractionation analysis, Cdk5 and p35 
proteins were detected throughout the cells with a much lower level in the nucleus 
(Qu et al., 2002). p35 is enriched in the membrane fraction and the association of 
Cdk5-p35 with the plasma membrane is directed by the myristoyl moiety linked to the 
N-terminal glycine of p35 (Patrick et al., 1999; Patzke and Tsai, 2002). Moreover, 
Cdk5-p35 extracted from a membrane preparation of rat brains exhibited the 
biochemical property of large molecular complexes (R. Gao and R.Z. Qi, unpublished 
observation). Conceivably, the membrane localization is important for Cdk5 to exert 
many of its physiological effects and some of its substrates are likely to be membrane-
integral or membrane-associated proteins. Additionally, an active Cdk5-p35 kinase 
has been shown to be present in Golgi membranes, where it associates with a 
detergent-insoluble fraction that contains actin (Paglini et al., 2001). Suppression of 
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the Cdk5 activity blocks the formation of membrane vesicles from the Golgi 
apparatus, possibly suggesting a role for Cdk5-p35 in membrane trafficking. Further, 
Cdk5-p35 may be involved in the reorganization of actin in the growth cone and on 
the Golgi membrane during neurite outgrowth. 
 
Under certain conditions, p35 is converted to p25 by a proteolytic cleavage, 
resulting in the truncation of the smaller N-terminal fragment of p35, commonly 
known as p10 (Kusakawa et al., 2000; Lee et al., 2000). The transformation of p35 to 
p25 appears to exclude it from most of the components of the Cdk5-p35 
macromolecular complexes, implying that the p10 region of p35 might be required for 
interaction with other proteins. Indeed, deletion analyses have provided proof of 
specific and direct interaction between p10 and at least one p35-interacting protein 
(Qu et al., 2002). Another region of 26 amino acids spanning residues 145 to 170 of 
p35 has also been identified to contain the binding site for a few of the identified p35-
binding proteins (Wang et al., 2000; Cheng et al., 2002). This short stretch is 
proximal to the N-terminal boundary of the Cdk5-binding and activating domain in 
p35, and contains an amphipathic α-helix (Chin et al., 1999). Further evidence from 
the interaction studies indicates that the hydrophilic face of the helix is involved in the 
interaction with the binding proteins while the hydrophobic face is involved in the 
association with Cdk5 (Wang et al., 2000). This unique feature of the p35 structure 
may be necessary to support a number of other functions when bound to its interacting 
proteins, in addition to kinase activation. 
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1.3.3.1 Methods used in isolating protein-interacting partners 
 
Various methods have been described in an increasing number of reports over 
the last few years to uncover the protein components of Cdk5 macromolecular 
complexes in the brain. Using the yeast two-hybrid system, a number of proteins have 
been found by screening mammalian brain libraries that specifically interact with 
Cdk5, p35, or p39 (Dhavan et al., 2002; Ching et al., 2000; Moorthamer and 
Chaudhuri, 1999). The yeast two-hybrid interaction screen is a sensitive method with 
which transient or weak interactions can be detected. However, it is not ideal for the 
screening of membrane-associated proteins, and proteins which are not able to 
translocate into the nucleus. Moreover, the usage of this method is also limited to the 
detection of dimeric protein complexes and, therefore, is not particularly effective for 
identifying multimolecular complexes. Further, some interactions may require certain 
post-translational modifications of their protein partners. However, such 
modifications may not occur in yeast. 
 
Another major method to identify protein-protein interactions at a high 
throughput and at a proteome-wide scale is the biochemical isolation of protein 
complexes from animal tissues or cultured cells (Ho et al., 2002; Gavin et al., 2002). 
In several laboratories, biochemical isolation of Cdk5 and p35-associated proteins 
was conducted using affinity chromatography media prepared by coupling antibodies 
recognizing Cdk5 or p35 or by coupling recombinant proteins derived from Cdk5 and 
p35 to agarose beads (Qu et al., 2002). The identity of isolated interacting proteins 
from rat brain extracts was established using mass spectrometry. An advantage of this 
method is the ability to isolate protein complexes and interacting proteins in their 
native states. It is particularly useful in identifying indirectly interacting proteins, 
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since multiprotein complexes can be isolated at ease. However, it is less favorable 
with proteins having weak or transient interactions. Therefore, this approach would be 
a good complement to the yeast two-hybrid interaction screen. 
 
Another favored procedure of isolating components of a multiprotein complex 
is the use of combinatory chromatography procedures (Luo and Roeder, 1995; 
Rosales et al., 2000). In general, total lysate, prepared from cultured cells or tissue in 
a preferred buffered system, is subjected to differential chromatography procedures 
where the elution profile of the protein of interest (bait protein) is followed commonly 
by its immunoreactivity. Fractions from a previous chromatography separation were 
pooled, dialyzed and enriched before subjected to a subsequent chromatography 
procedure. Samples of near homogeneity were then analyzed by SDS-PAGE and 
subsequently isolated protein bands were identified by protein analysis 
methodologies. Likewise, this protocol allows the isolation of interacting partners in a 
native state where indirect interacting molecules of a protein complex can be 






1.4 Microtubule Dynamics  
 
Microtubules, together with actins and intermediate filaments, are the key 
components of the eukaryotic cytoskeleton. Microtubule is an essential component of 
the cellular cytoskeleton providing mechanical support for the shape maintenance of 
cell and serves as tracks along which motor proteins move organelles and transport 
vesicles from one part of the cell to another. Microtubules are long, filamentous, tube-
shaped protein polymers that are crucial in the development and maintenance of cell 
shape, in the transport of vesicles, mitochondria and other components throughout 
cells, in cell signaling and in cell division and mitosis. To perform these functions, a 
cell must control the assembly and orientation of its microtubule cytoskeleton. 
Microtubule arrays in cells are generally dynamic, capable of assembly, disassembly 
and rearrangement on a time scale of seconds to minutes. Microtubule dynamics in 
vivo are based on intrinsic dynamic properties of the polymers themselves, being 
determined by biochemical properties of the microtubule building block, the tubulin 
αβ heterodimer. Tubulin is able to interact with a bewildering number of proteins and 
small molecules such as nucleotides and drugs. Furthermore, tubulin is a GTPase. 
GTP hydrolysis during tubulin assembly is apparently a phenomenon of central 
importance for microtubule physiology. 
 
Tubulins are ubiquitously expressed in eukaryotes. α- and β-tubulin 
monomers are proteins of about 450 amino acids each and are about 50% identical at 
the amino acid level (Wade and Hyman, 1997). Each monomer has a Mr of about 50 
kDa and binds a GTP molecule that is non-exchangeable in α-tubulin and 
exchangeable in β-tubulin. GTP from β-tubulin is required for microtubule assembly 
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and its hydrolysis follows addition of a dimer to the microtubule end, upon which it 
becomes non-exchangeable within the microtubule. The structure of the tubulin dimer 
has been solved by electron crystallography of the two-dimensional, crystalline sheets 
of tubulin that form in the presence of zinc ions (Nogales et al., 1998). This atomic 
model of tubulin provides structural information and gives a picture of the properties 
of tubulin and microtubules at the molecular level (Nogales et al., 1999). 
 
The organization of α- and β-tubulin heterodimers in the microtubule lattice is 
polarized, and this feature results in structural and kinetic differences at the 
microtubule ends. The faster growing end (named the plus end) has the β-tubulin 
subunit of each heterodimer exposed, whereas the slower growing end (named the 
minus end) has the α-tubulin subunit exposed. In vivo, the minus end of the 
microtubule is associated with the centrosome. It is localized near the center of the 
cell, whereas the plus end is peripheral. Once assembled, tubulin addition to and loss 
from the existing microtubules occurs only at the microtubule ends. 
 
In vitro, the aggregation of purified tubulin to form microtubules can be 
induced in a variety of conditions. Two factors play an important role. First, 
microtubules do not form at low temperatures. Therefore, tubulin aggregation is 
generally induced by warming up tubulin solutions to 30-37°C. Secondly, tubulin is 
incorporated into microtubules as a complex with GTP. Following warming and GTP 
addition to the soluble tubulin dimers, tubulin assembly proceeds and one of the 
widely used methods used to follow microtubule assembly has been the turbidity 
measurements. Microtubule suspensions are turbid and cause an apparent increase in 
absorption at 340-350 nm. This property is used to measure the total mass of 
 41
assembled microtubules and gives information about the behavior of the whole 
microtubule population (Fig. 5). 
 
 
FIG. 5. Microtubule assembly. Various phases of microtubule assembly as seen in turbidmetry. 
Modified from (Valiron et al., 2001). 
 
As measured by turbidity, the first phase of assembly is usually referred to as 
the nucleation phase. During this phase, poorly defined microtubule seeds are formed. 
Microtubule seeds do not convert into microtubules below a tubulin threshold 
concentration defined as critical concentration, which essentially depends on 
experimental conditions. This critical concentration depends on experimental 
assembly conditions. The second phase is that of elongation where tubulin dimers are 
added at the end of microtubule. During this phase, tubulin dimers add at the end of 
microtubule. The third phase of assembly is that of steady-state. Analysis of steady-
state microtubules has demonstrated that a fixed proportion of tubulin is in the 
assembled forms whereas another tubulin pool remains soluble. The concentration of 
free tubulin dimers at steady state varies with buffer conditions and corresponds to the 
so-called tubulin critical concentration for microtubule assembly. Tubulin assembly 
has two main features: the microtubules formed are intrinsically labile and, at steady 
state, the microtubule system remains out of equilibrium. Microtubules are readily 
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disassembled by temperature drop below 10-15°C, removal of GTP or dilution of 
microtubule suspensions and subsequent decrease of the free tubulin concentration. 
Microtubule disassembly can also be triggered by adding specific drugs to a 
microtubule solution such as colchicine, vinblastine or nocodazole. Drugs like 
colchicine and vinblastine poison tubulin assembly onto microtubule ends and thereby 
induce microtubule disassembly. Nocodazole acts by sequestering tubulin dimers, 
with which it forms an inactive complex. Hence, the free tubulin concentration 
decreases, and when it drops below the critical concentration, microtubules 
disassemble. 
 
At steady state, microtubules remain out of equilibrium. Continuous GTP 
hydrolysis and thereby energy consumption is required for the maintenance of steady-
state microtubules, which apparently use energy to generate active exchanges between 
their constitutive subunits and the tubulin molecules of the soluble pool. Two 
mechanisms are thought to account for such tubulin exchanges. The first has been 
known treadmilling. Treadmilling relies on a particular property of microtubules: at 
steady state, microtubule ends behave differently (Margolis and Wilson, 1978). The 
plus end continuously incorporates new tubulin dimers, whereas the minus end 
continuously looses them. When microtubule ends are not anchored at a fixed 
position, treadmilling results in an apparent microtubule migration that actually 
reflects the propagation of a wave of tubulin assembly-disassembly. When 
microtubule ends are kept stationary, treadmilling generates an apparent flux through 
the polymers of tubulin molecules traveling from the plus ends towards the minus 
ends (Margolis and Wilson, 1981). The second mechanism through which steady state 
microtubules exchange their constitutive tubulin with soluble tubulin relies on another 
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property known as dynamic instability (Mitchison and Kirschner, 1984). In this 
model, although a population of microtubules exhibits a bulk steady state, an 
individual microtubule never reaches an equilibrium length but persists in prolonged 
phases of assembly and rapid phases of disassembly that interconvert frequently. 
Transit from slow assembly to fast disassembly is referred to as ‘catastrophe’ and 
transition from disassembly to assembly as ‘rescue’. Moreover, microtubules 
sometimes pause for a period of time, during which their length remains constant 
(Walker et al., 1988). 
 
Microtubule dynamics in vivo share fundamental features with microtubule 
dynamics in vitro. Cellular microtubules are highly dynamic, and both dynamic 
instability and treadmilling have been observed in vivo. Cellular microtubules exhibit 
a more rapid assembly rate and higher transition frequencies than in vitro 
microtubules formed from pure tubulin (Cassimeris, 1993). In addition, microtubule 
dynamics in vivo are regulated by many MAPs, and these are usually classified into 
two main groups: proteins that stabilize microtubules and proteins that destabilize 
microtubules (Desai and Mitchison, 1997; Mandelkow and Mandelkow, 1995). The 
former includes several mammalian MAPs that promote tubulin assembly and 
stabilize microtubules once they are formed (often referred as structural MAPs), 
although they do not prevent disassembly (Hirokawa, 1994). Members of this family 
include the neuronal proteins tau and MAP2, which are localized to the axon and the 
dendrites, respectively, and MAP4, which is present in all non-neuronal vertebrate 
cells. In all three proteins, the microtubule binding domain is contained within the C-
terminus, where the N-terminus domain protrudes from the microtubule surface. The 
effect of MAPs on microtubule stability often depends on phosphorylation, and all 
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structural MAPs have been shown to be in vitro substrates for several protein kinases. 
For instance, microtubule-affinity-regulating kinases have been described as 
mammalian serine/threonine kinases that phosphorylate the tubulin binding domain of 
MAPs, cause their detachment from microtubules and therefore increase microtubule 
dynamics (Drewes et al., 1998). 
 
On the other hand, gene targeting experiments have been used to establish that 
these structural MAPs are necessary for the proper development of the nervous 
system (Harada et al., 2002; Teng et al., 2001; Takei et al., 2000; Takei et al., 1997; 
Harada et al., 1994). For instance, MAP1B-/- mice showed a slightly decreased brain 
weight and a delay in the development of the nervous system. Hence, MAP1B is not 
essential for survival, but it is essential for the normal time course of brain 
development (Takei et al., 1997). 
 
More recently, another group of microtubule-associated proteins that is able of 
inducing much higher microtubule stability has been described and these proteins 
include Lis1 and doublecortin, BPAG1 and STOP proteins. Lis1 is a subunit of the 
platelet-activating factor acetylhydrolase, and in vitro experiments showed that the 
protein interacts with tubulin and microtubules. It reduces microtubule catastrophe 
events, and this leads to an increase in the maximum length of the microtubules (Sapir 
et al., 1997). Doublecortin associates directly with microtubules in vitro and in vivo 
and stabilizes them. Its sequence does not contain any known microtubule binding 
domain, suggesting that it defines a new microtubule-binding structure (Horesh et al., 
1999). In transfected cells, BPAG1 binds and stabilizes microtubules, which become 
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2 Materials and Methods 
2.1 Materials  
2.1.1 Chemicals and reagents   
 
Colchicine, PMSF, nerve growth factor (NGF), common chemicals and 
reagents were purchased from Sigma Chemical Co (St. Louis, MO). Roscovitine was 
purchased from Calbiochem (La Jolla, CA), while Complete™ protease inhibitor 
cocktail was from Roche Molecular Biochemicals (Mannheim, Germany). Cell 
culture reagents as well as IPTG were purchased from Invitrogen (Carlsbad, CA), 
while restriction enzymes were from New England Biolabs (Beverly, MA). The one-
step RT-PCR kit was purchased from Qiagen GmbH (Hilden, Germany) while 
PfuTurbo® DNA polymerase was from Stratagene (La Jolla, CA). Protein A 
sepharose fast flow and Glutathione sepharose 4B (GSH-sepharose) were purchased 
from Amersham Pharmacia Biotech (Uppsala, Sweden), while nickel-NTA beads 
were from Qiagen (Hilden, Germany).  The enhanced chemiluminescence (ECL) kit 
was purchased from Pierce (Rockford, IL). Purified tubulin (>99% pure and MAP-
free), rhodamine-labeled tubulin and the microtubule-associated protein spin-down kit 
were purchased from Cytoskeleton Inc (Denver, CO). siRNA duplexes used were 
synthesized by Dharmacon Inc. (Lafayette, CO). CK2 holoenzyme protein was from 
New England Biolabs, while CK2α and CK2β were purchased from Calbiochem. 
EffecteneTM transfection reagent was purchased from Qiagen GmbH, Lipofectamine 
reagent from Invitrogen and TransIT-TKO reagent was from Mirus (Madison, WI). 
Nitrocellulose and PVDF membranes were from Amersham Pharmacia Biotech and 
Millipore, respectively. [γ-32P] dATP was purchased from Amersham Pharmacia 
Biotech. The vectors, pSG5 containing chicken CK2α (pSG5-CK2α) and 
CK2αK68A (pSG5-CK2αK68A) cDNA used for transient transfection were kindly 
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provided by Claude Cochet (Leroy et al., 1997). Tau protein expression vector was 
from Michel Goedert (Goedert et al., 1995). 
 
2.1.2 Cell lines 
 
To reduce the danger of contamination, all works were carried out under 
sterile conditions in a laminar flow hood. Work area surfaces were readily cleaned 
and all the items used in cell culture were purchased as sterile, disposable items. The 
cell lines used in this study include COS-7 monkey kidney cells, HeLa human 
cervical carcinomas cells, 293T human kidney epithelial cells, PC-12 rat 
pheochromocytoma cells and SH-SY5Y neuroblastoma cells. COS-7, HeLa, 293T and 
SH-SY5Y cells were maintained in DME low glucose (1000 mg/l) medium 
supplemented with 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin 
and 100 mg /ml streptomycin. PC-12 cells were maintained in DME high glucose 
(4500 mg/l) medium supplemented with 10% horse serum, 5% FCS, 1% L-glutamine, 
100 U/ml penicillin and 100 mg /ml streptomycin. All cells were kept at 37°C under a 
partial CO2 pressure of 5%. Passaging, thawing and freezing of cells were performed 
using standard protocols (Freshney, 1992). PC-12 cells were induced with 100ng/ml 




Monoclonal antibodies against α- and β−tubulin were purchased from Sigma 
Chemical Co (St. Louis, MO). The following polyclonal antibodies: anti-p35 (C19 
and N20), anti-Cdk5 (C8), anti-CK2α (C18 and H-286), anti-CK2β (C19), anti-β-
tubulin (H-235), anti-actin (I-19) and anti-c-Myc; and monoclonal antibodies: anti-
Cdk5 (DC17), anti-CK2α, anti-CK2β and anti-GST were purchased from Santa Cruz 
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Biotech (Santa Cruz, CA). CK2α and CK2β monoclonal antibodies were also 
purchased from Transduction Laboratories (Lexington, KY). Polyclonal antiserum 
against CK2α was purchased from Calbiochem. The immobilized c-Myc monoclonal 
antibody was purchased from Convance Inc (Princeton, NJ). Monoclonal anti-HA 
antibody was from Cell Signaling Technology (Beverly, MA), while anti-c-Myc and 
anti-His monoclonal antisera were purchased from Clontech (Palo Alto, CA). Anti-V5 
monoclonal antibody was purchased from Invitrogen. The secondary antibodies are 
Fluor594/Fluor488 conjugated goat anti-mouse IgG, Fluor594/Fluor488 conjugated 
anti-rabbit IgG and Fluor488 conjugated donkey anti-goat IgG from Molecular Probes 
(Eugene, OR).  Secondary HRP-conjugated anti-IgG antibodies for immunoblotting 




2.2 Experiment Procedures 
2.2.1 Plasmid constructions 
 
Various fragments of p35 were engineered by PCR into the vectors pGEX2T 
or pGEX4T (Amersham-Pharmacia) for preparation of GST fusion proteins. They are 
p10 (residues 1-98 of p35), p16 (residues 1-149 of p35), p35 (53-149) and p35 (150-
307). The constructs of GST-Cdk5 and GST-p25, which includes residues 99-307 of 
p35, have been reported previously (Qi et al., 1995). The coding sequence of Cdk5 
was cloned by PCR into the pET32a vector for the expression of His-Cdk5 protein. 
The expression construct of p35-His was generated by insertion of a PCR sequence of 
p35 into pQE12 (Qiagen). The resulting plasmid, p35/pQE12, allows expression of 
p35 with a C-terminal His-tag. DNA fragment encoding p35-His was restricted from 
the pQE12 construct and inserted into pGEX2T vector for expression of GST-p35-His 
recombinant protein. Cdk5 and p35 were also engineered into pcDNA3.1 (Invitrogen) 
and pCI-neo (Promega) for protein expression in mammalian cells. 
 
The coding sequences of chicken CK2α and its kinase-inactive mutant 
(CK2αK68A) were subcloned into pGEX4T, pET32a (Novagen) and pDneo-myc 
(Tang et al., 2001). The full-length sequence of human CK2β was cloned by RT-PCR 
and inserted into pQE30 (Qiagen). CK2α/CK2αK68A and CK2β were engineered by 
PCR into the bicistronic vector pBudCE4.1 (Invitrogen). All clones were verified 
after sequencing entirely in both directions and propagated in Escherichia coli strain 
XL1-blue or DH5α. All plasmids were purified using miniprep or midiprep kit 
(QIAGEN) for subsequent use in transfection experiments. 
 
2.2.2 Recombinant protein preparation 
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The GST fusion proteins were prepared as described previously (Qi et al., 1995). 
Briefly, GST-tagged proteins were individually expressed in E. coli BL21 (DE3). The 
host cells were cultured in 1 liter of LB medium containing 100 µg/ml ampicillin to 
an OD600 of 0.5-0.8 at 37°C. The synthesis of GST recombinant protein was induced 
with 0.5 mM IPTG for a subsequent incubation of 3 hrs at 25°C. The cells were 
harvested by centrifugation at 2000 g. The cell pellets were washed with PBS and 
pelleted again for subsequent purification of the recombinant proteins. The cell pellets 
were resuspended in 20 ml of 50 mM Tris-HCl (pH 7.4) buffer containing 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM DTT, 0.25 mM PMSF, and protease 
inhibitor mixture (lysis buffer). All procedures for the purification were carried out at 
4°C. The cells were lysed by sonication and centrifuged at 18000 g for 30 mins. The 
supernatant was applied onto a 2 ml column of GSH-sepharose which had been 
equilibrated with the lysis buffer. The column was sealed and allowed to sit on an 
end-over-end shaker for 2 hrs. After loading, the column was washed with 10 bed 
volume of lysis buffer supplemented with 0.5 M NaCl, and 5 bed volume of the lysis 
buffer without detergent (Buffer L). The GST fusion protein was eluted by 5 mM 
reduced glutathione in Buffer L and dialyzed in a 25 mM Tris-HCl (pH 7.4) buffer 
containing 100 mM NaCl, 1 mM EDTA and 1 mM DTT (dialysis buffer). 
 
Expression of His6-tagged recombinant proteins in bacteria and purification 
with Ni-NTA beads were performed according to the manufacturer’s instruction. 
Briefly, bacteria expressing the His-tagged protein were cultured, harvested and 
washed as mentioned above. The cell pellet was resuspended in a sodium phosphate 
(pH 8.0) buffer containing 150 mM NaCl, 1% Triton X-100, 20 mM imidazole, 10 
mM β-mercaptoethanol and protease inhibitor mixture (lysis buffer). The cells were 
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sonicated, cell extract was harvested by sonication, and the supernatant was applied to 
a Ni-NTA column. After incubation, the column was washed with 10 bed volume of 
the lysis buffer without detergent (washing buffer) and eluted with 250 mM imidazole 
in the washing buffer. Eluted proteins were dialyzed in the dialysis buffer described 
above. Purification of GST-p35-His was performed by sequential chromatography 
using GSH-sepharose and Ni-NTA beads, respectively, to yield a purer p35 
recombinant protein. Purified proteins were stored in small aliquots at -80°C until 
used. 
 
2.2.3 Isolation of p35-binding proteins 
 
The whole isolation procedure was carried out at 4°C. Rat brains were 
homogenized in Buffer A (25 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 
mM DTT, 0.5% Triton X-100, 1 mM PMSF, 0.1 mM benzamidine and Complete 
protease inhibitor cocktail). The crude homogenate was centrifuged at 100,000 g for 1 
hr and the lysate was carefully collected. GSH beads coated with 100 µg of GST, 
GST-p10, GST-p16 or GST-p35-His were mixed with the lysate and incubated for 4 
hrs with gentle shaking. The beads were then extensively washed with Buffer B (25 
mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM DTT, 1 mM EDTA, 0.1% NP-40, 1 mM 
PMSF and 0.1 mM benzamidine). After briefly washing the beads with Buffer C (25 
mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM DTT and 1 mM EDTA), the coupled 
proteins were eluted by incubation in Buffer C supplemented with 1 M NaCl (Elution 
buffer). The beads were eluted twice with the elution buffer. The eluates were 
combined and 3 volumes of cold acetone were added to precipitate the proteins at -
20°C for overnight. The precipitates were washed with cold 70% methanol and 
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dissolved in SDS-PAGE sample buffer. The samples were resolved by SDS-PAGE 
and visualized by colloidal Coomassie Blue staining (Pierce). 
 
2.2.4 Mass spectrometry 
 
Protein bands excised from SDS-PAGE gels were destained, reduced with 
DTT, alkylated with iodoacetamide and then in-gel digested with modified trypsin 
(Promega, Madison, WI) (Shevchenko et al., 1996). The extracted peptides were 
analyzed on a quadrupole/Time-of-Flight mass spectrometer (QSTAR Pulsar, PE 
Sciex) equipped with a nanoelectrospray ion source. Protein identities were revealed 
by  querying sequence databases using the MASCOT search engine 
(http://www.matrixscience.com) with peptide sequence tags generated from tandem 
mass spectrometry (Wilm et al., 1996; Mann and Wilm, 1994). Fig. 1 shows a 
schematic overview of this procedure. 
 
2.2.5 Biochemical binding assays 
 
For Cdk5/p35 binding assays, 5 µg of GST-tagged proteins were incubated 
with 10 µg CK2 proteins as indicated in Buffer A for 1 hr at 30°C. The GST-tagged 
proteins were retrieved by further incubation with GSH-Sepharose for 1 hr at 4°C. 
The beads were washed four times with 1 ml of the binding buffer. Bound proteins 
were released by boiling in the SDS-PAGE loading buffer and subsequently analyzed 
by immunoblotting. 
 
To test tubulin binding, GSH-Sepharose beads (Amersham-Pharmacia) pre-
bound with GST, GST-CK2α or the complex of GST-CK2α/His-CK2β were 
incubated with purified tubulin (>99% pure and MAP-free, Cytoskeleton) for 1 hr at 
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4°C. After being extensively washed with the binding buffer (20 mM Tris-HCl, pH 
7.4, 50 mM NaCl, 20 mM MgCl2, 1 mM DTT and 0.1% NP-40), the beads were 
boiled in the SDS-PAGE sample buffer and analysed by immunoblotting. Antibodies 
against α- and β-tubulin were from Sigma. The binding of His-tagged proteins with 
tubulin was performed with Ni-NTA beads in the binding buffer without DTT. In the 
microtubule binding assay, microtubules, which were pre-assembled with taxol in the 
PEM buffer (80 mM PIPES, pH 6.8, 1 mM MgCl2, 1 mM EGTA) supplemented with 
1 mM GTP, were incubated with the respective proteins. The samples were 
subsequently loaded onto a buffered cushion (50% glycerol in the PEM buffer) and 
centrifuged to pellet the microtubules and associated proteins. The pellet and the 
supernatant were analyzed by immunoblotting. 
 
2.2.6 Protein size exclusion chromatography 
 
All procedures were carried out at 4°C. Rat brains were homogenized in 
Buffer B (25 mM Hepes, pH 7.3, 150 mM NaCl, 1 mM EDTA, and 1 mM DTT) with 
5µg/ml leupeptin/aprotinin/antipain protease inhibitors cocktail. The crude 
homogenate was centrifuged at 100, 000 g for 1 hr and the supernatant was carefully 
collected. Ten milligram of the supernatant was applied to an FPLC Amersham 
Pharmacia Superdex 200 (HR16/50) gel filtration equilibrated in Buffer A. One ml 
fractions were collected. Proteins in each fraction were concentrated by overnight 
acetone precipitation and analyzed by immunoblotting using the antibodies indicated. 
Molecular weight calibration of the Superdex 200 column was performed under the 
same conditions using a gel filtration calibration kit from Amersham Pharmacia. The 
column was calibrated with Dextran blue (2,000 kDa; void volume), thyroglobulin 
(670 kDa), ferritin (440 kDa), aldolase (158 kDa) and albumin (67 kDa). 
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 2.2.7 Cdk5 in vitro kinase assay 
 
The Cdk5 kinase assay was performed according to the method described 
previously (Qi et al., 1995), with modification in accordance to Ching et al. (Ching et 
al., 2002). Briefly, the histone kinase activity of the sample was measured in 30 mM 
MOPS, pH 7.4, and 10 mM MgCl2 at 30°C for 10 mins. The reaction was stopped by 
the addition of trichloroacetic acid and the incorporation of phosphate into the histone 
H1 peptide was measured by a scintillation counter. To assess the effect of 
CK2α/CK2 holoenzyme on Cdk5 activity, proteins were incubated for 30 mins at 
room temperature before commencement of the assays. 
 
2.2.8 Transient transfections 
 
Transient transfections were performed with Lipofectamine in accordance 
with the manufacturer’s instructions. Briefly, cells were seeded on 100 mm plates 
overnight before transfection with a total of 12 µg of the various plasmids. Fresh 
growth medium was replaced after 5 hrs of transfection and cells were further 





For immunoprecipitation, transfected cells or rat brains were lysed in a buffer 
containing 25mM Tris-HCl, pH 7.4, 100mM NaCl, 1mM EDTA, 0.5% Triton X-100 
and protease inhibitor mixture (Buffer C). The lysate were clarified by centrifugation 
and protein A beads, and used for immunoprecipitation with the indicated antibodies. 
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After extensive washing with Buffer C, the precipitated proteins were resolved by 
SDS-PAGE and detected by immunoblotting using the antibodies indicated. 
 
2.2.10 Microtubule assembly 
 
Microtubules were assembled in vitro from the purified MAP-free tubulin at 2 
mg/ml in the PEM buffer supplemented with 1 mM GTP at 35°C and the turbidity of 
the solutions was monitored at 340 nm (Gaskin, 1982). CK2 was added at various 
amounts as indicated to promote assembly. To visualize assembled microtubules, 
tubulin and rhodamine-labelled tubulin at the ratio of 7:1 were used in the 
polymerization (Belmont et al., 1990). Microtubules were fixed with 0.5% 
gluteraldehyde and visualized by fluorescence microscopy. 
 
2.2.11 Differential tubulin extraction from intact cells 
 
Differential extraction of tubulin heterodimers and polymers from cells was 
performed using a protocol described previously (Lieuvin et al., 1994). Briefly, 
cultured cells were lysed with the microtubule-stabilizing buffer (80 mM PIPES, pH 
6.8, 1 mM MgCl2, 1 mM EGTA, 0.5% Triton X-100, 10% glycerol and protease 
inhibitors), which was prewarmed to 35°C, to extract cytosolic soluble tubulin 
heterodimers and to preserve microtubules (assembled insoluble tubulin polymers). 
The extract was cleared by centrifugation and the supernatant is designated as the free 
tubulin fraction. After a brief wash with the microtubule-stabilizing buffer, the pellet 
was extracted in the microtubule-destabilizing buffer (20 mM Tris, pH 7.4, 150 mM 
NaCl, 1% Triton X-100, 10 mM CaCl2 and protease inhibitors). The extract was 
clarified by centrifugation to yield the polymerized tubulin fraction. Both fractions 
were analyzed by immunoblotting and each band on the blots was quantitated using a 
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Bio-Rad GS-700 imaging densitometer and analyzed with the Multi-Analyst (version 




The siRNA sequence designed for human CK2α/α’ is 5’-
CCAGCUGGUAGUCAUCUUGUU-3’, which has high sequence homology between 
both catalytic isoforms but many discrepancies to the corresponding sequence of 
chicken CK2α/α’ (Ulloa et al., 1993). Twenty µM of the CK2α/α' siRNA or a 
scrambled siRNA sequence was used the transfection using TransIT-TKO 
transfection reagent, according to the manufacturer’s instructions. Simultaneous 
transfection of siRNA and plasmid DNA was done using TransIT-TKO and 
Lipofectamine concurrently. After transfection, the cells were cultured for 24 hrs 
before the treatment of 0.2 µM colchicine (Sigma) for 3 hrs. The cells were subjected 
to the differential extraction of free and polymerized tubulin or immunostaining. For 
SH-SY5Y cells, transfected cells were incubated for 48 hrs prior to 
immunoprecipitation and Cdk5 kinase assay. 
 
2.2.13 Immunofluorescence microscopy 
 
 At the end of each respective transfection or treatment period, the cells were 
washed twice in PBS and fixed in PBS containing 4% paraformaldehyde before 
permeabilization in PBS containing 0.2% Triton X-100. After the blocking wash with 
10% goat serum and 0.1% Triton X-100 in PBS, the immunostaining was performed 
with the indicated primary antibodies, which was followed by the respective 
secondary antibodies at room temperature. Excess antibodies were removed by 
extensive washing in PBS. Labelled cells were visualized with a Carl Zeiss Axioplan 
 57
microscope equipped with a BioRad MRC-1024  confocal optics system (Coe et al., 
1999) or a microscope equipped with an AxioCam CCD camera (Carl Zeiss, 
Oberkochen, Germany).  Images were converted to the tagged-information-file format 
and processed with the Adobe Photoshop program. 
 
2.2.14 Miscellaneous techniques 
 
To determine the concentration and purity of DNA solution, the OD at 260 nm 
and 280 nm was measured in a spectrophotometer. The absorption of 1 at OD260 is 
equivalent to 50 mg/ml of double stranded DNA. The ratio of the readings at 260 nm 
and 280 nm (A260/A280) provides an estimate of the purity of the DNA with respect to 
contaminants that absorb in the UV, such as proteins. Molecular biology techniques 
were performed using standard protocols (Sambrook et al., 1989). Protein 
concentration was measured by the method of Bradford (Bradford, 1976). SDS-PAGE 
was performed by the method of Laemmli (Laemmli, 1970) in 10% vertical slab gels, 
unless otherwise stated. For immunoblot, proteins were transferred to nitrocellulose or 
PVDF membranes and immunostained with the indicated antibodies. 
 
2.2.15 Statistical analysis and presentation of data 
 
All experiments were performed at least thrice. In the case of western blot 
analysis representative data from one experiment are presented. All numerical data are 
expressed as mean ± SD. Data were analyzed using the two tailed t-test or ANOVA. 





FIG. 1. Schematic diagram depicting the identification of various isolated p35-interacting 
proteins. From the gel, unique bands found in the sample lane, but not in the control, were excised. 
Proteins were reduced with DTT and alkylated with iodoacetamide, prior to digestion with modified 
sequencing grade trypsin. The digested samples were analyzed by mass spectrometry and sequences of 
some peptides were generated. Peptide sequences were queried against known databases to acquire 
their protein identities. Some here is the protein sequence of the catalytic α subunit of rat protein kinase 











Results and Discussions 
 
 
3.1 Isolation of p35-Associated Proteins and Identification of Protein 
Kinase CK2 as an Inhibitor of Neuronal Cdk5 kinase 
 












Section 3 - Part I 
 
 
3.1 Isolation of p35-Associated Proteins and Identification of Protein 




Protein kinase CK2 is a serine/threonine protein kinase that is messenger-
independent, ubiquitously expressed and highly conserved in evolution, indicating a 
vital cellular role for this kinase (Allende and Allende, 1995; Pinna and Meggio, 
1997). CK2 phosphorylates a great number of substrates involved in essential 
processes, including cell growth and proliferation (Meggio and Pinna, 2003). Until 
recently, CK2 was believed to represent a kinase especially required for cell cycle 
progression in non-neural cells. At present, with respect to recent findings, few 
essential features suggest potentially important roles for this enzyme in specific neural 
functions. CK2 is very abundant in the brain, with numerous neural-specific 
substrates (Meggio and Pinna, 2003). In addition, some data have suggested that CK2 
might play a role in processes underlying progressive disorders due Alzheimer’s 
disease and ischemia. 
 
Cdk5 plays important roles in the regulation of neuronal differentiation, 
degeneration and cytoskeletal dynamics (Dhavan and Tsai, 2001; Lee and Tsai, 2003). 
Monomeric Cdk5 has no enzymatic activity since its activation is dependent on its 
association with the neuronal-specific regulatory subunits p35 or p39 (Lew et al., 
1994; Tsai et al., 1994; Tang et al., 1995). Cdk5 and p35 are essential for the proper 
development of the central nervous system since p35 and Cdk5 knockout mice display 
cell-positioning defects in the cerebral cortex (Chae et al., 1997; Ohshima et al., 
1996). Cdk5 phosphorylates a number of cytoskeletal proteins and in turn mediates 
neurite outgrowth and neuronal migration during brain development (Baumann et al., 
1993; Nikolic et al., 1998; Grant et al., 2001; Rashid et al., 2001; Ackerley et al., 
2003; Xie et al., 2003b). There is growing evidence implicating aberrant regulation of 
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Cdk5 in neurodegeneration and cell death (Lim and Qi, 2003). Indeed p25, a truncated 
C-terminal fragment of p35, accumulates in AD brains and its associated Cdk5 kinase 
activity induces cytoskeletal disruption, morphological degeneration and apoptosis 
(Lee et al., 2000; Ahlijanian et al., 2000; Noble et al., 2003; Cruz et al., 2003). 
 
Evidence has been accumulating in implicating Cdk5/p35 as a multifunctional 
enzyme that exists in many protein complexes in cells (Lim et al., 2003). In addition, 
biochemical studies of Cdk5 in bovine brain extract suggested the existence of 
inhibitory factors present together with Cdk5 and p35 in macromolecular protein 
complexes (Lee et al., 1996a). To learn more about the functional and regulatory roles 
of this kinase, we utilized recombinant p35 in affinity isolation of their binding 
proteins from rat brain homogenates and then identified using mass spectrometry. 
Herein, we present evidence showing that the catalytic α subunit of protein kinase 
CK2 as one of the component in the p35 protein complex. Both the catalytic subunit 
and the holoenzyme of CK2 are able to interact physically with p35. Using deletion 
mutants of p35, we show that CK2 binds to two separate regions located separately at 
the N- and C-terminal halves of p35. Intriguingly, the binding of CK2 to p35 prevents 





3.1.2.1 Isolation of p35-binding proteins by affinity purification and co-
immunoprecipitation 
It has been shown that Cdk5/p35, but not Cdk5/p25, exists in macromolecular 
complexes in brain extracts, implying that the N-terminal 98 amino acids of p35 is 
important for interaction with other proteins (Lee et al., 1996a). Moreover, many 
proteins have been shown to interact with Cdk5 via their association with p35. 
Previous studies have reported p35 to be an unstable protein, and can be cleaved into 
a smaller p25 fragment in the presence of calcium-dependent proteases such as 
calpain (Lee et al., 2000). Hence, p35 was expressed as a GST-fusion protein with a 
C-terminus His6-tag (GST-p35-His). Using sequential affinity purification, we were 
able to obtain a sufficiently pure form of the p35 protein. To test if the bacterial-
purified recombinant proteins were functional, in vitro Cdk5 kinase assays were 
performed with these p35 and Cdk5 proteins and results obtained suggested that they 
are functional since the recombinant p35 proteins were able to activate Cdk5 activity 
(results not shown). To isolate proteins binding to p35, GST and GST-p35-His were 
utilized in affinity binding experiments with rat brain extracts. The bound proteins 
were either eluted at a high salt condition (1 M NaCl) or by boiling the GST/GST-
p35-His immobilized beads in SDS-PAGE buffer. After resolving the eluted proteins 
by SDS-PAGE, several distinct polypeptide bands found in the GST-p35-His lane, but 
not in the GST control, were excised and subjected to in-gel digestion and mass 
spectrometry analysis. The identities of the isolated proteins were summarized in 
Table 1. Of the few proteins isolated, both NFM and actin have been previously 
reported to be p35-associated proteins (Grant et al., 2001; Humbert et al., 2000a). 
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Heat-shock protein 70 (HSP-70), β-tubulin, α-tubulin, drebrin A and neuronal protein 
25 are novel putative p35-interacting proteins identified using this method. 
 
In order to identify p35-interacting proteins that are found in complex with 
p35 in the cells, a co-immunoprecipitation approach was also employed. Antibody 
against p35 (C19) was incubated with pre-cleared rat brain extract and proteins were 
eluted by boiling in SDS-PAGE buffer. Proteins were resolved by SDS-PAGE and 
distinct polypeptide bands found in the C19 immunoprecipitate, but not in the IgG 
control, were excised for in-gel digest and mass spectrometry analysis. Table 1 
summarized a list of proteins isolated using this method. This approach identified 
several proteins, including the catalytic subunit of phosphatidylinositol 3-kinase (PI3-
K), dynamin I, pRb, c-Jun NH2-terminus kinase 3 (JNK3), the catalytic subunit of 
calmodulin-dependent kinase 2 (CaMKIIα), CK1δ and actin that have been 
previously shown to be interacting proteins of Cdk5/p35 kinase (Li et al., 2003; Tan 
et al., 2003; Tomizawa et al., 2003; Lee et al., 1997; Li et al., 2002; Dhavan et al., 
2002; Liu et al., 2001; Humbert et al., 2000a). 
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Method of isolation 
Heat-shock protein 
70 (rodent)ψ
Chaperon protein GST-p35-His6 
affinity isolation 
 




α-tubulin ψ Microtubule component GST-p35-His6 
affinity isolation 
Neurofilament M 
(Grant et al., 2001) 
 
Intermediate filament protein GST-p35-His6 
affinity isolation 
Drebrin A ψ Actin-associated protein GST-p35-His6 
affinity isolation 
 




Actin (Humbert et 
al., 2000a) 




PI3-K, p110 catalytic 
subunit (Li et al., 
2003) 
 




Dynamin I (Tan et 
al., 2003; Tomizawa 
et al., 2003) 
 




pRb (Lee et al., 1997) Cdk5 substrate; cell cycle regulator; 




JNK-3 (Li et al., 
2002) 
Mediates neuronal apoptosis Co-
immunoprecipitation 
 
CamKIIα (Dhavan et 
al., 2002) 






Iδ (Sharma et al., 
1999) 
 




3.1.2.2 Identification of CK2α as a p35-binding protein 
As described above as well as in a previous report (Qu et al., 2002), we 
performed the isolation of p35-interacting proteins from rat brain extracts using an N-
terminal (p16) fragment of p35, which comprises residues 1-149 of p35. It was 
produced as a GST-fusion protein and used as “bait” in the affinity “pull-downs”. 
Bound proteins were eluted with high salt and subsequently resolved by SDS-PAGE. 
Several protein bands, inclusive of an approximately 45 kDa were clearly observed in 
GST-p16 pull-downs, but not in those from the GST control sample (Fig. 1A). To 
reveal its identity, this 45 kDa protein band was excised, subjected to in-gel digestion 
and mass spectrometry analysis. Sequence database searches with tandem mass 
spectrometric data generated from several prominent peptide signals showed that the 
sequences from these peptides matched those of rat CK2α, which is the catalytic 
subunit of protein kinase CK2 (Fig. 1A). To confirm this result, samples from a 
subsequent pull-down were used for immunoblot analysis. In addition to GST-p16, a 
shorter N-terminal fragment of p35, GST-p10 (a.a. 1-98 of p35), was also included in 
the pull-down analysis. As shown in Fig. 1B, a CK2α immunoblot clearly indicated 
that it was specifically pulled-down by GST-p16. Interestingly, GST-p10 failed to 
pull-down CK2α from the brain extract (Fig. 1B), implicating that the region spanning 
a.a. 99-149 of p35 is required for the association of CK2α. 
 67
 
FIG. 1. Isolation of CK2α as a p35-binding protein from brain lysate. (A) GST and GST-p16 were 
used in the pull-down experiments of rat brain lysate as described in the “Experimental Procedures”. 
Proteins co-precipitated through the GST-tagged proteins by GSH beads were separated by SDS-
PAGE. The protein band at ~45 kDa in the GST-p16 lane was identified by mass spectrometry as the 
rat CK2α protein. Underlined are peptide sequences of rat CK2α identified by tandem mass 
spectrometry of the 45 kDa protein band. (B) Pull-downs of the rat brain lysate using GST, GST-p10 
and GST-p16 were analyzed by anti-CK2α immunoblotting. 
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3.1.2.3 CK2α associates with p35 and Cdk5 in vivo 
Cdk5 (with p35) is a multifunctional enzyme found in many macromolecular 
protein complexes (Lee et al., 1996a). To investigate the association of CK2 with p35 
and Cdk5 in vivo, rat brain extracts were fractionated by size exclusion 
chromatography using a Superdex 200 column. Fractions were collected and analyzed 
by immunoblotting to examine elution patterns of Cdk5, p35 and the CK2 subunits. 
Figure 2A shows the elution profiles derived. Almost all p35 was found in the high 
molecular weight fractions, migrating nearly at the void volume of the column (Fig. 
2A). Cdk5 was eluted across a fairly broad range of fractions (Fig. 2A), characteristic 
of various Cdk5 complexes present in brain extracts. Substantial amounts of Cdk5 
were found in the high molecular weight fractions, co-fractionating with p35. The low 
molecular weight fractions corresponding to a molecular mass of ~30 kDa presumably 
represents the monomeric form of Cdk5. CK2α immunoreactivity was detected in the 
high molecular weight fractions of p35 and Cdk5 with the peak fractions closely 
aligned with that of p35 (Fig. 2A). Intriguingly, the high molecular weight fractions 
containing Cdk5, p35 and CK2α are completely devoid of CK2β (Fig. 2A), suggesting 
that CK2α but not the holoenzyme complexes with Cdk5 and p35 in the large protein 
complexes in brain. To further demonstrate the in vivo association of CK2α with 
Cdk5 and p35, proteins were immunoprecipitated from the rat brain lysate with 
antibodies directed to p35 and Cdk5. As shown in Figure 2B, CK2α was specifically 
detected in immunoprecipitates of both p35 and Cdk5. In addition, cellular 
localization patterns of CK2α and p35 were revealed by immunofluorescent staining 
of transfected COS-7 cells and NGF-induced PC-12 cells. Microscopic imaging of 
CK2α displayed a clearly defined co-localization with p35 in the cytoplasm (Fig. 2C), 
providing further evidence for the interaction between CK2α and Cdk5/p35. 
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 FIG. 2. In vivo association of CK2α with Cdk5 and p35. (A) Rat brain lysate containing 10 mg of 
proteins was analyzed by gel filtration chromatography using a Superdex 200 column as described 
under “Experimental Procedures”. Proteins in alternate fractions were concentrated by acetone 
precipitation, resolved in 10% SDS-PAGE and subsequently immunoblotted with antibodies 
recognizing Cdk5, p35, CK2α and CK2β. (B) Rat brain lysate was subjected to immunoprecipitation 
with p35- and Cdk5-specific antibodies, followed by Western blotting with anti-CK2α antibody. Non-
specific rabbit IgG was used in the immunoprecipitation as control. (C) Top row, COS-7 cells were co-
transfected with the p35 and Myc-CK2α expression vectors. Immunostaining was performed using 
anti-p35 (red) and anti-Myc (green) antibodies on the transfected cells. Bottom row, double 
immunostaining was performed on NGF-induced PC-12 cells to label endogenous CK2α (green) and 
p35 (red) proteins. Bar = 20 µm 
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3.1.2.4 Direct association of CK2 with p35 and Cdk5 
The physical association of CK2 with p35 and Cdk5 was further examined 
using purified recombinant proteins. The CK2 holoenzyme comprises two α and two 
β subunits (Niefind et al., 2001). GST-tagged p35 and Cdk5 were individually 
incubated with CK2α, CK2β or the holoenzyme, respectively. The GST-tagged 
proteins were immobilized on GSH affinity beads and co-precipitated proteins were 
analyzed by immunoblotting using a mixture of CK2α and CK2β antibodies. Western 
blots clearly showed an interaction between p35 and either CK2α or the holoenzyme 
but not CK2β (Fig. 3A). In addition to p35, Cdk5 also displayed direct binding to 
CK2α although it failed to interact with the CK2 holoenzyme (Fig. 3A). These results 
indicated that p35 is able to associate with CK2 holoenzyme via its interaction with 
CK2α, while Cdk5 binds only to CK2α. 
 
Upon identifying p35 as a binding partner of CK2, we proceeded to delineate 
the CK2-binding regions in p35. As CK2α was isolated by the p16 fragment but not 
the p10 fragment of p35, two truncated fragments of p16, GST-p35 (a.a. 1-141) and 
GST-p35 (a.a. 53-149), were constructed and the respective recombinant proteins 
with a GST tag were prepared. Two C-terminal constructs of p35, namely p25 and 
p35 (a.a. 150-307), were also employed side-by-side in the GST pull-down assays. As 
shown in figure 3B, p16, but none of the shorter constructs, could interact with CK2α, 
suggesting that any further truncation of p16 would destroy its CK2-binding 
capability. Unexpectedly, p25 and p35 (a.a. 150-307) also exhibited interaction with 
CK2α although the bindings were relatively weak (Fig. 3B). The C-terminal half of 
p35 constitutes the Cdk5-binding and activating domain, which spans a.a. 150-292 
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(Tang et al., 1997; Poon et al., 1997). Thus, CK2 appears to interact with two regions 
of p35, one of which overlaps with the Cdk5-binding domain. 
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FIG. 3. Direct binding of CK2 to p35 and Cdk5. (A) CK2 associates with p35 and Cdk5. 10 µg of 
GST-p35 or GST-Cdk5 were incubated individually with CK2α (0.5 µg), CK2β (0.5 µg) and the CK2 
holoenzyme (1 µg). After precipitating the GST proteins using GSH beads, bound proteins were 
immunoblotted using a mixture of CK2α and CK2β antibodies. (B) Mapping CK2-binding domain in 
p35. 10 µg of GST-tagged fragments of p35 or GST were incubated with CK2α (0.5 µg). The GST 
proteins were then retrieved by GSH beads and analyzed by anti-CK2α immunoblotting. A schematic 
diagram depicting the various deletion constructs of p35 is shown. 
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3.1.2.5 CK2 inhibits Cdk5 activation 
It has been established that Cdk5 can be activated in vitro by reconstitution 
with p35 or its truncated form p25 (Qi et al., 1995). To understand the function of 
such interactions between CK2 with p35 and Cdk5, we carried out in vitro Cdk5 
kinase assays using recombinant proteins to examine the potential effects of CK2. 
Cdk5 kinase assay shows that reconstitution of Cdk5 and p35 in the presence of CK2α 
or CK2 holoenzyme resulted in an inhibition of the Cdk5 kinase activity in a dose-
dependent manner (Fig. 4A). Compared to CK2α, the holoenzyme of CK2 exhibited a 
slightly higher potency in inhibiting Cdk5 activity. Since p25 constitutes a second 
binding site for CK2, we went on to examine the effect of CK2 on the activation of 
Cdk5 by p25. Similar to the p35 results, CK2α and CK2 holoenzyme strongly 
inhibited Cdk5 activity when they were included in the reconstitution mixtures of 
Cdk5 and p25 (Fig. 4B). Thus, CK2 inhibited Cdk5 activation by p35 and p25 with 
similar potencies. 
 
Cdk5 is a ubiquitously expressed protein. To further investigate the mode of 
Cdk5 inhibition by CK2, we introduced p35 and CK2 into cultured COS-7 cells by 
transient transfection. p35 was immunoprecipitated to test its associated Cdk5 
activity. When p35 was co-transfected with an empty vector, a high Cdk5 kinase 
activity was obtained from the p35 immunoprecipitates (Fig. 5A). However, when 
p35 was transfected with CK2α or the CK2 holoenzyme expression constructs, the 
p35-associated Cdk5 activities were significantly reduced (Fig. 5A). Western blots 
detected the over-expressed CK2α and CK2 holoenzyme in the immunoprecipitates of 
p35, corroborating the association of p35 and CK2. In agreement with the in vitro 
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reconstitution assays, the expression of the CK2 holoenzyme (CK2α/CK2β) imposed 
a stronger inhibition on the p35-associated Cdk5 activity compared to the CK2α. 
 
To evaluate the physiological role of CK2 on Cdk5 activity, we proceeded to 
knock down CK2α/α’ in human neuroblastoma SH-SY5Y cells using a siRNA 
duplex. As shown by cell lysate immunoblots, the introduction of CK2α/α’-specific 
siRNA led to a significant decrease in the cellular CK2α protein level (Fig. 5B), while 
the protein contents of Cdk5 and p35 were not affected. To assess the knockdown 
effect on Cdk5 activity, p35 was immunoprecipitated to determine its associated Cdk5 
activity. The introduction of CK2α/α’-specific siRNA yielded a notably higher Cdk5 
activity as compared to the control sample (scrambled siRNA sequence) (Fig. 5C), 




 FIG. 4. CK2 inhibits Cdk5 activation in vitro. (A) CK2 inhibits the p35 activation of Cdk5. GST-
Cdk5 (0.5 µg) was mixed and incubated with GST-p35 (0.5 µg) in the absence and presence of 
increasing amounts of CK2α or CK2 holoenzyme. The samples were incubated for 1 hr at room 
temperature before being assayed for the Cdk5 kinase activity. (B) CK2 inhibits the p25 activation of 
Cdk5. GST-Cdk5 (0.5 µg) was incubated with GST-p25 (0.5 µg) and CK2α (5 µg) or CK2 holoenzyme 
(5 µg) for 1 hr at room temperature. The Cdk5 kinase activity was then determined and expressed as 
percentages of the Cdk5 activity in the absence of the CK2 proteins. Data shown here are averages of 
three separate experiments. 
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FIG. 5. (A) Cdk5 is inhibited by CK2 in transfected cells. The p35 expression construct was co-
transfected with the plasmid expressing CK2α or the holoenzyme CK2α/CK2β (CK2 holoenzyme) into 
COS-7 cells. In a control experiment, p35 was co-transfected with the empty vector of the CK2 
constructs. The expressed proteins of CK2α and CK2β contain V5 and Myc tags, respectively. 
Following immunoprecipitation of p35, the activity of co-precipitated Cdk5 was determined and 
expressed as percentages of that in the control sample. The plot represents an average of three 
individual experiments. The anti-p35 immunoprecipitates were subjected to immunoblotting to 
visualize p35, CK2α and CK2β by antibodies against p35, V5 and Myc, respectively. (B-C) CK2 
inhibits Cdk5 activity in neuroblastoma cells. SH-SY5Y cells were introduced with the siRNA of 
human CK2α/α’ or a scrambled sequence. (B) The knockdown of CK2α/α’ was monitored by anti-
CK2α, p35 and Cdk5 immunoblotting. The protein level of CK2α in the knockdown cells was 
expressed as a percentage of that in the control sample. (C) Following immunoprecipitation of p35, the 
activity of co-precipitated Cdk5 was determined. Data shown in the graph are the averages of three 
individual experiments (ρ = 0.005). 
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3.1.2.6 CK2 inhibits Cdk5 in a phosphorylation-independent manner 
CK2 is a protein Ser/Thr kinase that phosphorylates a multitude of proteins 
(Meggio and Pinna, 2003). To investigate the possible role of CK2 kinase activity in 
the inhibition of Cdk5, recombinant CK2αK68A, a kinase-dead mutant of CK2α, was 
employed. When recombinant CK2αK68A was added into the reconstitution mixture 
with Cdk5 and p35, the Cdk5 activity was strongly inhibited. CK2αK68A displayed 
an inhibitory activity that is similar to the wild-type protein on Cdk5 activity (Fig. 6). 
Cdk5 inhibition was also achieved using the kinase-dead holoenzyme of CK2, which 
was reconstituted from CK2αK68A and CK2β (Fig. 6). From these results, we 
concluded that the CK2 inhibition of Cdk5 is independent of its kinase activity. 
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 FIG. 6. The kinase activity of CK2 is not required for the inhibition of Cdk5. GST-Cdk5 (0.5 µg) 
was mixed with GST-p35 (0.5 µg) and one of the following proteins (5 µg) for each sample: CK2α, 
CK2αK68A, the wild-type holoenzyme CK2α/CK2β and the kinase-dead holoenzyme 
CK2αK68A/CK2β. The samples were incubated for 1 hr at room temperature before the Cdk5 kinase 
assay. Data shown in the graph represent an average of three separate experiments. 
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3.1.2.7 CK2 blocks complex formation between Cdk5 and p35 
To further characterize the inhibition of Cdk5 activity by CK2, we designed 
kinase assay experiments where Cdk5, p35 and the CK2 proteins were pre-
reconstituted in different orders. Interestingly, it was found that the Cdk5 inhibition 
depends on the order of the protein reconstitution. The Cdk5 activity was strongly 
blocked if Cdk5, p35 and CK2 were added in the following two ways: p35 was 
incubated with CK2 prior to the addition of Cdk5; or Cdk5, p35 and CK2 were added 
simultaneously during the incubation (Fig. 7). However, if Cdk5 and p35 were 
incubated prior to the addition of CK2, the preformed complex of Cdk5-p35 was 
completely resistant to CK2 inhibition (Fig. 7). Thus, CK2 acts to block the Cdk5 
activation, but does not affect the activity of Cdk5 already in complex with p35. 
 
In order to understand how CK2 inhibits Cdk5 activation, we utilized pull-
down binding assays to examine if CK2 competes with Cdk5 in binding to p35. GST-
p35 was pre-incubated with or without an excessive amount of CK2 (CK2α or CK2 
holoenzyme). After GST-p35 was retrieved using GSH-beads and unbound materials 
were washed off, it was subjected to a binding assay with Cdk5. As shown in Figs 
8A/B, p35 preincubated with CK2 completely lost its ability to interact with Cdk5. 
We extended this analysis to test whether CK2 can bind to the complex of Cdk5-p35. 
This time, GST-p35 was pre-complexed with Cdk5 and subsequently subjected to 
CK2 binding. As shown in Figs. 8C & 8D, the complex of Cdk5-p35 had no observed 
binding activity to CK2. Hence, CK2 and Cdk5 are mutually exclusive in their 
binding to p35. However, they are not able to displace one another if either protein is 
pre-complexed to p35. 
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FIG. 7. CK2 blocks Cdk5 activation but does not affect the activity of pre-activated Cdk5. 5 µg 
of CK2 or CK2α were incubated with GST-p35 for 1 hr, followed by addition of GST-Cdk5 (1 µg) and 
a further incubation for 1 hr (pre-incubation) at room temperature. For co-incubation, all three proteins 
were mixed together at the same time. For post-incubation, GST-p35 and GST-Cdk5 were mixed and 
incubated for 1 hr before the addition of CK2 or CK2α and a further incubation for 1 hr. In the “No 
inhibitor” sample, GST-Cdk5 and GST-p35 were reconstituted without the CK2 proteins for 2 hrs. The 
Cdk5 kinase activity in each sample was then assayed. Data shown here are representatives of three 
separate experiments and expressed as percentages of the Cdk5 activity of the “No inhibitor” sample. 
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FIG. 8. CK2 and Cdk5 are mutually exclusive in their binding to p35. (A) GST-p35 (1 µg) was 
pre-incubated with or without CK2α (5 µg) for 1 hr at room temperature. GST-p35 was retrieved using 
GSH beads to remove unbound materials, and then subjected to incubation with His-Cdk5 (8 µg) for 1 
hr at room temperature. After the incubation, His-Cdk5 bound to the beads was analyzed by Cdk5 
immunoblotting. An immunoblot of the His-Cdk5 input in the incubation was shown in the bottom 
row. (B) The competitive binding assay described in (A) was performed using the holoenzyme 
CK2α/CK2β instead of CK2α. (C) GST-p35 (1 µg) was pre-incubated with or without His-Cdk5 (5 µg) 
for 1 hr at room temperature. After GST-p35 was retrieved using GSH beads and unbound materials 
were removed by washing, the beads were incubated with CK2α (8 µg) for 1 hr at room temperature. 
CK2α bound to p35 immobilized to the GSH beads was detected by Western blotting. An immunoblot 
of the CK2α input in the incubation was shown in the bottom row. (D) The competitive binding assay 




Using both affinity isolation as well as co-immunoprecipitation approaches, a 
number of Cdk5/p35-interacting proteins were isolated (Table 1). Several of these 
proteins are known to participate in controlling cytoskeletal organization while a 
handful of others are proteins involved in cellular signal transduction processes. 
Among the cytoskeletal proteins identified, drebrin is an actin-associated protein 
where it co-localizes with actin filaments and has been suggested to regulate assembly 
and disassembly of actin filaments (Shirao et al., 1994; Asada et al., 1994). p39 has 
been previously reported to bind actin. Hence, their interaction with p35 suggests that 
Cdk5 may have a role in modulating cellular actin dynamics. Microtubule is a major 
component of the cytoskeleton. The interaction between p35 and α- and β-tubulin 
imply a role for p35 in the regulation of cellular microtubule dynamics. 
 
Several proteins with putative signaling functions were also isolated and one 
of them is the catalytic subunit of protein kinase CK2. CK2 is a serine/threonine 
kinase highly conserved in eukaryotic cells. It is a ubiquitously expressed pleiotropic 
enzyme that is involved in the control of various cellular processes such as cell cycle, 
apoptosis, transcriptional regulation and signal transduction (Allende and Allende, 
1995; Pinna and Meggio, 1997; Litchfield, 2003; Meggio and Pinna, 2003). CK2 is 
much more abundant in brain than any other tissue. There appear to be a myriad of 
CK2 substrates in neural cells which have clear implications in neural development, 
neuritogenesis, synaptic transmission and plasticity (Blanquet, 2000). The 
holoenzyme of CK2 is generally a heterotetramer, composed of two catalytic α or α’ 
and two regulatory β subunits (Niefind et al., 2001). The α and α’ subunits are 
catalytically active, whereas the β-subunit is inactive but appears to confer stability to 
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the holoenzyme and to modulate the enzyme activity and substrate specificity by 
targeting the holoenzyme to its substrates (Allende and Allende, 1995; Pinna and 
Meggio, 1997). In addition, several lines of evidence have indicated that CK2 
subunits can exist individually in vivo to interact with other cellular proteins, implying 
that the CK2 subunits may have biological functions other than those assigned to the 
holoenzyme (Chen et al., 1997; Chen and Cooper, 1997; Heriche et al., 1997; Guerra 
et al., 1999; Litchfield, 2003). 
 
Evidence presented here identifies the catalytic α subunit of CK2 as an 
interacting partner of p35 and Cdk5. Based on the protein co-elution profiles of the rat 
brain lysate, CK2α but not the CK2 holoenzyme coexists with p35 and Cdk5 in vivo, 
although the holoenzyme displayed p35-binding capacity in vitro. Interestingly, the 
elution patterns of α- and β-subunits of CK2 were quite different, although they co-
eluted in certain fractions. Increasing data had suggested that there are free 
populations of both CK2 subunits, either totally on their own or in association with 
cellular structures (Guerra and Issinger, 1999). Moreover, CK2β is associated with the 
plasma membrane (Faust and Montenarh, 2000) and the rat brain lysate is devoid of 
membrane-associated protein (detergent-free fraction), these would account for the 
distinct elution profiles between the subunits of CK2. In agreement with these results, 
CK2α was observed in p35- as well as Cdk5-immunopecipitates from the rat brain 
lysate. In respect to these observations, further characterization showed that CK2 and 
Cdk5 interact with p35 in a mutually exclusive manner. In vivo, it is possible that 
there are independent pools of CK2 proteins that are associated with p35, as well as 
presence of p35-associated Cdk5 kinase. Hence, the binding of CK2 to p35 prevents 
Cdk5 from associating with p35 and thereby inhibiting the p35-associated Cdk5 
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activation. In agreement with the results from the in vitro inhibition assays, the co-
expression of CK2 and p35 in COS-7 cells inhibited the Cdk5 activation. In addition, 
the knockdown of CK2α/α’ significantly enhanced the p35-associated Cdk5 activity 
in the neuroblastoma cells. Although the Cdk5-inhibitory mechanism of CK2 is 
distinct from the Kip/Cip family of Cdk inhibitors (CKIs), it is reminiscent of the 
Cdk4/6 inhibition by the INK4 family members, which interact with both Cdk4/6 and 
cyclin D to block the Cdk4/6 association with cyclin D (Russo et al., 1998; Guan et 
al., 1996; Hirai et al., 1995). Taken together, these support the notion that p35, Cdk5 
and the CK2 proteins may form independent protein complexes in the cells. 
 
CK2 was found to bind p35 in two regions that are separately located in the N- 
and C-terminal halves. Given the results that CK2 displayed an inhibitory activity 
towards Cdk5 activation by p25 and p25 (which retains one of the two CK2-binding 
sites that lies within the Cdk5-binding domain at the C-terminal half of p35), it is 
tempting to conclude that CK2 competes with Cdk5 in binding to p35 at the Cdk5-
binding domain, and thereby prevents the association of p35 with Cdk5. Perhaps, the 
binding of CK2 to the N-terminal region of p35 prevent access to Cdk5. The binary 
complexes of p35-CK2 or p35-Cdk5 appear to be stable and cannot be dissociated by 
excessive amounts of Cdk5 or CK2, respectively. CK2 may act as a sentinel molecule 
in cells to control Cdk5 activation. Upon dissociation of CK2 from p35, p35 binds to 
and activates Cdk5, which in turn catalyses the phosphorylation of p35, promoting 
p35 degradation via the proteasome-dependent pathway (Patrick et al., 1998). 
Conceivably, the CK2 association prevents unwanted Cdk5 activation and p35 
turnover, thereby preserves p35 for prompt Cdk5 activation. Thus, it would be 
intriguing to understand how p35 is released from its association with CK2. In 
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addition, the p35-CK2 interaction might have some effect on CK2 activity, which 
may allow us to further understand the regulation of CK2 cellular functions. 
 
CK2 has a broad substrate spectrum which includes Cdc2 (Russo et al., 1992). 
We have examined if the kinase activity of CK2 is involved in its inhibition of Cdk5. 
Using the kinase-dead mutant of CK2, we found that the Cdk5-inhibiting activity of 
CK2 is independent of its kinase activity. This was corroborated with the results from 
the competitive protein binding assays. It becomes clear that CK2 imparts a direct 
inhibition on Cdk5 simply by competing with Cdk5 for the binding to p35, but not 
through its kinase activity. As a multifunctional enzyme, CK2 is thought to execute its 
functions through its phosphorylation of a myriad of proteins. The results presented 
here revealed a new CK2 function that is not linked to, or caused by its intrinsic 
kinase property. 
 
In conclusion, this study has presented the identification and characterization 
of a novel inhibitor of Cdk5. To date, all identified functions of Cdk5 are inextricably 
linked to the phosphorylation of its substrates. Our results revealed a novel regulatory 
mechanism of Cdk5 activation and possibly its actions in brain. The aberrant 
activation of Cdk5 by p25, a proteolytic product of p35, occurs during 
neurodegeneration and abnormally high activity of Cdk5 is detrimental to cell 
survival (Nguyen et al., 2001; Patrick et al., 1999). Since CK2 exhibited strong 
inhibition of Cdk5 activation by p25, the loss of this inhibitory mechanism might be 
one of the deregulated mechanisms during the neuronal degeneration. On the other 
hand, it has been proposed that CK2 is involved in processes underlying cell survival 
and has anti-apoptotic functions (Pinna, 2002; Ahmed et al., 2002; Litchfield, 2003). 
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CK2 may conceivably act to protect the cells against neurotoxicity through its 
inhibitory effect on Cdk5. Thus, the function described here for CK2 also provides a 












Section 3 - Part II 
 
 




Microtubules are fibrous elements in the cytoplasm of eukaryotic cells where 
they perform a wide variety of functions. Microtubules are major organizers of the 
cell interior and are vitally involved in motility events such as chromosome migration 
during cell division. To fulfill their physiological function, microtubule arrays have to 
undergo dramatic changes in their spatial arrangements and this depends on, to a large 
extent, the complex and special dynamic properties of the individual polymers. A few 
lines of evidence have implicated CK2 in the regulation of microtubule cytoskeleton 
reorganization (Diaz-Nido et al., 1988; Serrano et al., 1987; Serrano et al., 1989). 
CK2 was localized to microtubular structures such as the mitotic spindle of dividing 
cells and was found to associate with a cold-stable fraction of microtubules from the 
rat brain (Diaz-Nido and Avila, 1992; Serrano et al., 1989). More recently, the α and 
α’ subunits were shown to bind tubulin in a Far-Western assay (Faust et al., 1999). 
Further, CK2 is able to phosphorylate a number of proteins associated with 
microtubule, including MAP1B and a neuron-specific β-tubulin isotype (Meggio and 
Pinna, 2003). The phosphorylation of MAP1B was proposed to facilitate its 
microtubule association and thereby microtubule assembly, while the physiological 
role of the neuronal β-tubulin isotype phosphorylation is still unclear (Diaz-Nido et 
al., 1988; Diaz-Nido et al., 1990). Despite these findings, a direct role for CK2 in 
regulating microtubule stability has not yet been established. 
 
In the present study, we have investigated the physical association of CK2 
with microtubules and documented a direct effect of CK2 on microtubule dynamics. 
Our results show that CK2 is a microtubule-associated protein (MAP) that induces 
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microtubule assembly and bundling in vitro. The CK2-polymerized microtubules 
appear to be stable against cold treatment. In cultured cells, knockdown of CK2α/α' 
has a severe effect on the microtubule stability, indicating that CK2 is important for 
microtubule integrity in vivo. A kinase-inactive mutant of CK2 displayed similar 
microtubule-polymerizing and stabilizing activity in vitro and in vivo. Thus, the 




3.2.2.1 CK2 forms a direct complex with microtubules 
The possible association between CK2 and microtubules was probed by a series 
of binding assays using recombinant CK2 and purified MAP-free tubulin as well as 
pre-assembled microtubules. Both the α- and β-tubulin was found to associate with the 
catalytic α subunit as well as the holoenzyme of CK2 (Fig. 1A). CK2β alone did not 
bind tubulin (Fig. 1B), which is in agreement with a previous observation made using 
Far-Western blotting (Faust et al., 1999). To verify the microtubule association of CK2, 
taxol-assembled microtubules were incubated with the CK2 holoenzyme or its 
individual subunits. The microtubules were then pelleted by centrifugation to test 
whether these proteins were co-precipitated with the microtubules. Consistently, CK2α 
and the holoenzyme of CK2 were found to associate with the microtubule pellets, 
whereas CK2β and GST (as a control) failed to co-precipitate with the microtubules 
(Fig. 1C). These results indicate that the CK2 holoenzyme associates with microtubules 
through CK2α. 
 
Cellular localization of CK2 to microtubule networks was revealed by 
immunofluorescent staining of cultured COS-7 cells. Microscopic imaging of the 
endogenous CK2α and CK2β revealed its colocalization with the microtubule network, 
particularly at the cell periphery (Fig. 2A). In addition, pools of tubulin existed as free 
heterodimers or polymers (microtubules) were differentially extracted from the 
cultured cells and the extent of codistribution of CK2 with these fractions was 
examined (Lieuvin et al., 1994). Both CK2α and CK2β appeared in the microtubule 
fraction as well as the fraction of free tubulin heterodimers, though there appeared to be 
more CK2β in the microtubule fraction (Fig. 2B). Taken together with the results from 
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the in vitro binding assays, this data provide evidence for direct association of CK2 
with cellular microtubules. 
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 FIG. 1. Microtubule association of CK2. (A) Direct interaction of CK2 and tubulin heterodimers. 5 
µg of GST, GST-CK2α or a complex of GST-CK2α/His-CK2β were incubated with 2.5 µg of purified 
tubulin. The GST fusion proteins were then retrieved using GSH beads and bound proteins were 
analyzed by immunoblotting with antibodies recognizing α- and β-tubulin. The protein input column 
was visualized by Coomassie Blue staining. (B) CK2β does not interact physically with tubulin. 5 µg 
of His-CK2α or His-CK2β, were incubated with 2.5 µg of purified tubulin. There was no His-CK2α or 
His-CK2β in the beads control sample. After pull-down with Ni-NTA beads, bound proteins were 
analyzed by anti-β-tubulin immunoblotting. (C) Direct association of CK2 with microtubules. 1 µg of 
GST, CK2α, CK2β or the CK2 holoenzyme was incubated with microtubules pre-assembled using 
taxol from 10 µg of purified tubulin. After precipitation of the microtubules, proteins in the supernatant 
and the microtubule pellet were analysed by immunoblotting using an antibody mixture recognizing 
GST, CK2α and CK2β. The protein input (50%) shows the amount of the individual proteins used in 




FIG. 2. Cellular localization of CK2α and CK2β to microtubules. (A) COS7 cells were 
immunostained for confocal microscopic analysis. Top row, double-staining of CK2α and β-tubulin; 
bottom row, CK2β and β-tubulin. The secondary antibody used for CK2α/β was Fluor488-conjugated 
anti-mouse IgG, while tubulin was stained with Fluor594-conjugated anti-rabbit IgG. Bar = 20 µm (B) 
Soluble tubulin heterodimers (free tubulin) and microtubules (polymerized tubulin) were differentially 
extracted from HeLa cells. Both fractions as well as the total cell lysate (TCL) were analysed by 
immunoblotting using antibodies as indicated. The histogram shows the relative amounts of CK2α and 
CK2β in the free and polymerized tubulin fractions. These data are representatives of three independent 
experiments.  
 94
3.2.2.2 CK2 induces microtubule polymerization 
We next probed whether CK2 has any effect on microtubule dynamics by using 
an in vitro turbidometric assay for microtubule assembly from purified MAP-free 
tubulin (Gaskin, 1982). As tubulin polymerizes or depolymerizes in the assay, the 
turbidity change of the solution is measured. In the absence of CK2, there is minimal 
self polymerization of tubulin even after prolonged incubation (Figs. 3A & 3B). 
Addition of CK2 to tubulin at a ratio of 1:240 resulted in substantial polymerization of 
tubulin into microtubules (Figs. 3A & 3B). Clearly, both the rate and the extent of the 
polymerization were dramatically enhanced by CK2. When the amount of CK2 was 
increased, the rate of tubulin polymerization increased in a dose-dependent manner 
(Figs. 3A & 3B). To verify microtubule formation, rhodamine-labelled tubulin was 
added into the polymerization mixtures for direct visualization of the assembled 
microtubules by fluorescence microscopy (Belmont et al., 1990). As shown in Fig. 3C, 
microtubule filaments and bundles were readily observed with the CK2-incubated 
tubulin, whereas the incubation of tubulin without CK2 showed no obvious 
microtubule formation. Therefore, in addition to its high affinity for tubulin and 
microtubules, CK2 also induces the assembly of tubulin into microtubules. Moreover, 
CK2 appears to cause microtubule bundling, suggesting a strong stabilizing effect on 
the microtubules. 
 
The holoenzyme of CK2 is a tetrameric complex of two α or α’ subunits and 
two β subunits (Niefind et al., 2001). Given the observation that CK2α of the 
holoenzyme interacts with microtubules, we explored if the microtubule-assembling 
activity of CK2 is restricted to the holoenzyme by examining the α and β subunits of 
CK2 individually in the microtubule assembly assay. In contrast to the holoenzyme, 
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both the α or β subunit induced only very minimal polymerization of tubulin even after 
prolonged incubation (Fig. 4). Both the CK2α and CK2β-polymerized samples were 
not markedly different from background tubulin polymerization in the GST-incubated 
sample. Thus, only the CK2 holoenzyme, but not any of the individual subunits, has the 
ability to induce microtubule assembly, even though CK2α on its own has microtubule-
binding activity. 
 
CK2 has been known to catalyze the phosphorylation of a neural isoform of β-
tubulin and some of the MAPs, raising the possibility that it may affect microtubule 
dynamics through its kinase activity (Diaz-Nido et al., 1988; Diaz-Nido et al., 1990). 
Although ATP was not present in the in vitro microtubule assembly assay, CK2 is 
capable of utilizing either ATP or GTP as a phosphate donor in its phosphorylation 
reactions (Niefind et al., 1999). We therefore sought to assess the role of the CK2 
kinase activity in inducing microtubule assembly. A kinase-inactive holoenzyme of 
CK2, in which CK2α was replaced with the kinase-inactive mutant CK2αΚ68A, was 
tested in the microtubule assembly assay. Fig. 5 shows that the kinase-inactive CK2 
conferred similar microtubule-polymerizing activity as the wild-type enzyme, 
indicating that the microtubule assembly activity of CK2 is independent of its kinase 
activity and did not result from the phosphorylation of any microtubule-associated 
proteins. 
 
Microtubules from brains can be separated into two biochemically distinct 
pools, namely the “cold labile” and the “cold stable” pools, according to whether they 
are resistant to cold treatment, which disassembles microtubules (Webb and Wilson, 
1980). It was found that CK2 was enriched in the cold stable fraction of the 
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microtubule preparation from rat brain (Serrano et al., 1989). This observation, 
together with our findings that CK2 associates with microtubules to promote 
microtubule assembly, prompted us to explore the possibility that CK2 may contribute 
to the cold stability of microtubules. To test this likelihood, CK2-polymerized 
microtubules were incubated on ice and the turbidity change was monitored. As a 
comparison, tau-polymerized microtubules were treated under the same condition 
(given the fact that tau does not confer the cold stability to microtubules (Baas et al., 
1994)). As expected, the tau-polymerized sample was depolymerized almost 
completely within a few minutes (Fig. 6). However, the turbidity of the CK2-
polymerized sample was only marginally reduced, even after a prolonged incubation on 
ice (Fig. 6). This result indicates that CK2 functions to stabilize microtubules against 
cold-induced disassembly. 
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 FIG. 3. Effect of CK2 on microtubule assembly. (A) The turbidmetric assay of tubulin 
polymerization. Microtubule assembly from purified MAP-free tubulin was carried out in the 
presence of the CK2 holoenzyme at various concentrations (in terms of molar ratios to 
tubulin). The concentration of tubulin was kept constant in each assay at 2 mg/ml. (B) A 
histogram of the microtubule assembly at various amounts of CK2. The assembly assay was 
performed as described in (A) for 30 min. The data shown are averages of three separate 
experiments. (C) Fluorescent imaging of microtubules polymerized from a mixture of 
rhodamine-labelled and unlabelled tubulin (7:1). The tubulin concentration is 2 mg/ml and the 
CK2 concentration is 62 µg/ml. The arrows point to microtubule bundles in the CK2-
polymerized sample. Bar = 20 µm 
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 FIG. 4. Microtubule assembly can be induced by the CK2 holoenzyme but not its 
individual subunits. GST, GST-CK2α and His-CK2β were applied as indicated at 0.1 mg/ml 
in the microtubule-assembly assay. As a control, the CK2 holoenzyme reconstituted from the 
same amount of GST-CK2α and His-CK2β as described above was applied. Microtubule 
assembly was performed at 2 mg/ml of tubulin as described in the Experimental Procedures. 
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 FIG. 5. The kinase activity of CK2 is not required for its function to induce microtubule 
assembly. The wild-type CK2 enzyme (GST-CK2α/His-CK2β) and the kinase-inactive 
enzyme (GST-CK2αK68A/His-CK2β) were applied as indicated at 0.1 mg/ml in the 
microtubule assembly assay. GST-CK2αK68A and GST were also tested at the same 
amount. Microtubule assembly was performed with 2 mg/ml of tubulin as described in the 
Experimental Procedures. 
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 FIG. 6. CK2 confers cold stability to microtubules. Microtubules were polymerized with 
0.05 mg/ml of CK2 or 0.16 mg/ml of tau protein for 30 min at 35˚C, where they had attained 
similar turbidity measurement. The microtubule samples were then incubated on ice and the 
turbidity measurement was started. The absorbance was expressed as percentages of the 
measurement when the ice incubation was started. 
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3.2.2.3 CK2 stabilizes microtubules in vivo 
To evaluate the role of CK2 in microtubule dynamics in vivo, we knocked down 
the expression of CK2α/α' in HeLa cells by a gene silencing approach using a siRNA 
duplex designed based on the human cDNA sequence of CK2α/α' (Sayed et al., 2001; 
Ulloa et al., 1993). As shown by the CK2α immunoblot, the introduction of CK2α/α' 
siRNA into the cells led to a dramatic decrease of the CK2α/α' proteins  to a minimal 
level (approximately 80% decreased) (Fig. 7A). To assess the effect of CK2α/α' 
knockdown on microtubules, the amounts of cellular microtubules (assembled 
insoluble tubulin polymers) were determined using the differential extraction method 
followed by immunoblotting (Lieuvin et al., 1994). In addition, the integrity of the 
cellular microtubule network was examined by immunofluorescent staining and 
confocal microscopy. The knockdown of CK2α/α' significantly reduced the cellular 
content of microtubules (Figs. 7A & 7B), suggesting CK2 as one of the factors 
stabilizing microtubules in vivo. We further assessed the microtubule stability using 
colchicine, a microtubule-disrupting agent. When colchicine was applied at a low 
concentration (0.2 µM) onto the cells which were transfected with a scrambled siRNA 
sequence, most of the microtubule structure remained intact (Figs. 7A & 7B). However, 
such a low dose of colchicine caused severe disruption of the microtubule structure in 
the CK2α/α'-depleted cells with the microtubule networks collapsed towards the 
perinuclear region (Fig. 7B). Only negligible amount of microtubules could be 
extracted from these cells (Fig. 7A). Apparently, the removal of CK2α reduced the 
stability of cellular microtubules. As a result, it was readily disrupted by colchicine at a 
very low concentration. 
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To further substantiate the microtubule-stabilizing function of CK2, we tested 
whether the microtubule stability could be restored by expression of chicken CK2α in 
cells where endogenous CK2α/α' had been depleted. As observed with the HeLa cells, 
knockdown of CK2α/α' in cultured human 293T fibroblasts using the siRNA strongly 
destabilized the microtubule network, resulting in almost complete disruption of the 
microtubules by colchicine at 0.2 µM (Fig. 7C). When chicken CK2α was expressed in 
the 293T cells in which endogenous CK2α/α' was knocked down, the cellular 
microtubules completely retained their integrity against 0.2 µM colchicine-induced 
disruption (Fig. 7C). More interestingly, when the kinase-inactive mutant CK2αK68A 
was expressed, it exhibited the same effect as the wild-type CK2α in rescuing the 
microtubules from being disrupted by the colchicine treatment (Fig. 7C). These data 
demonstrate that CK2 is an important mediator of cellular microtubule stability and 




FIG. 7. CK2 stabilizes microtubules in vivo. (A) HeLa cells were introduced with siRNA of 
human CK2α/α' or a scrambled sequence. Knockdown of CK2α was monitored by anti-CK2α 
immunoblotting. The cells were subsequently treated with 0.2 µM of colchicine or its solvent. 
Tubulin in the form of polymers (microtubules) was extracted from the cells for β-tubulin 
immunoblotting. The histogram reflects relative amounts of the microtubules extracted from 
the cells as indicated to that of the control, which is the sample transfected with the scrambled 
siRNA sequence and treated without colchicine. The data are representatives of three 
separate experiments. (B) Cells in the experiments described in (A) were fixed and stained 
with the β-tubulin antibody for confocal microscopic imaging. Bar = 20 µm (C) Expression of 
the wild-type or the kinase-inactive mutant of chicken CK2α restored the microtubule stability 
against the colchicine treatment in CK2α/α'-depleted cells. Prior to treatment of colchicine 
(0.2 µM), 293T cells were double transfected with siRNA of human CK2α/α' and one of 
following expression constructs: chicken CK2α, the kinase-inactive mutant of chicken CK2α 
(CK2αK68A) and the empty vector. Expression of Myc-tagged chicken CK2α and CK2αK68A 
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was detected by anti-Myc immunoblotting of the cell lysates. Microtubules were extracted 
using the differential extraction method (see Experimental Procedures) for anti-β-tubulin 




In living cells, the microtubule architecture is stabilized by structural MAPs, 
which associate with microtubules and promote microtubule assembly in vitro (Desai 
and Mitchison, 1997; Mandelkow and Mandelkow, 1995). The evidence presented here 
identifies CK2 as a structural MAP that mediates microtubule dynamics. We have 
conducted experiments showing that CK2 is localized to and co-extracted with 
microtubules. The in vitro binding assays demonstrate a direct interaction of CK2 with 
microtubules as well as tubulin heterodimers. Microtubule-binding sequences are often 
found in MAPs as repeated sequence stretches enriched in basic amino acids. Although 
the sequence of CK2α contains some basic regions, there is no typical microtubule-
binding motif. Thus, the microtubule association of CK2α suggest the existence of 
novel microtubule-binding domains within the molecule. In addition, although CK2α 
also binds p35, both p35 and microtubule are likely to bind CK2α mutually since a 
p35-CK2 complex interacts physically with tubulin and induces microtubule assembly 
synergistically (Lim, AC and Qi, RZ, unpublished data). 
 
Structural MAPs such as MAP2 and tau are known to stimulate microtubule 
assembly from tubulin heterodimers. In our microtubule assembly assays, CK2 
exhibited a potent activity in inducing microtubule assembly and bundling from 
purified tubulin. The physical association of CK2 to microtubules and tubulin 
heterodimers stimulates both the rate and the extent of microtubule growth. Although 
CK2α can bind microtubules, the microtubule-assembling and stabilizing function is 
solely a property of the holoenzyme and neither of the subunits alone can induce 
polymerization. In addition, CK2-polymerized microtubules display greatly enhanced 
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stability against the cold treatment, suggesting that CK2 is a strong stabilizer of 
microtubules. Taken together with the observation that a substantial amount of CK2 
exists in the cold-stable microtubules of rat brain (Serrano et al., 1989), our findings 
suggest that CK2 is a new factor endowing cold stability to microtubules. To date, the 
STOP proteins, doublecortin and BPAG1n3 are the only known MAPs conferring cold 
stability to microtubules (Denarier et al., 1998; Gleeson et al., 1999; Guillaud et al., 
1998; Horesh et al., 1999; Yang et al., 1999). 
 
Structural MAPs are known to contribute to microtubule stability and 
distribution within cells (Feng and Walsh, 2001). The finding of CK2 as a structural 
MAP prompted us to evaluate the regulatory role of CK2 in vivo in the microtubule 
cytoskeleton. The knockdown of CK2α/α' from cells has a strong destabilizing effect 
on the microtubule architecture. As a result, the microtubule network is very vulnerable 
and can be readily destroyed by a colchicine insult at 0.2 µM, while such a low 
concentration of colchicine had no significant effect on microtubules of the cells with 
intact CK2. Thus, CK2 appears to have an indispensable role in stabilizing cellular 
microtubules. This is substantiated by the experiment in which chicken CK2α was 
introduced into the cells to compensate for the loss of the endogenous CK2α/α'. The 
microtubule instability caused by the deficit of CK2α/α' can be rectified completely by 
the expression of chicken CK2α, reassuring that CK2 is a vital structural MAP 
conferring the microtubule stability in vivo. It is noteworthy that the removal of 
CK2α/α' did not by itself cause severe disruption of the microtubules, possibly due to 




CK2 is a Ser/Thr protein kinase with a broad substrate spectrum that includes 
MAP1B and a neural-specific isoform of β-tubulin. We have examined if the kinase 
activity of CK2 is involved in the microtubule assembly stimulated by CK2. Our in 
vitro assays of microtubule assembly using the kinase-inactive mutant of CK2 indicate 
that the microtubule-assembling activity of CK2 is independent of its kinase activity. 
This was corroborated using the CK2α/α'-knockdown cells, in which expression of the 
kinase-inactive mutant of chicken CK2α completely compensated for the loss of the 
endogenous CK2α/α', rendering the microtubules resistant to colchicine. With these 
results, it becomes clear that CK2 imparts a direct regulation of microtubule 
organization through its physical association with microtubules but not through any 
enzymatic action. As a multifunctional enzyme, CK2 has been thought to execute its 
functions through its phosphorylation of a wide range of substrates. The results 
presented here have revealed a novel CK2 function that is not associated from its 
intrinsic kinase activity. 
 
It has been proposed that CK2 plays an important role in the maintenance of 
cell morphology and polarity. Depletion of the catalytic subunits of CK2 in 
neuroblastoma cells using an antisense approach blocks neuritogenesis (Ulloa et al., 
1993; Ulloa et al., 1994). Pertinent observations also came from yeasts, where the use 
of temperature-sensitive mutants of CK2α and CK2β demonstrated the importance of 
these proteins in cell morphogenesis (Rethinaswamy et al., 1998; Roussou and Draetta, 
1994; Snell and Nurse, 1994). The function described here for CK2 in microtubule 
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4. Summary and Perspectives 
 
Cdk5 is a unique member of the Cdk family of small protein kinases. Despite 
having 60% sequence identity with Cdk1 and Cdk2, a role for Cdk5 in cell cycle 
regulation has yet to be identified. Cdk5 is dependent on the association with its 
protein activator (p35 or p39) for its kinase activity. Although Cdk5 is ubiquitously 
expressed, its kinase activity is restricted almost exclusively to the nervous system by 
the neural-specific expression of its regulators p35 and p39 (Ko et al., 2001). Though 
Cdk5 has been shown to play pivotal roles in a variety of cellular processes occurring 
in the CNS, little is known about the regulation of this kinase. To investigate the 
regulation and functional properties of Cdk5, we employed the immunoprecipitation 
methodology, as well as an affinity purification approach to isolate novel p35-binding 
proteins from rat brain extracts. With the latter approach, the catalytic α subunit of 
protein kinase CK2 was identified as a novel binding protein of p35 (section 3.1). The 
evidence presented here suggests that CK2 is a negative regulator of Cdk5-p35 
kinase. Based on the results from the protein size exclusion chromatography as well 
as co-immunoprecipitation assays, CK2α but not the CK2 holoenzyme co-exists with 
p35 and Cdk5 in vivo, though the holoenzyme exhibits a p35-binding capability in 
vitro. CK2 exhibited a strong inhibition on the Cdk5 activation by p35 in vitro and in 
vivo. The Cdk5 inhibition is however not associated with CK2 kinase activity since 
the kinase-dead CK2 mutant displayed an analogous effect as the wild-type protein. 
Surprisingly, the binding of CK2 to p35 is sufficient to block complex formation 
between p35 with Cdk5, thereby inhibiting the p35-associated Cdk5 activation. 
Hence, CK2 and Cdk5 interact with p35 in a mutually exclusive manner and this 
inhibition effect is reminiscent of the Cdk4/6 inhibition by the INK4 family members 
(Russo et al., 1998; Guan et al., 1996; Hirai et al., 1995). In addition, it is noteworthy 
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that cells with higher proliferation rates generally exhibit higher levels of CK2 
(Munstermann et al., 1990), whereas no Cdk5 activity was found in proliferating 
neuronal precursors (Tsai et al., 1993). Possibly, the presence of CK2 in the 
proliferating cells helps to maintain Cdk5 activity to a minimal level. 
 
Cdk5 is currently the only functional Cdk found in healthy mature neurons, 
where it has been implicated in various important cellular activities. There is growing 
evidence that Cdk5 kinase activity might be elevated during neurodegeneration and 
deregulation of Cdk5 activity is detrimental to cell survival (Nguyen et al., 2001; 
Patrick et al., 1999). The production of p25 (p29 in p39), a truncated form of p35, in 
neurons correlates with their susceptibility to agents that disrupt calcium homeostasis 
(Lee et al., 2000; Patzke and Tsai, 2002). Calpain, a calcium-dependent protease, 
induces the conversion of p35 to p25 (Lee et al., 2000; Kusakawa et al., 2000). 
Though p25 contains all the elements necessary for Cdk5 binding and activation (Qi 
et al., 1995; Poon et al., 1997), its in vivo properties are distinct from those of p35 
(Patrick et al., 1999). Firstly, p25 has a substantially longer half-life than p35 and is 
able to associate with Cdk5 leading to a sustained activation of the kinase (Patrick et 
al., 1999; Patzke and Tsai, 2002). Secondly, in brain extracts Cdk5-p35 exists in 
macromolecular complexes displaying little kinase activity while Cdk5-p25 exists as a 
highly active heterodimer. Thirdly, in contrast to p35, p25 lacks the myristoylation 
sequence for membrane targeting and therefore is not associated with the plasma 
membrane (Patrick et al., 1999; Patzke and Tsai, 2002). Presumably, the conversion 
of p35 to p25 relocates Cdk5 from its normal compartments since p25 is concentrated 
in the cell body and nucleus (Patrick et al., 1999). One of the major pathological 
targets of the Cdk5/p25 complex is the microtubule-associated protein tau. Abnormal 
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phosphorylation of tau has been implicated in the pathology of several 
neurodegenerative diseases, such as AD and Parkinson’s disease. The expression of 
p25/Cdk5 in cultured cortical neurons induced hyperphosphorylation of tau, neurite 
retraction, cytoskeletal abnormalities and apoptosis (Patrick et al., 1999). This is 
further supported by recent studies showing that mice overexpressing p25 caused 
hyperphosphorylation of tau and neurofilaments, cytoskeletal disruption and 
behavioral deficits reminiscent of AD (Ahlijanian et al., 2000; Noble et al., 2003; 
Cruz et al., 2003). Hence, dysregulation of Cdk5 activity may lead to neuronal 
degeneration. 
 
Neuronal Cdk5 kinase has been implicated in the pathological degeneration of 
neurons and hence modulating its kinase activity is important. Here, we have 
identified CK2 as a novel interacting protein, as well as a negative regulator of Cdk5. 
We have also presented a novel function of CK2 since its inhibitory activity on Cdk5 
is not associated with its intrinsic kinase activity. What remains to be determined is 
the understanding of when and where in the cells CK2 acts to regulate Cdk5 
activation. Also the mechanism of how p35 is released from its association with CK2 
needs to be established. The binary complexes of p35-CK2 or p35-Cdk5 are stable 
and cannot be dissociated by introducing Cdk5 or CK2, respectively. CK2 may act as 
a sentinel molecule in cells to control the Cdk5 activation. Upon dissociation of CK2 
from p35, the latter will bind to and activate Cdk5, which in turn catalyses the 
phosphorylation of p35, promoting the p35 degradation via the proteasome-dependent 
pathway (Patrick et al., 1998). Conceivably, the CK2 association prevents unwanted 
Cdk5 activation and p35 turnover, thereby preserving the supply of p35. Previously, 
biochemical separation of brain extract hinted the presence of inhibitory factor(s) in 
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Cdk5-p35 macromolecular complexes and this inhibitory effect can be liberated when 
fractionation was performed in the presence of 10% ethylene glycol (Lee et al., 
1996a). Preliminary investigation showed that the elution profiles of Cdk5, p35 and 
CK2α were unaffected by the presence of ethylene glycol, but surprisingly, CK2β co-
eluted together with Cdk5, p35 and CK2α at the void volume of the column under 
this new condition (Lim AC and Qi RZ, unpublished result). We showed that Cdk5 
binds to the catalytic subunit but not the holoenzyme of CK2 in vitro. Possibly under 
normal conditions, CK2α that is devoid of its regulatory β-subunit interacts physically 
with Cdk5, thereby inhibiting the formation of Cdk5-p35 kinase. The presence of 
ethylene glycol may have caused a distinctive change in the elution profile of CK2β, 
and in so doing liberated CK2α from some of its binding proteins including Cdk5 and 
p35 to form the holoenzyme with CK2β. Hence, it is possible that endogenous Cdk5 
monomer may then be activated by adding its exogenous activator. 
 
In addition to CK2α, a list of other Cdk5/p35-interacting proteins was also 
identified and these proteins can be mainly classified into two different categories. 
The former includes cytoskeletal and cytoskeleton-associated proteins. Cdk5 is the 
only kinase that affects the electrophoretic mobility of human NF-H and is thought to 
be the major neurofilament kinase (Kesavapany et al., 2003b). Cdk5 is involved in 
crosstalk with other signal transduction pathways such as the MAPK and the myelin-
associated glycoprotein pathways to influence the phosphorylation of neurofilaments 
and other cytoskeletal proteins. Both the hyperactivation of Cdk5 activity and the 
subsequent hyperphosphorylation of neurofilaments and tau protein have been 
implicated in the pathogenesis of neurodegenerative disorders such as AD and 
amyotrophic lateral sclerosis. Drebrin is an actin-associated protein where it co-
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localizes with the actin filaments and has been suggested to regulate the assembly and 
disassembly of actin filaments (Shirao et al., 1994; Asada et al., 1994). Previously, 
p39 has been reported to bind actin and hence, Cdk5 may play a role in the 
modulation of the cellular actin dynamics. The interaction between p35 with α- and β-
tubulin may have a role in the regulation of cellular microtubule dynamics. The latter 
group of p35-binding proteins isolated includes proteins that are involved in signal 
transduction and other neuronal processes. Coincidentally, some of these proteins 
have been reported previously to be Cdk5/p35-interacting proteins (Table A & B). 
 
Microtubule dynamics is essential for many vital cellular processes such as 
morphogenesis and motility. Previous reports have established the co-existence of 
Cdk5-p35 kinase with microtubule in brain extract (Sobue et al., 2000; Paudel et al., 
1993). Furthermore, we have isolated CK2 as a p35-binding protein and previous 
studies have also implicated CK2 in regulating of microtubule cytoskeleton 
reorganization (Serrano et al., 1987; Diaz-Nido et al., 1988; Serrano et al., 1989). 
These few lines of evidence prompted us to explore the involvement of CK2 complex 
in mediating microtubule dynamics. We showed that the CK2 holoenzyme interacts 
directly with both microtubules and tubulin heterodimers through its catalytic subunit 
(section 3.2). Though CK2α does not have any typical microtubule-binding motif, its 
sequence contains some basic regions, reminiscent of new microtubule-binding 
domains. We demonstrated that the CK2 holoenzyme, but neither of its individual 
subunits, exhibited a potent activity of inducing microtubule assembling and 
bundling. Moreover, CK2-polymerized microtubules were strongly stabilized against 
cold-induced depolymerization, suggesting CK2 as a new factor in endowing the cold 
stability on microtubules. Interestingly, CK2 enzymatic activity is not necessary for 
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its microtubule assembling and stabilizing function since a kinase-dead mutant 
displays analogous activity as the wild-type protein. Given the fact that CK2 is a 
serine/threonine protein kinase with a myriad of substrates (Meggio and Pinna, 2003), 
we have presented a novel CK2 function that is independent to its intrinsic kinase 
property. In vivo, CK2 has a strong stabilizing effect on the microtubule architecture 
since knockdown of its catalytic subunit renders the cells very vulnerable to 
destruction by low concentration of colchicines insults. Microtubule instability can be 
rectified completely by the expression of chicken CK2α in CK2α-depleted cells, 
substantiating the notion that CK2 is a vital structural MAP that confers microtubule 
stability in vivo. Several studies have indicated that CK2 is instrumental and 
necessary in cell survival (Ahmed et al., 2002; Pinna, 2002; Litchfield, 2003). In this 
regard, CK2 has been postulated to play a central role in protecting cells against 
stress-induced apoptosis. Taken together, our observation that CK2 confers protection 
against colchicine-induced disruption of microtubule network implies that CK2 may 
be a cell survival molecule. 
 
It remains to be determined if the effects and mechanism reported here are 
important in neuronal cells. Observations from our laboratory showed that p35 is also 
associated and co-localized with the cellular microtubule network. Since both p35 and 
CK2 have direct effect on microtubule dynamics independently, it would be of further 
interest to define if a p35-CK2 complex may enhance or have further effect on the 
cellular microtubule architecture. Our preliminary results show that this protein 
complex has a major direct effect on enhancing microtubule polymerization 
synergistically in vitro (Lim AC and Qi RZ, unpublished result). Seemingly, the 
physical association between p35 and CK2 may serve more than one function, though 
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this is yet to be further explored. Possibly, p35 may play independent roles with CK2 
at “the right place and the right time”. The sequence of CK2α contains several basic 
regions, reminiscent of the typical nuclear localization sequence (NLS). Although no 
nuclear import of CK2α has been reported, CK2α has been observed to be localized 
to the nucleus (Filhol et al., 2003), hinting a possible role for these basic regions in 
the localization of CK2α. Analogous to Cdk5-p35, CK2 is a protein kinase that brings 
about phosphate transfer reactions in order to regulate various cellular functions. CK2 
binds Cdk5/p35 and down-regulates the activation of Cdk5 by p35. It remains to be 
determined what complementary effects Cdk5 and/or p35 may have on CK2 in the 
cells. Since CK2 interacts with tubulin as well as p35, it would also be desirable to 
fine map the regions on CK2 that interacts with either proteins. More importantly, the 
significance and detailed molecular mechanisms underlying the interactions between 
CK2 with p35 and tubulins, respectively, remain to be further elucidated. 
 
Immense progress has been made in identifying the regulatory mechanisms 
involved in Cdk5 signaling. Recent results have broadened our perspective and 
include more variables in our perception of the cellular functions of Cdk5. Moreover, 
there is growing evidence implying that aberrant regulation of Cdk5 leads to 
neurodegeneration and cell death. Hence, instead of identifying a conclusive 
regulatory mechanism for this enzyme, its network of signaling mechanisms is much 
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Cables enhances c-Abl’s association and phosphorylation 
of Cdk5 at Tyr15 
(Zukerberg et 
al., 2000) 
Fyn promotes Cdk5 activity through phosphorylation 
of Tyr15 
(Sasaki et al., 
2002) 
SET enhances Cdk5-p35 activity (Qu et al., 
2002) 
C42 inhibits Cdk5 activation by p35 (Ching et al., 
2002) 




DbpA inhibits Cdk5-p35 activity (Moorthamer 
et al., 1999) 
Ubiquitin proteasomal degradation of p35 (Patrick et 
al., 1998) 
Rac phosphorylation of PAK1  (Nikolic et 
al., 1998; 
Rashid et al., 
2001) 
PAK1 phosphorylation of PAK1 (Nikolic et 
al., 1998; 
Rashid et al., 
2001) 
Actin potential role in actin dynamics (Humbert et 
al., 2000a) 




NFH/NFM phosphorylation of NFH/NFM (Lew et al., 
1994; Grant 
et al., 2001) 




Munc 18 phosphorylation of Munc 18 (Fletcher et 
al., 1999; 
Shuang et al., 
1998) 
Syntaxin 1A mediates trafficking and secretion (Shuang et 
al., 1998) 
Amphiphysin 1 phosphorylation of amphiphysin 1 (Floyd et al., 
2001) 
CaMKIIα regulation of synaptic plasticity (Dhavan et 
al., 2002) 
β-Catenin regulates N-cadherin-mediated cell adhesion and 
the association of β-catenin with presenilin 1 




et al., 2001) 
PP1 phosphorylation of PP1.I-2 (Agarwal-
Mawal and 
Paudel, 2001)
pRb phosphorylation of pRb (Lee et al., 
1997) 
PCTAIRE1 phosphorylation of PCTAIRE1 (Cheng et al., 
2002) 
Lipofuscin putative pathogenic process of ALS (Bajaj et al., 
1998) 
ErbB mediates neuregulin-induced AChR expression at 
neuromuscular junction 
(Fu et al., 
2001) 
C48 not known (Ching et al., 
2000) 
C53 not known (Ching et al., 
2000) 
IC53 human homologue of rat C53 and potential role in 
cell proliferation 
(Chen et al., 
2002) 
IC53-2 human homologue of rat C53 and potential role in 
cell proliferation 
(Xie et al., 
2003a) 
Cyclin D Cdk5 binding protein and potential regulator of 
Cdk5 
(Xiong et al., 
1992) 




Ik3-2 homologue of Cables (ik3-1) (Sato et al., 
2002) 




phosphorylates and regulates CPRK activity (Kesavapany 
et al., 2003a) 









Table B. Cdk5 substrates 
Cdk5 Substrate 
 
Putative function of phosphorylation 
 
Reference(s) 
p35 suppresses the proteolytic conversion of p35 
to p25 by calpain and facilitates the 
proteasomal degradation of p35 
(Patrick et al., 
1998) 
Cables mediates its interaction with Cdk5 (Zukerberg et 
al., 2000) 
PAK1 inhibits PAK1 activity and regulates 
cytoskeletal dynamics 
(Nikolic et al., 
1998; Rashid 
et al., 2001) 




Tau regulates microtubule binding and dynamics (Baumann et 
al., 1993) 
MAP1B regulates microtubule stability (Pigino et al., 
1997; Paglini 
et al., 1998) 
Nudel regulates dynein-mediated axonal transport (Niethammer 
et al., 2000) 
Synapsin 1 regulates synaptic transmission (Matsubara et 
al., 1996) 
Munc 18 mediates the interaction between Munc 18 
and syntaxin 1A 
(Shuang et al., 
1998) 
Amphiphysin 1 regulates synaptic vesicle endocytosis and 
neurite outgrowth 










regulates synaptic transmission, plasticity and 
hippocampal CA1 cell death 
(Li et al., 
2001; Wang 
et al., 2003) 
Src regulates functions of Src in neurons (Kato and 
Maeda, 1999) 
β-APP mediates APP localization and function (Iijima et al., 
2000) 
β-catenin regulates N-cadherin-mediated cell adhesion 
and the association of β-catenin with 
presenilin 1 
(Kwon et al., 
2000; 
Kesavapany 
et al., 2001) 
Presenilin 1 regulates PS1 stability and metabolism (Lau et al., 
2002) 




DARPP-32 regulates dopamine signaling and the (Bibb et al., 
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stimulant action of caffeine 1999; 
Lindskog et 
al., 2002) 
MEK1 inhibition of MEK1 activity (Sharma et 
al., 2002) 
JNK3 inhibits JNK3 activity and mediates neuronal 
apoptosis 
(Li et al., 
2002) 





pRb mediates neuronal apoptosis (Lee et al., 
1997) 
p53 mediates p53 transcriptional activity (Zhang et al., 
2002b) 
MEF2 inhibits MEF2 transcriptional activity and 
mediates neuronal apoptosis 
(Gong et al., 
2003) 
Dab1 mediates neuronal migration (Keshvara et 
al., 2002) 
PCTAIRE1 promotes the PCTAIRE1 activation (Cheng et al., 
2002) 
ErbB mediates neuregulin signaling at the 
neuromuscular junction 
(Fu et al., 
2001) 
ErbB2/ErbB3 regulates neuregulin-induced Akt activity and 
neuregulin-mediated neuronal survival 
(Li et al., 
2003) 
Outer Dense Fibers Regulation of sperm tail development (Rosales et 
al., 2003) 
FAK mediates microtubule organization, nuclear 
movement and neuronal migration 




regulates CPRK activity (Kesavapany 
et al., 2003a) 
Nestin regulates organization of nestin and its 
association with p35 
(Sahlgren et 
al., 2003) 
Pγ (retinal cGMP 
phosphodiesterase) 
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Abstract. There is increasing evidence suggesting that cyclin-dependent kinases (Cdks) that normally regulate cell cycle progres-
sion may also be involved in the pathogenesis of neurodegenerative disorders and in the apoptotic death of neurons subjected to
various insults. Deregulation of Cdks has been observed in an increasing number of neurological disorders, including Alzheimer’s
and Parkinson’s diseases as well as amyotrophic lateral sclerosis (ALS). Unchecked expression of these proteins can potently
induce apoptotic or necrotic neuronal cell death. Cdks initiate death pathways by derepressing E2F-1/pRb-dependent transcription
at neuronal G1/S checkpoint. On the contrary, deregulation of Cdk5, which is not involved in cell cycle control, contributes
to neurodegeneration by altering the phosphorylation state of non-membrane-associated proteins. This review describes work
indicating Cdks’ roles in the nervous system and how they may cogitate in leading neurons to their demise.
Keywords: Cyclin-dependent kinases, cell cycle, neuronal development, degeneration
1. Introduction
The regulation of cell cycle progression is a tightly
controlled process. The timing through the various
phases of G1/S/G2 and M is mediated through an or-
dered progression of Cdk activation [1,2]. Cyclin-
dependent kinases (Cdks) are proline-directed ser-
ine/threonine kinases whose activities are controlled
through a complex series of mechanisms, including
binding to their appropriate cyclin partners, activating
and inactivating phosphorylation modifications, and
endogenous inhibitors of the Cdk activity [2,3]. In gen-
eral, each Cdk periodically interacts with a specific sub-
set of cyclins to regulate the Cdk activity. There are at
least nine different Cdks (Cdk1-Cdk9) and many more
cyclins (cyclin A through T). Cyclin/Cdk complexes
are in turn regulated in defined stoichiometric combi-
nation with specific small inhibitory proteins, the Cdk
inhibitors (CKIs). There are two families of CKIs: the
∗Corresponding author. Tel.: +65 68743782; Fax: +65 67791117;
E-mail: mcblab30@imcb.nus.edu.sg.
INK4 (inhibitor of Cdk4) family members, p16 ink4a,
p15ink4b, p18ink4c and p19ink4d, specifically inhibit cy-
clin D-associated kinases, and the KIP (kinase inhibitor
protein) family members, p21cip1/waf1, p27kip1 and
p57kip2, bind and inhibit the activity of cyclin E/Cdk2,
cyclin A/Cdk2 and cyclin B/Cdk1 complexes [4,5].
In contrast to cell cycle progression, cell death en-
tails a different setup. Cell death can occur through
a spectrum of both necrotic and genetically regulated
processes. The former is associated with the release of
cellular components and inflammation while the latter
(apoptosis) proceeds through highly controlled mech-
anisms [6]. Apoptosis, or programmed cell death, is a
fundamental and essential process in the development
and tissue homeostasis of multicellular organisms. It
is particularly important for the proper development of
highly differentiated organs such as the brain and other
parts of the nervous system. It was reported that half
of all the neurons produced during neurogenesis die
apoptotically before the nervous system matures [7].
In addition, apoptosis is also involved in various neu-
rodegenerative disorders such as Alzheimer’s disease
(AD) and amyotrophic lateral sclerosis (ALS).
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Though cell cycle and apoptosis are quite different
processes, there is evidence that suggests they do share
common connections [8]. During both processes, cells
lose attachment and volume, condense their nuclei, dis-
assemble the nuclear lamina, and display membrane
blebbing. Furthermore, cell cycle and apoptosis share
some common participants including pRb, E2F and
p53. A growing body of evidence has indicated that
deregulation of the cell cycle can either directly trig-
ger apoptosis or increase sensitivity to apoptotic induc-
ers [8,9]. Although neurons are in a state of terminal
differentiation and incapable of undergoing cell divi-
sion, nonetheless they retain certain elements of the cell
cycle machinery and have the capability of reactivating
aspects of the replicative mechanism when under stress.
Here, we discuss the different aspects and roles of the
Cdks and their participation in neural development and
degeneration.
2. Cell cycle Cdks in neural development
Cdks are pivotal cell cycle mediators that regulate
proliferation, differentiation, senescence and apopto-
sis [10]. Neural development involves proliferation of
the precursor cells, cell fate determination, as well as
apoptosis. Cell cycle Cdks are crucial regulators of
proliferation in the precursor stage; their activities are
being blocked by sophisticated mechanisms including
the binding of CKIs once the cells start differentiation;
and eventually in the differentiated cells, these Cdks
are disappeared. Cdks appear to mediate cell cycle pro-
gression by phosphorylating a panel of key substrate
targets. An important and well-characterized target of
Cdks is the retinoblastoma protein (pRb). In mid-to-
late G1, pRb is phosphorylated by cyclin D1/Cdk4/6
and cyclin E/Cdk2 complexes. This phosphorylation
inhibits the negative influence of pRb on the E2F tran-
scription factors, which then proceed to induce expres-
sion of genes controlling DNA replication and subse-
quently cell cycle progression [11]. By using dominant
negative mutants of Cdks, Ferguson and co-workers
showed that both Cdk2 and Cdk4/6 are crucial for cell
cycle regulation in neural precursor cells [12]. More-
over, growth arrest induced by the Cdk4/6 mutants is
pRb-dependent, highlighting the importance of the pRb
regulatory pathway in neuronal development and cell
cycle regulation [12].
Neural development requires a strict control of the
Cdk activities to mediate the entry into, as well as
the withdrawal from the cell cycle. The Wee kinases
block the entry into mitosis by phosphorylating and in-
hibiting the activity of the mitotic kinase, Cdk1. The
unique temporal and spatial patterns of the expression
of various Xenopus Wee kinases were implied to exe-
cute roles in the coordination of neural tissue develop-
ment [13]. Xenopus Wee1 is expressed only as a ma-
ternal gene product; Xenopus Wee2 is predominantly a
zygotic gene product; while a third Wee kinase, Xeno-
pus Myt1, is both a maternal and a zygotic gene prod-
uct. In accord with the changing levels of these Cdk
inhibitory kinases, the pattern of embryonic cell divi-
sion becomes asynchronous and spatially restricted in
the Xenopus embryo. Intriguingly, at the onset of zy-
gotic transcription, Wee2 is expressed in regions of the
embryo that are devoid of mitotic cells whereas Myt1
is expressed in regions of the embryo that have high
levels of proliferation [13].
Another regulatory mode of Cdk activities is through
the CKIs. By insitu hybridization of mouse embryos,
members of the INK4 family, p18 ink4c and p19ink4d,
but not p16ink4a and p15ink4b, were shown to be ex-
pressed in the central nervous system (CNS) during
mouse brain development [14]. Expression of p18 ink4c
in developing brain is restricted to the dividing neu-
roblasts and not the differentiating postmitotic neurons.
Likewise, p18ink4c was expressed precisely at those
developmental stages when neuroblasts switch from a
symmetric to an asymmetric pattern of cell division.
In contrast, p19ink4d expression was seen in the dorsal
root ganglia, spinal cord, and focally throughout the
brain, but primarily in the postmitotic neurons [14].
To further support the notion that there is a region-
specific expression of CKIs in the brain, Legrier and
co-workers exemplified that a number of cell cycle in-
hibitors are expressed in the adult brain either in a ubiq-
uitous fashion (as p19ink4d) or in specific brain regions
(p15ink4b in the forebrain, p27kip1 and p21cip1/waf1
in the cerebellum) [15,16]. In contrast, p18 ink4c ex-
pression was detectably only in the highly neurogenic
olfactory epithelium [15]. Interestingly, p19 ink4d and
p27kip1 were found in mature neurons of the neocortex
and hippocampus, suggesting a dormant cell cycle that
potentially can be activated under appropriate circum-
stances [16]. Indeed, the expression of CKIs in neurons
correlates with their withdrawal from the cell cycle [17,
18].
3. Cell cycle Cdks and neurodegeneration
There is increasing evidence suggesting that Cdks
may have functions beyond the cell cycle regulation.
A.C.B. Lim and R.Z. Qi / Cyclin-dependent kinases in neural development and degeneration 331
Fig. 1. A schematic overview of the involvement of cell cycle Cdks in cell death and neurodegeneration.
A number of reports have indicated the requirement
of Cdk signals for the death of cultured postmitotic
neurons that are exposed to certain death insults. In-
appropriate cyclin B and cyclin D1 transcripts have
been observed in neuronal PC12 cells and sympathetic
neurons deprived of trophic support [19,20]. In addi-
tion, the cyclin D1-associated kinase activity, as well
as the phosphorylation of its substrate pRb, increases
during the death of cultured embryonic neurons that
have been exposed to DNA damage [21] or amyloid-
β [22], the latter being a major toxic component in AD
(Fig. 1). In addition, using transgenic mice express-
ing a mutant superoxide dismutase (SOD1G37R) asso-
ciated with ALS, Nguyen and co-workers showed an
upregulation and mislocalization of Cdk4 in the motor
neurons of these mice. The elevated Cdk4 activity is
associated with increased expression of nuclear Cdk4
and cyclin D1 as well as the abnormal phosphorylation
of pRb protein at the Cdk phosphorylation sites [23].
Previously, apoptotic death was thought to be exclu-
sively related to the process of neuronal selection dur-
ing the CNS development. It is certainly unexpected
that a repertoire of events typical of proliferating cells
might be activated in degenerating neurons. The induc-
tion of Cdks in neurons is associated with their dedif-
ferentiation and triggered neuronal death, which can be
rescued by the use of Cdk inhibitors or the expression of
dominant-negative forms of the kinases [24,25]. Taken
together, inappropriate activation of cell cycle signal,
in particular Cdk4/6-pRb pathway, in the environment
of differentiated postmitotic neuron may lead to death.
4. Cdk5: a Cdk that isn’t cyclin-dependent
Cdks are a family of small protein kinases that share
greater than 40% identity and the activation of Cdks
requires the binding of cyclin [2]. Cdk5 is a unique
member of this family. It was originally discovered
by virtue of its sequence homology to the cell cycle
Cdks [26]. Despite having 60% sequence identity with
Cdk1 and Cdk2, a role for Cdk5 in cell cycle regula-
tion has yet to be identified. Cdk5 is dependent on
the association with two protein activators for its ki-
nase activity. The first activator of Cdk5 was isolated
from mammalian brains and subsequently cloned as a
35-kDa protein, now known as p35 [27,28]. Another
regulator of Cdk5 (p39) was identified by its sequence
homology to p35, with which it shares 57% amino acid
identity [29]. The Cdk5 kinase activity is restricted vir-
tually exclusively to the nervous system by the neural-
specific expression of p35 and p39 [27,29], though re-
cent observations showed it can also be located in other
cell types [30–32]. Despite their distinctiveness, struc-
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amyloid-   , oxidative stress, etcβ
Fig. 2. Cleavage of p35 and p39 is neurotoxic. p35/p39 targets Cdk5 to the membrane, where it phosphorylates several substrates. Calpain,
a calcium-dependent protease, can be activated by oxidative stress and the β-amyloid peptide and it converts p35 and p39 to p25 and p29,
respectively. p25/p29 lacks the myristoylation signal and this leads to aberrant Cdk5 activity, which may results in neuronal death.
tural studies suggest that p35 takes up a cyclin-like fold
that interacts with Cdk5 [33].
The regulation of kinase activity by phosphorylation
is also different for Cdk5. Though the activation of the
authentic Cdks, Cdk1 and Cdk2 requires phosphoryla-
tion of Thr161 and Thr160 respectively in the T-loop,
this step is dispensable for the Cdk5 activation [33,34].
Furthermore, phosphorylation of Tyr15 by Wee1/Myt1
dual-specific kinases inhibits most Cdk family mem-
bers, but not Cdk5 [35]. Interestingly, its activity in-
creases upon phosphorylation at Tyr15 by the enzymes
Abl and Fyn [36,37]. In addition, Cdk5 activity is not
affected by any members of the CKIs [38], which fur-
ther substantiates Cdk5 as a unique member of the Cdk
family.
5. Cdk5 in CNS development
Cdk5 is currently the only functional Cdk found in
healthy mature neurons of the CNS. During neural dif-
ferentiation, the expression of cell cycle Cdks is di-
minished while Cdk5 (and its activators) becomes the
most abundant Cdk [39]. Gene targeting experiments
showed a fundamental role of Cdk5 in CNS develop-
ment. Mice that are deficient of Cdk5 die just before or
after birth and exhibit widespread disruptions in neu-
ronal layering of many brain structures, possibly due to
impairment in neuronal migration [40]. Expression of
the Cdk5 transgene under the p35 promoter in Cdk5-
deficient mice rescues the defects in the nervous system
of the Cdk5-null phenotype, and further demonstrates
that Cdk5 activity is necessary for normal development
of the nervous system [41].
Mice that lack p35 show an inverted layering of cor-
tical neurons, a mild similarity to that seen inCdk5−/−
mice. In contrast to the Cdk5-null mutants, these mice
are viable and fertile, although they are particularly sus-
ceptible to seizures and early lethality [42]. Disruption
of the p35 gene is not lethal due to compensation of the
other activator, p39 [43]. While the p39-deficient mice
do not show any noticeable defects, the phenotype of
the p35/p39 double-mutant mice is indistinguishable
from that of the Cdk5-null mice [43]. Thus, p35 and
p39 are probably the only essential activators of Cdk5
in the brain, and p35 and p39 have redundant as well
as distinct roles in neural development.
p35 knockouts also have defects in the bundling of
nerve fibres of several prominent axon tracts [44]. Both
Cdk5 and p35 are present in axon shafts and growth
cones [45], and inhibition of Cdk5 activity in cultured
neurons shows a decreased capacity to grow or main-
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tain neuritic projections [45], as well as response to
laminin [46]. In Drosophila, an increase or decrease of
Cdk5 activity results in defects in axon pathfinding and
target recognition of the abdominal motor nerves [47],
further establishing a role for Cdk5 in axon guidance
and targeting.
6. Deregulation of Cdk5 and neurodegeneration
There is growing evidence that Cdk5 kinase activ-
ity might be elevated during neurodegeneration and
deregulation of Cdk5 activity is detrimental to cell sur-
vival [48,49]. When Cdk5 was initially isolated from
mammalian brains, it was shown to exist in a het-
erodimeric complex with a 25 kDa regulatory protein
(p25), which was subsequently demonstrated to be a
truncated form of p35 [27,28,50]. The production of
p25 (p29 in p39) in neurons correlates with the expo-
sure to the agents that disrupt calcium homeostasis [51,
52]. Calpain, a calcium-dependent protease, induces
the conversion of p35 to p25 [51,53]. Though p25
contains all the elements necessary for Cdk5 binding
and activation [34,35], its in vivo properties are distinct
from those of p35 [49]. Firstly, p25 has a substantially
longer half-life than p35 and is able to associate with
Cdk5 leading to a sustained activation of the kinase [49,
52]. Secondly, in brain extracts Cdk5-p35 exists in
macromolecular complexes displaying little kinase ac-
tivity while Cdk5-p25 exists as a highly kinase-active
heterodimer. Thirdly, in contrast to p35, p25 lacks
the myristoylation sequence for membrane targeting
and therefore is not associated with the plasma mem-
brane [49,52]. Presumably, the conversion of p35 to
p25 relocates Cdk5 from its normal compartments since
p25 is concentrated in the cell body and nucleus [49]
(Fig. 2).
Both p35 and p39 contain several Cdk5 phospho-
rylation consensus sites. Phosphorylation of p35 by
Cdk5 reduces its stability, leading to its degradation by
the proteasome system, and hence prevents the cleav-
age of p35 by calpain [54]. Proteasome inhibition
may thus keep the p35 level high. As such, the gen-
eration of p25 disrupts the normal regulation of Cdk5
by causing prolonged activation and mislocalization of
Cdk5. One of the major pathological targets of the
Cdk5/p25 complex is the microtubule-associated pro-
tein tau. Abnormal phosphorylationof tau has been im-
plicated in the pathology of several neurodegenerative
diseases, such as Alzheimer’s and Parkinson’s diseases.
The expression of p25/Cdk5 in cultured cortical neu-
rons induced hyperphosphorylation of tau, neurite re-
traction, cytoskeletal abnormalities and apoptosis [49].
This is further supported by recent studies showing that
mice overexpressing p25 caused hyperphosphorylation
of tau and neurofilaments, cytoskeletal disruption and
behavioral deficits reminiscent of AD [55,56]. Tau
aggregation is a common trait of AD and hyperphos-
phorylation of tau has been implicated as an essential
pathogenic means of this process. Mice overexpressing
p25 display enhanced Cdk5 activity, and p25/tau dou-
ble transgenic mice exhibit increased tau hyperphos-
phorylation and accumulation of highly aggregated tau
in the brainstem and cortex, leading to the develop-
ment of neurofibrillary tangles [56], which is a charac-
teristic of many neurodegenerative diseases including
AD. Therefore, Cdk5 may have a major impact on tau
pathology progression, and hence, neurodegeneration.
7. Concluding remarks
Cdks are protein switches of the cell cycle that are
commonly known to regulate cell proliferation. Inter-
estingly, these typical cell cycle regulators can also af-
fect apoptotic signaling, though no clear-cut pro- and
anti-apoptotic effects can be described. Unlike clas-
sical Cdks, Cdk5 has no known role in the cell divi-
sion cycle, but plays important regulatory functions in
mammalian brain development. Growing evidence in-
dicates that these cell cycle regulators, as well as Cdk5,
are becoming mandatory components of the cell death
pathways in neurons. Alteration in expression, cellu-
lar distribution and enzyme activity of these molecules
have been observed in neurons of postmortem samples
in AD, ALS, and several other neurodegenerative dis-
eases. Moreover, aberrant activation of these Cdks can
be triggered in brain neurons after cerebral ischemia
or kainite-induced excitotoxicity as well as in cultured
neurons after treatment with DNA-damaging agents,
deprivation of toxic factors or β-amyloid peptide. Un-
der such in vivo and in vitro conditions, neuronal cell
death can be rescued by the use of CKIs or dominant
negative forms of the kinases. Interestingly, CKIs have
no effect on Cdk5, though a few protein inhibitors of
Cdk5 have been identified. (unpublished observation)
Although Cdk5 is known to be quite different from
other Cdks, there are some interesting similarities be-
tween Cdk5 and its close relative, the mitotic kinase
Cdc2 (Cdk1). For example, a similar process that might
be regulated by Cdk5 in neurons and Cdc2 in dividing
cells is the regulation of cytoskeleton-membrane cou-
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pling events [57]. Furthermore, both kinases have iden-
tical substrate specificities in vitro and several proteins
that function in both mitosis and migration are reported
to be substrates of both kinases. Hence, it is desirable
to develop kinase inhibitors that are highly specific for
each subset of Cdks. More importantly, manipulating
these Cdk activities may thus be beneficial for the treat-
ment of those neurodegenerative diseases, an emerging
killer in the ageing population.
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Abstract
Cdk5 is a unique member of the cyclin-dependent kinase
(Cdk) family of small protein kinases. In association with
its neuron-specific activator p35 or p39, Cdk5 displays
many regulatory properties distinct from other Cdks. A
growing body of evidence has suggested that Cdk5-p35
has important implications in a variety of neuronal activi-
ties occurring in the central nervous system. In brain,
Cdk5-p35 appears to exist as large molecular complexes
with other proteins, and protein-protein interactions ap-
pear to be a molecular principle for Cdk5-p35 to conduct
its physiological functions. Over the past decade, a num-
ber of proteins have been identified to associate with
Cdk5-p35. While the majority of these proteins mediate
their interaction with Cdk5 through p35, implying that
p35 may act not only as an activator of Cdk5 but also as
an adaptor to associate Cdk5 with its regulators and
physiological targets, a small group of other proteins are
found to link directly with Cdk5. In addition, Cdk5 has
been found to phosphorylate a diverse list of substrates,
further implicating its regulatory roles in a wide range of
cellular processes. In this review, we present an updated
inventory of the interacting proteins of Cdk5-p35 kinase
and its substrates as well as a discussion on the impli-
cated effects of these interactions.
Copyright © 2003 S. Karger AG, Basel
Introduction
The process by which extracellular signals are relayed
from the plasma membrane to specific intracellular sites
is highly regulated to control and alter many cellular func-
tions. Protein phosphorylation is one such cellular mecha-
nism, and protein kinases contribute in a variety of ways
to mammalian signal transduction pathways [1, 2]. Cy-
clin-dependent kinases (Cdks), with the exception of
Cdk3 and Cdk5, require the binding of cyclin for their
activation [3, 4]. The active Cdk enzymes mediate the cell
cycle progression by phosphorylating a variety of protein
substrates at the proline-directed Ser/Thr residues. More-
over, the definition of Cdks does not limit their biological
functions to the control of cell proliferation. They also
play a role in differentiation, senescence, and apoptosis
[5].
Cdk5 was initially identified independently by virtue
of its close sequence homology to human Cdk1 (Cdc2), by
biochemical purification from bovine brain based on its
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proline-directed Ser/Thr kinase activity, and by affinity
isolation as a cyclin D1-associated protein in fibroblasts
[6–8]. Cdk5 is an atypical member of the Cdk family.
Despite its close sequence homology with Cdk1, it is not
activated by any cyclin, although it can bind cyclin D1
and cyclin E [8, 9]. The first known activators of Cdk5 are
p35 and its proteolytic product p25 which were isolated as
binding partners of Cdk5 in the brain extract [10]. p25,
which is a 208-residue carboxyl-terminal fragment of p35,
retains the Cdk5 binding and activating domain of p35
[11, 12]. Another activator of Cdk5, p39, was identified
by its sequence homology to p35, with which it shares
57% amino acid identity [13, 14]. Monomeric Cdk5 does
not display any enzymatic activity. The binding to p35,
p25, or p39 activates its kinase activity in the absence of
any Cdk5 modification and association of any other pro-
tein factors [10, 15, 16]. Though Cdk5 is a ubiquitously
expressed protein, its kinase activity is restricted to the
nervous system by the neuron-specific expression of its
activators p35 and p39 [17].
Although Cdk5 is a member of the Cdk family, it is not
involved in cell cycle regulation. Since its discovery more
than a decade ago, Cdk5 has been shown to play an impor-
tant role in many cellular processes occurring within neu-
rons in the central nervous system (CNS) [18]. For exam-
ple, Cdk5 is well known to participate in the regulation of
cytoskeleton organization, axon guidance, membrane
transport, synaptic function, dopamine signaling, and
drug addiction [19]. Gene-targeting experiments have
demonstrated an essential role of Cdk5 in the cellular
organization of the CNS. Mice that are deficient of Cdk5
die just before or after birth and show widespread disrup-
tions in the neuronal layering of many brain structures
[20–22]. The lethality of the Cdk5-deficient mice is likely
to be a result of the defects in the nervous system, since it
can be completely rescued by expressing the Cdk5 trans-
gene under the p35 promoter [23]. In contrast to Cdk5-
deficient mice, p35–/– mice are viable and fertile, though
they have an increased susceptibility to seizures [24, 25].
p35-deficient mice show an inverted layering of cortical
neurons comparable to that observed in the Cdk5–/– mice,
but have only mild disruptions in the hippocampus and
have a fairly normal cerebellum. p39/p35 double knock-
out mice display the same phenotype as the Cdk5–/– mice,
further establishing these proteins as the primary activa-
tors of Cdk5 [17].
It has been shown that cellular Cdk5 exists in three
forms: free monomeric Cdk5, a heterodimeric complex of
Cdk5-p25, and multiprotein complexes of Cdk5-p35 [26,
27]. As revealed by a protein fractionation procedure,
Cdk5-p35 exists as large molecular complexes of more
than 670 kD in the extract of brain tissues. Consistently,
an increasing number of proteins has been reported to
associate with Cdk5-p35, linking Cdk5 to its physiological
functions. This article discusses the regulatory and func-
tional properties of Cdk5 in relation to its known interact-
ing proteins and substrates.
Molecular Organization of Cdk5 Complexes
A body of evidence has suggested that Cdk5-p35 shows
a high-affinity binding to specific cellular proteins. To
date and to our best knowledge, there are about 30 pro-
teins with diverse functions being identified to associate
to Cdk5-p35 or Cdk5-p39 (table 1). Cdk5 appears to bind
directly with a small subset of these proteins which in-
clude Cables, tau, PP1, dbpA, and L34. Many of the other
proteins interact with Cdk5 via p35 or p39, implicating
that p35 and p39 not only act as the activators of Cdk5
but also are important mediators of the Cdk5 functions.
In addition, a number of proteins have been established to
be substrates of Cdk5 (table 2). The majority of these sub-
strates, as well as the Cdk5-p35- and Cdk5-p39-associated
proteins, have revealed numerous important functional
and regulatory properties of Cdk5.
Cdk5, p35, and p39 are abundantly expressed in adult
brains, and high levels of Cdk5 kinase activity are de-
tected in postmitotic neurons of the nervous system, in
accordance with the expression pattern of p35 and p39.
As neurons differentiate, cell cycle Cdks are downregu-
lated, while the Cdk5 activity is increased [11]. p35 is
highly expressed in the postmitotic neurons of the devel-
oping cortex, but is not found in proliferating neuronal
precursors. On the other hand, the highest level of p39
expression in the CNS occurs postnatally. Apparently,
p35 and p39 display an overlapping, but distinct temporal
and spatial pattern in brain [28]. Thus, Cdk5-p39 may
arbitrate functions distinct from those involving Cdk5-
p35 during neurodevelopment.
Using immunocytochemistry and cellular fractiona-
tion protocols, Cdk5 and p35 proteins were detected
throughout the cells with a much lower level in the
nucleus [29]. p35 is enriched in the membrane fraction,
and the association of Cdk5-p35 with the plasma mem-
brane is directed by the myristoyl moiety linked to the
N-terminal glycine of p35 [30, 31]. Moreover, Cdk5-p35
extracted from a membrane preparation of rat brains
exhibited the biochemical property of large molecular
complexes [Gao and Qi, unpubl. observation]. Conceiv-
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Cables enhances c-Abl’s association and
phosphorylation of Cdk5 at Tyr15
47
Fyn promotes Cdk5 activity through
phosphorylation of Tyr15
48
SET enhances Cdk5-p35 activity 29
C42 inhibits Cdk5 activation by p35 50
Ribosomal
protein L34 inhibits Cdk5-p35 activity 53
DbpA inhibits Cdk5-p35 activity 52
Ubiquitin proteasomal degradation of p35 85
Rac phosphorylation of PAK1 55, 86
PAK1 Phosphorylation of PAK1 55, 86
Actin potential role in actin dynamics 14
·-actinin1 potential role in the localization of
Cdk5 to the synaptic cytoskeleton
70
NFH/NFM phosphorylation of NFH/NFM 10, 58
Tau phosphorylation of tau 16, 87
Munc 18 phosphorylation of Munc 18 65, 68
Syntaxin 1A mediates trafficking and secretion 68
Amphiphysin 1 phosphorylation of amphiphysin 1 67
CaMKII· regulation of synaptic plasticity 70
ß-Catenin regulates N-cadherin-mediated cell
adhesion and the association of
ß-catenin with presenilin 1
71, 72
PP1 phosphorylation of PP1.I-2 88
pRb phosphorylation of pRb 79
PCTAIRE1 phosphorylation of PCTAIRE1 36
Lipofuscin putative pathogenic process of ALS 89
ErbB mediates neuregulin-induced AChR
expression at neuromuscular junction
90
C48 not known 82
C53 not known 82
IC53 human homologue of rat C53 and
potential role in cell proliferation
91
IC53-2 human homologue of rat C53 and
potential role in cell proliferation
92
Cyclin D Cdk5 binding protein and potential
regulator of Cdk5
8
Cyclin E Cdk5-binding protein and potential
regulator of Cdk5
9
Ik3-2 homologue of Cables (ik3-1) 93







p35 suppresses the proteolytic conversion
of p35 to p25 by calpain and facilitates
the proteasomal degradation of p35
85
Cables mediates its interaction with Cdk5 47
PAK1 inhibits PAK1 activity and regulates
cytoskeletal dynamics
55, 86
NFH/NFM regulates axonal transport of neuro-
filaments
58, 94
Tau regulates microtubule binding and
dynamics
87
MAP1B regulates microtubule stability 95, 96
Nudel regulates dynein-mediated axonal
transport
64
Synapsin 1 regulates synaptic transmission 66
Munc 18 mediates the interaction between
Munc 18 and syntaxin 1A
68
Amphiphysin 1 regulates synaptic vesicle endocytosis
and neurite outgrowth
67







regulates synaptic transmission and
plasticity
78
Src regulates functions of Src in neurons 97
ß-APP mediates APP localization and
function
98
ß-catenin regulates N-cadherin-mediated cell
adhesion and the association of
ß-catenin with presenilin 1
71, 72






inhibits the neurotransmitter release
in synaptic transmission
77
DARPP-32 regulates dopamine signaling and the
stimulant action of caffeine
73, 100
MEK1 inhibition of MEK1 activity 76





activates I-1 and I-2 to mediate PP1
activity
88, 101
pRb mediates neuronal apoptosis 79
p53 mediates p53 transcriptional activity 80
MEF2 inhibits MEF2 transcriptional activity
and mediates neuronal apoptosis
81
Dab1 mediates neuronal migration 102
PCTAIRE1 promotes the PCTAIRE1
activation
36






mediates PDE activity and
phototransduction
103, 104
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ably, the membrane localization is important for Cdk5 to
exert many of its physiological effects, and some of its
substrates are likely to be membrane-integral or mem-
brane-associated proteins. Additionally, an active Cdk5-
p35 kinase has been shown to be present in Golgi mem-
branes, where it associates with a detergent-insoluble frac-
tion containing actin [32]. Suppression of the Cdk5 activi-
ty blocks the formation of membrane vesicles from the
Golgi apparatus, possibly suggesting a role for Cdk5-p35
in membrane trafficking. Furthermore, Cdk5-p35 may be
involved in the reorganization of actin in the growth cone
and on the Golgi membrane during neurite outgrowth.
Under certain conditions, p35 is converted to p25 by
proteolytic cleavage, losing the smaller N-terminal frag-
ment of p35, commonly known as p10 [33, 34]. The trans-
formation of p35 to p25 appears to lose most of the com-
ponents of the Cdk5-p35 macromolecular complexes, im-
plicating that the p10 region of p35 might be required for
interaction with these proteins. Indeed, deletion analyses
have provided proof of specific and direct interaction
between p10 and at least one p35-interacting protein [29].
Another region of 26 amino acids, spanning residues 145–
170 of p35, has also been identified to contain the binding
site for a few of the identified p35-binding proteins [35,
36]. This short stretch is proximal to the N-terminal
boundary of the Cdk5-binding and Cdk5-activating do-
main in p35 and contains an amphipathic ·-helix [37].
Further evidence from interaction studies indicates that
the hydrophilic face of the helix is involved in the interac-
tion with the binding proteins, while the hydrophobic face
is involved in the association with Cdk5 [35]. Possibly
this unique feature of the p35 structure is necessary to
support a number of other functions when bound to its
interacting proteins, in addition to the kinase activation.
Cdk5 Regulation Imposed by Regulatory
Proteins
The association with a cyclin is essential in the activa-
tion of Cdks. However, the Cdk5 activity has not been
found to associate with any cyclin. Instead, p35 and p39
were found to be two specific activators of Cdk5. Al-
though p35 and p39 have little sequence similarity to any
cyclin, studies by computer modeling and mutagenesis
have predicted that p35 might adopt a cyclin-like tertiary
structure [38–40]. Recently, these predictions were fur-
ther established by results from crystallization of a Cdk5-
p25 complex [41].
Members of the Cdk family are also regulated by at
least three distinct phosphorylation/dephosphorylation
events. Phosphorylation of Cdk1 and Cdk2 at Thr14 and
Tyr15 by the dual-specificity kinases Wee1, Myt1, and
Mik1 inhibits their activities [42–44]. In contrast, phos-
phorylation of Thr160 in the T-loop of Cdk2 (or Thr161
of Cdk1) by the Cdk-activating kinase is necessary for its
maximal activation [45]. Though Thr14 and Tyr15 are
conserved, and Thr160 in Cdk2 is conservatively substi-
tuted with Ser159 in Cdk5, and their surrounding se-
quences are highly homologous to those of the authentic
Cdks, Cdk5 appears to adopt regulatory mechanisms dis-
tinct from those of the classical Cdks at these three phos-
phorylation sites. The Thr14 and Tyr15 sites in Cdk5 are
not phosphorylated by Wee1 in vitro [46]. Moreover,
Tyr15 of Cdk5 can be phosphorylated by the cytosolic
tyrosine kinase c-Abl, and such phosphorylation is facili-
tated by the Cdk5 association with Cables which is an
Abl-binding protein. Surprisingly, the phosphorylation of
Cdk5 at Tyr15 is stimulatory and enhances the Cdk5
kinase activity [47]. In addition to c-Abl, Fyn, which is a
member of the Src family of tyrosine kinases, is the other
enzyme observed to catalyze the stimulatory Tyr15 phos-
phorylation of Cdk5 [48]. The Cdk5 phosphorylation by
Fyn is necessary for the semaphorin-3A-induced growth
cone collapse in model neurons [48]. Lastly, the phos-
phorylation of Cdk5 at Ser159, which occupies a position
equivalent to the Thr160 site in the conserved T-loop of
Cdk2 (Thr161 of Cdk1), not only is dispensable, but also
dampens the activation of Cdk5 [41]. The crystal struc-
ture of Cdk5-p25 revealed that the interaction between
the regulatory subunit is sufficient to stretch the activa-
tion loop of unphosphorylated Cdk5 into a fully extended
active conformation, analogous with the phosphorylated
Cdk2-cyclin A complex [41].
Another mode of the Cdk regulation involves a diverse
family of inhibitory proteins (CKIs) that bind Cdks or
Cdk-cyclin complexes to inhibit the Cdk activity [5]. The
initial evidence of the existence of Cdk5 inhibitors came
from the biochemical separation of Cdk5 complexes in
brain extract. The Cdk5-p35 macromolecular complexes
are neither enzymatically active nor activable by the addi-
tion of a truncated form of p35 [26]. Furthermore, the
kinase activity was recovered, when the Cdk5-p35 com-
plexes were further fractionated by the size-exclusion
chromatography in the presence of 10% ethylene glycol,
suggesting that an inhibitor(s) could be dissociated from
the complexes under this stringent condition. Interesting-
ly, Cdk5 is not regulated by any of the CKIs that are
known for other Cdks, such as members of the INK and
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CIP/KIP families of inhibitors [49], suggesting distinct
structural and regulatory properties of Cdk5-p35. A few
protein candidates have been reported to be physiological
inhibitors of Cdk5. C42, which is a p35-binding protein,
has been shown to specifically inhibit the activation of
Cdk5 by p35 [50]. The inhibitory domain of C42 was
mapped to a region of 135 amino acids which is conserved
in Pho81, a yeast protein that inhibits the yeast cyclin-
dependent protein kinase Pho85 (yeast functional homo-
logue of mammalian Cdk5) [51]. DNA-binding protein
dbpA and ribosomal protein L34 are two other reported
inhibitors of Cdk5 [52, 53]. They were identified in a yeast
two-hybrid screen as Cdk5-binding proteins. In addition
to the inhibitors, the nuclear protein SET was found to
enhance the Cdk5 activity upon its physical association
with Cdk5-p35. The SET protein binds p35 in its N-termi-
nal region, which is lacking in p25, and, therefore, does not
affect the activity of Cdk5-p25, suggesting specific modu-
lation of the Cdk5-p35 activity in the nucleus [29].
Targets of Cdk5 and Mediated Functions
Over the last decade, a number of proteins have been
identified to act as direct substrates of Cdk5 (table 2), pro-
viding a good deal of knowledge on the biological roles of
Cdk5 in brain. It appears that Cdk5 acts prominently in
many of the essential cellular processes, including cyto-
skeletal dynamics, cell adhesion, axonal guidance, dopa-
minergic signaling, and synaptic membrane functions.
Cdk5 in Cytoskeletal Dynamics and
Microtubule-Based Transport
A body of evidence has implicated an indispensable
role of the Cdk5-p35 kinase in axonal guidance, cell motil-
ity, and neurite outgrowth. Overexpression of p35 in cul-
tured neurons induces the formation of longer neurites,
whereas inhibition of the Cdk5 activity or the expression
of a dominant negative form of the kinase prevents neu-
rite outgrowth [54]. Cdk5-p35 colocalizes with F-actin,
Rac, and PAK1 on the periphery of growth cones. Since
Cdk5-p35 downregulates the PAK1 kinase activity by
phosphorylating it at Thr212, it has been proposed to
have a role in regulating actin repolymerization and,
therefore, growth cone dynamics [55].
Another group of Cdk5 substrates are the intermediate
and heavy chains of neurofilament proteins (NFM and
NFH, respectively). NFM and NFH contain many KSP
(Lys-Ser-Pro) repeats in their long carboxyl terminal tails.
Phosphorylation at the KSP sites occurs during axonal
transport of neurofilaments, and phosphorylation is re-
quired for maintaining the axonal morphology. Cdk5 was
originally isolated from the brain as a neurofilament
kinase to catalyze the KSP phosphorylation at the tail
region of NFM and NFH [56]. Phosphorylation of these
domains by Cdk5 reduces their association with microtu-
bules as well as retards the axonal transport of these pro-
teins [57]. In vitro, NFH phosphorylated by Cdk5 dis-
played the same electrophoretic motility shift as that of
natively phosphorylated NFH [58]. Moreover, p35 asso-
ciates with NFM and NFH in a region adjacent to the
KSP-rich domains, suggesting a role of p35 in docking
Cdk5 to the substrates [59].
It has been found that Cdk5 associates with microtu-
bules and that it can be copurified with microtubules from
bovine brain [60, 61]. Several microtubule-associated
proteins, such as tau and MAP1B, are substrates of Cdk5.
Phosphorylation of tau by Cdk5 abolishes the ability of
tau to bind microtubules and, therefore, its ability to pro-
mote microtubule assembly [57]. In addition to phosphor-
ylation of the microtubule-associated proteins to mediate
microtubule stability, Cdk5 has been implicated to play a
role in regulating the dynein-mediated axonal transport.
Nudel is a cytoplasmic dynein-associated protein that is
expressed at a high level in the brain. Cdk5 can phosphor-
ylate Nudel in vitro and in vivo, and this is of importance,
since the introduction of a nonphosphorylatable mutant
of Nudel into the cultured neurons led to axonal swelling,
analogous to disruption of the dynein function in Dro-
sophila neurons [62].
Cdk5 in Synapses and Focal Adhesion Sites
Cdk5, p35, and p39 are present in subcellular fractions
enriched for synaptic membrane, and they are localized to
the pre- and postsynaptic compartments [63, 64], indicat-
ing that they may be involved in synaptic functions.
Indeed, several synaptic proteins have been identified as
Cdk5 substrates, including Munc 18, synapsin I, and
amphiphysin which are proteins implicated in synaptic
vesicle exocytosis [65–67]. Phosphorylation of Munc 18
by Cdk5 results in disassembly of the Munc 18-synaxin I
complex, implying a role for Cdk5 in modulating neurose-
cretion [68]. Most recently, interesting findings by Tan et
al. [69] established that Cdk5 has a role in synaptic vesicle
endocytosis. Cdk5 phosphorylates dynamin I in vitro as
well as in vivo at the nerve terminals of neuronal cells to
facilitate synaptic endocytosis [69]. Roscovitine, an an-
tagonist of the Cdk5 activity, blocks the rephosphoryla-
tion of dynamin I after repolarization of the synapto-
somes. Furthermore, phosphorylation by Cdk5 also in-
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creases the GTPase activity of dynamin I [69]. Hence,
Cdk5 may play a major role at synapses, since multiple
Cdk5 substrates are involved in the synaptic vesicle recy-
cling. In a yeast two-hybrid screen, ·-actinin 1 and the
·-subunit of Ca2+/calmodulin-dependent protein kinase
II (CaMKII·) were identified as p35- and p39-interacting
proteins [70]. Either of these two proteins forms a com-
plex with Cdk5 through the interaction with p35 or p39,
and these interactions potentially localize Cdk5 to the
postsynaptic density, where it may play a role contribut-
ing to synaptic plasticity, memory, and learning.
N-cadherin is a member of the transmembrane mole-
cules that promote cell adhesion by their calcium-depen-
dent homophilic interactions. The cytoplasmic tail of cad-
herins interacts with ·- and ß-catenin to anchor the cad-
herins to the actin cytoskeleton. Cdk5-p35 is associated
with ß-catenin and controls the N-cadherin/ß-catenin-
mediated cell adhesion through the phosphorylation of ß-
catenin [71, 72]. Additionally, phosphorylation of ß-cate-
nin by Cdk5 has also been shown to affect its binding to
presenilin which has a role in Alzheimer’s disease pathol-
ogy [72].
Cdk5 in Neurosignaling
Accumulating evidence has implicated that Cdk5 is
involved in many of the neuronal signal transduction
pathways. DARPP32 is a Cdk5 substrate that plays a key
role in dopamine signaling occurring in the dopaminocep-
tive neurons. When DARPP32 is phosphorylated by the
cAMP-dependent protein kinase (PKA), it becomes a
potent inhibitor of protein phosphatase 1. It appears that
the Cdk5 phosphorylation of DARPP32 transforms it
into an inhibitor of PKA, exerting an opposing effect on
dopamine signaling [73, 74]. In the MAPK (mitogen-acti-
vated protein kinase) and JNK (c-Jun N-terminal kinase)
pathways, Cdk5 is associated with JNK-3, where it inhib-
its the JNK-3 activity by phosphorylating JNK-3 at
Thr131 to mediate neuronal apoptosis [75]. Meanwhile,
Cdk5 downregulates the MAPK signaling by phosphory-
lating MEK1 at Thr286 and, therefore, inhibiting its
activity [76]. In addition, Cdk5 has been shown to me-
diate the activities of the P/Q-type voltage-dependent cal-
cium channel and the N-methyl-D-aspartate class of gluta-
mate receptors through a direct phosphorylation modifi-
cation [77, 78].
Cdk5 in Transcriptional Machineries
Recent studies have pointed to the localization of
Cdk5-p35 in the nucleus, where it may play a role in tran-
scriptional regulation. In an earlier report [79], Cdk5 was
found to bind and to phosphorylate the retinoblastoma
protein (pRb). p53 is a phosphorylation-regulated tran-
scription factor that plays a pivotal role in cell cycle pro-
gression and cell death. Cdk5 is able to modulate the p53
transcriptional activity through direct phosphorylation of
p53 as well as elevation of the p53 expression in the cells
[80]. More recently, myocyte enhancer factor 2 (MEF2)
was identified as a Cdk5 substrate [81]. Members of the
MEF2 family are transcription factors that play critical
roles in diverse cellular processes, including neuronal sur-
vival. Phosphorylation of MEF2 by Cdk5 results in the
inhibition of the MEF2 transactivation activity, while
MEF2 mutants that are resistant to the Cdk5 phosphory-
lation rescue neurons from neurotoxin/Cdk5-induced
apoptosis, suggesting the MEF2 phosphorylation by Cdk5
as a part of the molecular mechanism by which neurotox-
in/Cdk5 mediates apoptosis [81].
Methods Used in Identifying Cdk5 Complexes
Various methods have been described in an increasing
number of reports over the last few years to uncover the
protein components of Cdk5 macromolecular complexes
in the brain. Using the yeast two-hybrid system, a number
of proteins have been found by screening mammalian
brain libraries to specifically interact with Cdk5, p35, or
p39 [52, 70, 82]. This is a sensitive method with which
transient or weak interactions can be detected. However,
it could be disadvantageous for the screening of mem-
brane-associated proteins and proteins which are not able
to translocate into the nucleus. The usage of this method
is also limited to the detection of dimeric protein com-
plexes and, therefore, is disadvantageous for identifying
multimolecular complexes. Further, some interactions
may require certain posttranslational modifications of
their protein partners. However, such modifications may
not occur in yeast.
Another major method to identify protein-protein in-
teractions at a high throughput and at a proteome-wide
scale is biochemical isolation of the protein complexes
from animal tissues or cultured cells [83, 84]. In our labo-
ratory, biochemical isolation of Cdk5 and p35-associated
proteins was conducted using affinity chromatography
media which were prepared by coupling antibodies recog-
nizing Cdk5 or p35 or by coupling recombinant proteins
derived from Cdk5 and p35 to agarose beads [29]. The
identity of isolated interacting proteins from rat brain
extracts was established using mass spectrometry. An
advantage of this method is the ability to isolate protein
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complexes and interacting proteins in their native states.
It is especially useful in the identification of indirect inter-
acting proteins, since multiprotein complexes can be iso-
lated. However, it is less favorable with proteins having
weak or transient interactions. Therefore, this approach
would be a good complement to the yeast two-hybrid
methodology.
Concluding Remarks
A variety of cellular proteins have been found that
undergo specific and high-affinity association with Cdk5-
p35 or Cdk5-p39. Some of these protein-protein interac-
tions have been further characterized, and this character-
ization has provided insights into regulation, function,
and mechanism of the actions of Cdk5-p35 and Cdk5-
p39. Although Cdk5 was identified as a member of the
Cdks, it is not activated by any cyclin protein, nor is it
involved in regulating cell cycle progression. In contrast,
it is involved in various activities in postmitotic neurons,
including modulating the neuronal migration in the de-
veloping CNS. Cdk5 has also been implicated in patho-
logical pathways of several neurodegenerative diseases.
Thus, the identification of Cdk5-associated proteins and
Cdk5 substrates at the proteome-wide scale will lead us
towards a complete understanding of the role of Cdk5 in
the nervous system. With the availability of the human
genome sequences, building a functional proteome on
Cdk5 will further elucidate many more exciting insights
into the molecular basis of neurodevelopment and pro-
gression of diseases.
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Microtubule dynamics is essential for many vital cel-
lular processes such as morphogenesis and motility.
Protein kinase CK2 is a ubiquitous protein kinase that is
involved in diverse cellular functions. CK2 holoenzyme
is composed of two catalytic  or  subunits and two
regulatory  subunits. We show that the  subunit of
CK2 binds directly to both microtubules and tubulin
heterodimers. CK2 holoenzyme but neither of its indi-
vidual subunits exhibited a potent effect of inducing
microtubule assembly and bundling. Moreover, the po-
lymerized microtubules were strongly stabilized by CK2
against cold-induced depolymerization. Interestingly,
the kinase activity of CK2 is not required for its micro-
tubule-assembling and stabilizing function because a
kinase-inactive mutant of CK2 displayed the same mi-
crotubule-assembling activity as the wild-type protein.
Knockdown of CK2/ in cultured cells by RNA inter-
ference dramatically destabilized their microtubule net-
works, and the destabilized microtubules were readily
destructed by colchicine at a very low concentration.
Further, over-expression of chicken CK2 or its kinase-
inactive mutant in the endogenous CK2/-depleted
cells fully restored the microtubule resistance to the low
dose of colchicine. Taken together, CK2 is a microtu-
bule-associated protein that confers microtubule stabil-
ity in a phosphorylation-independent manner.
Protein kinase CK2 (formerly known as casein kinase 2) is
ubiquitously expressed and highly conserved in eukaryotic
cells (1–4). It comprises two catalytic  or  subunits and two
regulatory  subunits to form a heterotetrameric structure in
which the two  subunits dimerize to link the two  or 
subunits (5). As a protein serine/threonine kinase, CK2 has a
very broad phosphorylation spectrum, and over 300 protein
substrates of CK2 have been identified to date (6). A number of
studies have indicated that CK2 is involved in a wide variety of
cellular processes including cell cycle, apoptosis, transcrip-
tional regulation, and signal transduction (1, 3, 6). CK2 is
instrumental and necessary for promoting cell survival (3, 7).
Disruption of genes encoding both of the catalytic subunits of
CK2 is synthetic lethal in fission yeast (8, 9). Similarly, it is
embryonic lethal when CK2 is knocked down in Caenorhab-
ditis elegans by RNA interference or in mice by gene disruption,
reminiscent of an essential role of CK2 during embryonic
development and organogenesis (10, 11). Hence, production of
both the  and  subunits of CK2 appears to be mandatory for
cell viability.
A few lines of evidence have lead to implication that CK2
might be involved in the regulation of microtubule cytoskeleton
reorganization (12–14). CK2 was localized to microtubule
structures such as the mitotic spindle of dividing cells and was
found to associate with the cold-stable fraction of microtubules
from the rat brain (14, 15). More recently, the  and  subunits
were shown to bind tubulin in a far Western assay (16). Fur-
ther, CK2 is able to phosphorylate a number of microtubule
elements, including MAP1B and a neuron-specific -tubulin
isotype (6). The phosphorylation of MAP1B was proposed to
facilitate the microtubule association of MAP1B and thereby
microtubule assembly, whereas the physiological role of the
-tubulin isotype phosphorylation is still unclear (12, 17). De-
spite these findings, the direct correlation of CK2 and micro-
tubule stability has not been established.
In the present study, we have investigated the physical as-
sociation of CK2 with microtubules and the direct effect of CK2
on microtubule dynamics. Our results show that CK2 is a
microtubule-associated protein (MAP)1 that induces microtu-
bule assembly and bundling in vitro. CK2-polymerized micro-
tubules appear stable under cold treatment. In cultured cells,
knockdown of CK2/ has a severe effect on microtubule sta-
bility, which implies that CK2 mediates microtubule integrity
in vivo. Moreover, a kinase-inactive mutant of CK2 displayed
the same microtubule polymerizing and stabilizing activity in
vitro and in vivo. Thus, the microtubule assembling and stabi-
lizing action of CK2 is independent of its kinase function.
EXPERIMENTAL PROCEDURES
Plasmid Constructions—The coding sequences of chicken CK2 and
its kinase-inactive mutant (CK2K68A) were subcloned into pGEX4T
(Amersham Biosciences), pET32 (Novagen), and pDneo-Myc (18). The
full-length sequence of human CK2 was cloned by a reverse transcrip-
tion polymerase chain reaction and inserted into pQE30 (Qiagen).
Protein Binding Assay—Proteins tagged with GST or His6 were
bacterially expressed and prepared as described previously (19). To test
tubulin binding, GSH-Sepharose beads (Amersham Biosciences) pre-
bound with GST, GST-CK2, or the complex of GST-CK2/His-CK2
were incubated with purified tubulin (99% pure and MAP-free, Cy-
toskeleton) for 1 h at 4 °C. After being extensively washed with binding
buffer (20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 20 mM MgCl2, 1 mM
dithiothreitol, and 0.1% Nonidet P-40), the beads were boiled in SDS-
PAGE sample buffer and analyzed by immunoblotting. Antibodies
against - and -tubulin were from Sigma. The binding of His-tagged
proteins with tubulin was performed with nickel-nitrilotriacetic acid
beads (Ni-NTA, Qiagen) in binding buffer without dithiothreitol. In the
microtubule binding assay, microtubules, which were pre-assembled
using taxol in PEM buffer (80 mM PIPES, pH 6.8, 1 mM MgCl2, 1 mM
EGTA) supplemented with 1 mM GTP, were incubated with the indi-
cated proteins. The samples were subsequently loaded onto a buffered
cushion (50% glycerol in PEM buffer) and centrifuged to spin down the
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microtubules and associated proteins. The pellet and the supernatant
were analyzed by immunoblotting.
Microtubule Assembly—Microtubules were assembled in vitro from
the purified MAP-free tubulin at 2 mg/ml in PEM buffer supplemented
with 1 mM GTP at 35 °C, and the turbidity of the solutions was moni-
tored at 340 nm (20). CK2 was added at various amounts as indicated
to promote the assembly. To visualize assembled microtubules, tubulin
and rhodamine-labeled tubulin (Cytoskeleton) at the ratio of 7:1 were
used in the polymerization (21). Microtubules were fixed with 0.5%
gluteraldehyde and visualized by fluorescence microscopy.
Differential Tubulin Extraction from Intact Cells—Differential ex-
traction of tubulin heterodimers and polymers from cells was performed
using a protocol described previously (22). Briefly, cultured cells were
lysed with the microtubule-stabilizing buffer (80 mM PIPES, pH 6.8, 1
mM MgCl2, 1 mM EGTA, 0.5% Triton X-100, 10% glycerol, and Roche
protease inhibitor mixture), which was prewarmed to 35 °C, to extract
cytosolic soluble tubulin heterodimers and preserve microtubules (as-
sembled insoluble tubulin polymers). The extract was cleared by cen-
trifugation and the supernatant designated as the free tubulin fraction.
After a brief washing with the microtubule-stabilizing buffer, the pellet
was extracted in the microtubule-destabilizing buffer (20 mM Tris, pH
7.4, 150 mM NaCl, 1% Triton X-100, 10 mM CaCl2, and Roche protease
inhibitor mixture). The extract was clarified by centrifugation to yield
the polymerized tubulin fraction. Both fractions were analyzed by im-
munoblotting, and each band on the blots was quantitated using a
Bio-Rad GS-700 imaging densitometer and analyzed with the Multi-
Analyst, version 1.0.1, program (Bio-Rad).
Cell Culture, Transfection, and Immunofluorescence—COS-7, HeLa
and 293T cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum. The siRNA sequence de-
signed for human CK2/ is 5-CCAGCUGGUAGUCAUCUUGUU-3,
which has a few discrepancies with the corresponding sequence of
chicken CK2/. 20 M CK2/ siRNA or a scrambled siRNA sequence
was applied into the transfection using a TransIT-TKO transfection
reagent (Mirus). Simultaneous transfection of siRNA and plasmid DNA
was done using TransIT-TKO and LipofectAMINE (Invitrogen) concur-
rently. After transfection, the cells were cultured for 24 h before treat-
ment with 0.2 M colchicine (Sigma) for 3 h. The cells were subjected to
differential extraction of free and polymerized tubulin or to immuno-
staining. For immunofluorescence, the cells were fixed in PBS contain-
ing 4% paraformaldehyde and then permeabilized in PBS containing
0.2% Triton X-100. After a blocking wash with 10% goat serum and
0.1% Triton X-100 in PBS, immunostaining was performed with anti-
bodies as indicated. CK2- and CK2-specific antibodies were from
Santa Cruz Biotechnology. The secondary antibodies are Fluor594 goat
anti-mouse IgG and Fluor488 donkey anti-goat IgG (Molecular Probes).
The cells were then washed in PBS, mounted, and photographed on an
MRC-1024 laser scanning confocal microscope (Bio-Rad).
RESULTS
CK2 Forms a Direct Complex with Microtubules—The direct
association of CK2 and microtubules was probed by a series of
binding assays using recombinant CK2 and purified MAP-free
tubulin as well as pre-assembled microtubules. The / het-
erodimer of tubulin was found to associate with the catalytic 
subunit as well as the holoenzyme of CK2 (Fig. 1A). CK2 alone
did not result in the pull-down of any tubulin (Fig. 1B), which
is in agreement with a previous observation using far Western
blotting (16). To verify the microtubule association of CK2,
taxol-assembled microtubules were incubated with CK2 ho-
loenzyme or its individual subunit proteins. The microtubules
were then spun down to test whether these proteins co-precip-
itated with the microtubules. Consistently, CK2 and the ho-
loenzyme of CK2 were found to associate with the microtubule
pellet, whereas CK2 and GST, as a control protein, failed to
co-precipitate with the microtubules (Fig. 1C), indicating that
the CK2 holoenzyme associates with microtubules at a high
affinity through CK2.
Cellular localization of CK2 to microtubule networks was
revealed by immunofluorescent staining of cultured COS-7
cells. Microscopic imaging of endogenous CK2 and CK2 dis-
played a clearly defined positioning with the microtubule net-
work, particularly in the cell periphery (Fig. 2A). As confirma-
tion, pools of tubulin existing as free heterodimers or polymers
(microtubules) were differentially extracted from the cultured
cells to examine the distribution of CK2 (22). Both CK2 and
CK2 appeared in the microtubule fraction as well as the
fraction of free tubulin heterodimers, although there appeared
to be more CK2 in the microtubule fraction (Fig. 2B). Taken
together with the results from the in vitro binding assays, this
provides evidence of the direct association of CK2 with cellular
microtubules.
CK2 Induces Microtubule Polymerization—We next investi-
gated whether CK2 has any effect on microtubule dynamics by
using an in vitro assay of microtubule assembly from purified
MAP-free tubulin (20). During the assay, the turbidity change
of the solution was measured as tubulin polymerizes or depo-
lymerizes. In the absence of CK2, there was minimal polymer-
ization of tubulin even after a prolonged incubation (Fig. 3, A
and B). The addition of CK2 at a ratio of 1:240 to tubulin
resulted in substantial polymerization of tubulin into microtu-
bules (Fig. 3, A and B). Clearly, both the rate and extent of
polymerization were dramatically enhanced by CK2. When the
amount of CK2 was increased, tubulin polymerization was
increased in a dose-dependent manner (Fig. 3, A and B). To
verify the microtubule formation, rhodamine-labeled tubulin
was applied into the polymerization experiments for direct
visualization of the assembled microtubules by fluorescence
microscopy (21). As shown in Fig. 3C, microtubule filaments
and bundles were readily observed with the CK2-incubated
tubulin, whereas the incubation of tubulin without CK2
showed no obvious microtubule formation. Therefore, we have
found that CK2, in addition to showing high affinity binding to
tubulin and microtubules, induces the assembly of tubulin into
microtubules. Moreover, CK2 appeared to cause microtubule
bundling, suggesting a strong stabilizing effect on the
microtubules.
CK2 holoenzyme is a tetrameric complex of two  or 
subunits and two  subunits (5). Given that observation that
CK2 of the holoenzyme interacts with microtubules, we ex-
plored whether the microtubule assembling function of CK2 is
restricted to the holoenzyme by applying the  and  subunits
of CK2 individually into the microtubule assembly assay. In
contrast to the holoenzyme, when either the  or  subunit was
tested, there was minimal polymerization of tubulin even after
a prolonged incubation (Fig. 4). The CK2- and CK2-polymer-
ized samples had no marked difference from the background
tubulin polymerization, which was shown in the GST-incu-
bated sample. Thus, only CK2 holoenzyme, but not each of the
individual subunits, has the ability to induce microtubule as-
sembly even though CK2 has shown microtubule binding
activity.
CK2 has been known to catalyze phosphorylation of a neural
isoform of -tubulin and some of the MAPs, raising the possi-
bility that it may affect microtubule dynamics through a kinase
reaction (12, 17). Although ATP was not present in the in vitro
microtubule assembly assay, CK2 is capable of utilizing either
ATP or GTP as the phosphate donor in its phosphorylating
reactions (23). We designed an experiment to assess the role of
CK2 kinase activity in microtubule assembly. A kinase-inactive
holoenzyme of CK2, in which CK2 was replaced with the
kinase-inactive mutant CK268A, was tested in the microtu-
bule assembly assay. Fig. 5 shows that the kinase-inactive CK2
conferred the same microtubule polymerizing activity as the
wild-type enzyme, indicating that the microtubule assembly
entity of CK2 is independent of its kinase activity and phos-
phorylation of any microtubule proteins.
Microtubules from brains can be separated into two pools,
namely “cold labile” and “cold stable,” according to whether
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they are resistant to cold treatment for microtubule disassem-
bly (24). It has been found that CK2 is enriched in the cold-
stable fraction of the microtubule preparation from rat brain
(14). This observation, together with our findings that CK2
associates with microtubules to promote microtubule assembly,
prompted us to explore the possibility that CK2 may contribute
to the cold stability of microtubules. To test this likelihood,
CK2-polymerized microtubules were incubated on ice, and the
FIG. 1. Microtubule association of
CK2. A, direct interaction of CK2 and tu-
bulin heterodimers. 5 g of GST, GST-
CK2, or a complex of GST-CK2/His-
CK2 were incubated with 2.5 g of
purified tubulin. The GST fusion proteins
were then retrieved using GSH beads,
and bound proteins were analyzed by im-
munoblotting with antibodies recognizing
- and -tubulin. The protein input col-
umn was visualized by Coomassie Blue
staining. B, CK2 does not interact phys-
ically with tubulin. 5 g of His-CK2 or
His-CK2 were incubated with 2.5 g of
purified tubulin. There was no His-CK2
or His-CK2 in the beads control sample.
After pull-down with nickel-nitrilotriace-
tic acid beads, bound proteins were ana-
lyzed by anti--tubulin immunoblotting.
C, direct association of CK2 with microtu-
bules. 1 g of GST, CK2, CK2, or CK2
holoenzyme was incubated with microtu-
bules pre-assembled using taxol from 10
g of purified tubulin. After precipitation
of the microtubules, proteins in the super-
natant and the microtubule pellet were
analyzed by immunoblotting using an an-
tibody mixture recognizing GST, CK2,
and CK2.
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turbidity change was monitored. As a comparison, tau-poly-
merized microtubules were treated under the same condition,
given the fact that tau does not confer cold stability to micro-
tubules (25). As expected, the tau-polymerized sample was
depolymerized almost completely within a few minutes (Fig. 6).
However, the turbidity of the CK2-polymerized sample was
only marginally reduced even after a prolonged cold incubation
(Fig. 6), indicating that CK2 functions to stabilize microtubules
against cold-induced disassembly.
CK2 Stabilizes Microtubules in Vivo—To evaluate the role of
CK2 in microtubule dynamics in vivo, we knocked down
CK2/ in HeLa cells by gene silencing using a siRNA duplex
derived from the human sequence of CK2/ (26, 27). As
shown by the CK2 immunoblot, the introduction of CK2/
siRNA into the cells led to a dramatic decrease of the CK2/
proteins to a minimal cellular level (Fig. 7A). To assess the
knockdown effect on microtubules, the amount of cellular mi-
crotubules (assembled insoluble tubulin polymers) was deter-
mined using the differential extraction method and immuno-
blotting (22). In addition, the integrity of the cellular
microtubule network was examined by immunofluorescent
staining and confocal microscopy. The knockdown of CK2/
significantly reduced the cellular content of microtubules (Fig.
7, A and B), suggesting CK2 as one of the factors in stabilizing
microtubules in vivo. We further assessed microtubule stability
using colchicine, which is a microtubule-disrupting agent.
When colchicine was applied at a low concentration (0.2 M)
onto the cells that were transfected with a scrambled siRNA
sequence, most of the microtubule structure remained intact
(Fig. 7, A and B). However, such a low dose of colchicine caused
severe disruption of the microtubule structure in the CK2/-
depleted cells where the microtubule networks were collapsing
toward the perinuclear membrane (Fig. 7B); almost negligible
amount of microtubules was extracted from these cells (Fig.
FIG. 2. Cellular localization of CK2
and CK2 to microtubules. A, COS-7
cells were immunostained for confocal mi-
croscopic analysis. Top row, double staining
of CK2 and -tubulin; bottom row, CK2
and -tubulin. B, soluble tubulin het-
erodimers (free tubulin) and microtubules
(polymerized tubulin) were differentially ex-
tracted from HeLa cells. Both fractions as
well as the total cell lysate (TCL) were ana-
lyzed by immunoblotting using antibodies as
indicated. The histogram shows the relative
amounts of CK2 and CK2 in the free and
polymerized tubulin fractions. These data
are representative of three independent
experiments.
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7A). Apparently, the removal of CK2 had a strong effect on
cellular microtubule architecture, rendering it very unstable.
As a result, it was readily destructed by colchicine at a very low
concentration.
To further substantiate the microtubule stabilizing function
of CK2, we tested whether microtubule stability could be re-
stored by expression of chicken CK2 in endogenous CK2/-
depleted cells. As observed with the HeLa cells, knockdown of
CK2/ in cultured human 293T fibroblasts using siRNA
strongly destabilized the microtubule network, resulting in
almost complete disruption of the microtubules by colchicine at
0.2 M (Fig. 7C). When chicken CK2 was expressed in the
293T cells in which endogenous CK2/ was knocked down,
the cellular microtubules completely retained their integrity
against the colchicine-induced disruption (Fig. 7C). More inter-
estingly, when the expression was performed using the kinase-
inactive mutant CK2K68A, it exhibited the same effect as
wild-type CK2 in rescuing microtubules from colchicine treat-
ment (Fig. 7C). These data demonstrate that CK2 is an impor-
tant mediator of cellular microtubule stability and exerts its
effect in a phosphorylation-independent manner.
DISCUSSION
Microtubules are a major cytoskeletal constituent in all eu-
karyotes. In living cells, the microtubule architecture is stabi-
lized by structural MAPs, which associate with microtubules
FIG. 3. Effect of CK2 on microtubule assembly. A, the turbidi-
metric assay of tubulin polymerization. Microtubule assembly from
purified MAP-free tubulin was carried out in the presence of the CK2
holoenzyme at various concentrations (molar ratios to tubulin). The
concentration of tubulin was constant in each assay at 2 mg/ml. B,
histogram of the microtubule assembly at various amounts of CK2. The
assembly assay was performed as described in A for 30 min. The data
shown are representative of three separate experiments. C, fluorescent
imaging of microtubules polymerized from a mixture of rhodamine-
labeled and unlabeled tubulin (7:1). The tubulin concentration is 2
mg/ml, and the CK2 concentration is 62 g/ml. The arrows point to
microtubule bundles in the CK2-polymerized sample.
FIG. 4. Microtubule assembly can be induced by the CK2 ho-
loenzyme but not its individual subunits. GST, GST-CK2, and
His-CK2 were applied as indicated at 0.1 mg/ml in the microtubule
assembly assay. As a control, the CK2 holoenzyme reconstituted from
the same amount of GST-CK2 and His-CK2 as described under
“Experimental Procedures” was applied. Microtubule assembly was
performed at 2 mg/ml tubulin as described under ‘‘Experimental
Procedures.’’
FIG. 5. The kinase activity of CK2 is not required for its func-
tion to induce microtubule assembly. The wild-type CK2 enzyme
(GST-CK2/His-CK2) and the kinase-inactive enzyme (GST-
CK2K68A/His-CK2) were applied as indicated at 0.1 mg/ml in the
microtubule assembly assay. GST-CK2K68A and GST were also
tested at the same amount. Microtubule assembly was performed with
2 mg/ml tubulin as described under ‘‘Experimental Procedures.’’
FIG. 6. CK2 confers cold stability to microtubules. Microtubules
were polymerized with 0.05 mg/ml CK2 or 0.16 mg/ml tau protein for 30
min at 35 °C, where they attained similar turbidity measurements. The
microtubule samples were then incubated on ice, and the turbidity
measurement was begun. Absorbance was expressed as a percentage of
the measurement when ice incubation was started.
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and promote in vitro microtubule assembly (28, 29). The evi-
dence presented here identifies CK2 as a structural MAP that
mediates microtubule dynamics. We have conducted experi-
ments showing that CK2 is localized to and co-extracted with
microtubules. The in vitro binding assays demonstrate the
direct interaction of CK2 with microtubules as well as tubulin
heterodimers, and the binding affinity is comparable with that
of known MAPs. Microtubule binding sequences are often
found in MAPs as repeated sequence stretches rich in basic
amino acids. Although the sequence of CK2 contains some
basic regions, it is not found to have any typical microtubule-
binding motif in CK2. Thus, the microtubule association of
CK2 may suggest new microtubule-binding domains.
Structural MAPs such as MAP2 and tau are known to stim-
ulate microtubule assembly from tubulin heterodimers. In our
microtubule assembly assays, CK2 exhibited a potent activity
of inducing microtubule assembly and bundling from purified
tubulin. The physical association of CK2 to microtubules and
tubulin heterodimers stimulates both the rate and the extent of
microtubule growth. Although CK2 can bind microtubules,
the microtubule assembling and stabilizing function is solely a
property of the holoenzyme. In addition, CK2-polymerized mi-
crotubules display stability against cold treatment, suggesting
that CK2 is a strong stabilizer of microtubules. Taken together
with the observation that a substantial amount of CK2 exists in
the cold-stable microtubules of rat brain (14), our findings
suggest that CK2 is a new factor endowing the cold stability of
microtubules. To date, the STOP proteins, double-cortin and
BPAG1n3, are the only known MAPs that confer cold stability
on microtubules (30–34).
Structural MAPs are known to contribute to microtubule
stability and distribution within cells (35). The finding of CK2
as a structural MAP stimulated our interest in evaluating the
regulatory role of CK2 in vivo in microtubule cytoskeleton. The
knockdown of CK2/ from cells has a strong destabilizing
effect on the microtubule architecture. As a result, the micro-
tubule network is very vulnerable and can be readily destroyed
by colchicine insult at 0.2 M, whereas such a low concentration
of colchicine does not have any significant effect on microtu-
bules of cells with intact CK2. Thus, CK2 has an indispensable
role in stabilizing cellular microtubules. This is substantiated
by the introduction of chicken CK2 into the cells to compen-
sate for the loss of endogenous CK2/. The microtubule in-
stability caused by the deficit of CK2/ can be rectified com-
pletely by the expression of chicken CK2, which assures that
CK2 is a vital structural MAP conferring microtubule stability
in vivo. It is noteworthy that the removal of CK2/ did not
cause severe microtubule disruption in the cells, possibly be-
cause of the existence of multiple MAPs other than CK2 in the
cells, to support the microtubule network.
CK2 is a Ser/Thr protein kinase with a broad substrate
spectrum that includes MAP1B and a neural-specific isoform of
amounts of microtubules extracted from the cells as compared with the
control, which is the sample transfected with the scrambled siRNA
sequence and treated without colchicine. The data are representative of
three separate experiments. B, cells in the experiments described in A
were fixed and stained with the -tubulin antibody for confocal micro-
scopic imaging. C, expression of the wild-type or the kinase-inactive
mutant of chicken CK2 restored microtubule stability against colchi-
cine treatment in CK2/-depleted cells. Prior to treatment with col-
chicine (0.2 M), 293T cells were double transfected with siRNA of
human CK2/ and one of the following expression constructs: chicken
CK2, the kinase-inactive mutant of chicken CK2 (CK2K68A), or the
empty vector. Expression of Myc-tagged chicken CK2 and CK2K68A
was detected by anti-Myc immunoblotting of the cell lysates. Microtu-
bules were extracted using the differential extraction method (see ‘‘Ex-
perimental Procedures’’) for anti--tubulin immunoblotting. Represent-
ative results of three separate experiments are shown.
FIG. 7. CK2 stabilizes microtubules in vivo. A, HeLa cells were
introduced with siRNA of human CK2/ or a scrambled sequence.
Knockdown of CK2 was monitored by anti-CK2 immunoblotting. The
cells were subsequently treated with 0.2 M colchicine or its solvent.
Tubulin in the form of polymers (microtubules) was extracted from the
cells for -tubulin immunoblotting. The histogram reflects the relative
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-tubulin. We examined whether the kinase activity of CK2 is
involved in the microtubule assembly stimulated by CK2. Our
in vitro assays of microtubule assembly using the kinase-inac-
tive mutant of CK2 indicate that the microtubule-assembling
activity of CK2 is independent of its kinase activity. This was
corroborated by the experiment of expressing the kinase-inac-
tive mutant of chicken CK2 in the CK2/-knock-down cells,
which completely compensated for the lost of endogenous
CK2/, rendering the microtubules resistant to colchicine
attack. With these results, it becomes clear that CK2 imparts a
direct regulation of microtubule organization through its phys-
ical association with microtubules but not through any enzy-
matic action. As a multifunctional enzyme, CK2 has been
thought to execute its functions through its phosphorylation of
a wide range of substrates. The results presented here reveal a
novel CK2 function that is dissociated from its intrinsic kinase
property.
It has been proposed that CK2 plays an important role in the
maintenance of cell morphology and polarity. Depletion of the
catalytic subunits of CK2 in neuroblastoma cells using an an-
tisense approach blocks neuritogenesis (27, 36). Pertinent ob-
servations also came from yeasts, of which the temperature-
sensitive mutants of CK2 and CK2 demonstrated their
importance in cell morphogenesis (9, 37, 38). The function
described here for CK2 in microtubule dynamics may provide a
mechanistic explanation of its role in cell shape control.
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